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Abstract 
 
Antibiotic resistance remains a longstanding global threat, resulting in minimal therapeutic options 
for severe bacterial infections and propelling modern medicine into a post-antibiotic era. This 
circumstance is driven by several variables including the inability for current methodologies to 
rapidly diagnose infections which has led to unnecessary or incorrect administration of antibiotics. 
The unregulated availability of antibiotics in several countries and the use in livestock as a growth 
factor has facilitated the increase in resistance. This has allowed bacteria to develop an abundance 
of resistance encoded on mobile elements which are readily transferred between bacteria. 
Furthermore, there is a lack of new antibiotics entering the clinic. These factors account for the 
global dissemination of multidrug resistance and the increasing reports of pandrug resistance 
whereby bacteria harbour resistance against all available antibiotics.  
The World Health Organisation (WHO) and Centers for Disease Control and Prevention (CDC) 
urge that new antibiotics are paramount for fighting these bacteria with Enterobacteriaceae declared 
as one of the highest priorities. Klebsiella pneumoniae, belonging to the Enterobacteriaceae family, 
is a community and hospital-acquired pathogen which frequently harbours multidrug resistance and 
leads to high mortality. In particular, the advent of carbapenem resistance, the prior last-line 
antibiotic for resistant K. pneumoniae, was defined as a critical threat by both the WHO and CDC. 
In order to combat these infections, the polymyxin class of antibiotics are utilised. 
My thesis explores the genetic mechanisms utilised by K. pneumoniae to develop resistance against 
polymyxins. Understanding these pathways gives further insight into drug infiltration processes and 
engagement with their targets. Establishing in vitro studies to monitor this resistance acquisition can 
further unravel antimicrobial mechanisms of known and novel compounds and their future viability 
in the clinic. Furthermore, unravelling these mechanisms may indicate alternative procedures for 
rapid detection of resistance. Chapter 1 provides an overview of the current literature on these 
aspects. 
Initially explored in research Chapter 2 is the genetic basis for resistance in extensively drug-
resistant (XDR) K. pneumoniae clinical isolates sourced from Greece and Brazil. Whole genome 
sequencing (Illumina) and subsequent complementation assays revealed genomic variations 
contributing to and regulating resistance. Resistance was facilitated via chromosomal mutations 
rather than plasmid encoded resistance. Mutations were apparent in genes phoPQ, pmrAB and 
mgrB. Heteroresistance, where a subpopulation harbours resistance, was identified in these clinical 
isolates as well as heterogeneity of mutations. Interestingly, several mutations segregated with 
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resistance conferring variants were detected which may represent partial suppressor mutations. This 
highlights the difficulties associated with detecting polymyxin resistance via DNA sequencing. 
Due to the various combinations of genomic variants and the difficulty determining which 
contribute to polymyxin resistance, the transcriptome for several of these isolates was interrogated 
in Chapter 3. Utilizing Oxford Nanopore Technologies (ONT) direct RNA sequencing, the 
pathway involved in polymyxin resistance was investigated along with the transcription of acquired 
antibiotic resistance genes in these strains. ONT MinION sequencing was performed on four of 
these clinical isolates where one isolate was polymyxin-susceptible as a reference. This portable 
device has the capacity to read long fragments of DNA or RNA and analyse data in real-time. 
Hence, the genome for these isolates was assembled and the majority of acquired resistance (≥75%) 
was detected on up to 5 plasmids. A real-time emulation revealed ≥70% of resistance genes were 
identified in 2 hours. Direct RNA sequencing was able to discern resistance, however, low level 
transcription was not detected as validated by qRT-PCR. Elevated expression of the pmrHFIJKLM 
operon, encoding the 4-amino-4-deoxy-arabinose modification to lipid A, was evident in 
polymyxin-resistant isolates. 
In Chapter 4 a novel antibiotic under early stage development to address the increasing resistance 
against polymyxins, octapeptin C4, was investigated. This antibiotic is structurally similar to 
polymyxins, however, retains activity against polymyxin-resistant isolates. To assess the potential 
liabilities of this new antibiotic in terms of its ability to induce resistance, a polymyxin-susceptible 
XDR K. pneumoniae isolate was subjected to increasing concentrations of octapeptin C4 over 20 
days in vitro. In parallel, this isolate was exposed to polymyxin B and polymyxin E (colistin). 
Genomic alterations driven by polymyxin-induced resistance were comparable to that seen in the 
clinical isolates and produced high levels of resistance, although some novel variants in these genes 
were identified. In contrast, octapeptin C4 exposure resulted in a slow progression in resistance, 
vast differences in lipid A profiles and harboured variations in genes never associated with any 
other class of antibiotic. 
In conclusion, my PhD thesis has uncovered several new mutations regulating polymyxin resistance 
in K. pneumoniae which will aid the detection of resistance via sequencing. These findings further 
validate the potential for MinION sequencing to be ultilised as a rapid diagnostic, especially for 
bacteria harbouring high levels of resistance. Furthermore, the slow progression of resistance and 
mutations in an alternative pathway reveal octapeptins as a promising class of antibiotics to further 
explore for treating XDR infections. 
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Chapter 1 
General Introduction 
 
1.1. Global burden of antibiotic resistance 
 
The implementation of antibiotics has revolutionised medicine and improved survival rates for 
bacterial infections, saving countless lives. However, resistance towards antibiotics is rapidly 
increasing. This is a longstanding global threat, limits treatment options and is propelling modern 
medicine closer to a post-antibiotic era (1-3). The rise in antibiotic resistance is driven by a 
combination of circumstances, including delayed diagnosis of bacterial infections due to current 
diagnostics requiring at least 48 hours to characterise an infection (4). This has led to the inappropriate 
use of antibiotics during infections that are viral rather than bacterial, or the administration of the 
incorrect antibiotic for the type of bacteria, or its resistance profile. Additionally, the regulation of 
antibiotics are not stringent in many countries which has allowed for access without a prescription and 
the inappropriate use of antibiotics to promote growth in livestock (3). These factors have enabled the 
selection of highly resistant pathogens which frequently encode resistance on mobile elements or 
plasmids which can rapidly spread throughout the bacterial population via horizontal gene transfer (3). 
Few antibiotics have the capacity to combat these highly resistant infections and there is a lack of new 
antibiotic classes entering the clinic (Figure 1.1.) (5, 6). Resistance towards antibiotics frequently 
occurs shortly after entering the clinic. Consequently, pandrug resistance, defined by the inability for 
all available antibiotics to treat these infections, has emerged (7). 
 
Currently, antibiotic resistance contributes to 700 000 deaths globally per year (8). Furthermore, loss of 
productivity and extended hospital times corresponds to a high economic burden. This has been 
estimated to cost >$US 30 billion in the United States and $950 million in Australia annually (9, 10). 
The recent O’Neill report warns that if current trends sustain, antimicrobial resistance will claim 10 
million lives annually and cost $US 100 trillion globally in 2050 (8). The World Health Organisation 
(WHO) and Centers for Disease Control (CDC) urge that new antibiotics are paramount for fighting 
these bacteria, in particular, those with the capacity to target Gram-negative bacteria (9, 11).  
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Figure 1.1. Timeline representing the first introduction of an antibiotic into the clinic (top) and the 
initial report of bacterial resistance (below). Image collated from ((12, 13)). 
 
1.2. Bacterial cell wall organisation 
 
Gram-negative bacteria are difficult to target with antibiotics due to the architecture of their cell wall 
(Figure 1.2.). This structure has three principle layers: outer membrane (OM), peptidoglycan cell wall 
and the cytoplasmic or inner membrane (IM) (14). The OM is a distinctive feature of Gram-negative 
bacteria, compared to Gram-positive bacteria, and is the outermost layer.  This layer is composed of an 
inner phospholipid and outer glycolipid leaflet. The glycolipid layer contains lipopolysaccharide (LPS) 
which is divided into three sections: O-specific polysaccharide, core polysaccharide and the component 
attached to the surface, lipid A (15). Traversing this membrane are outer membrane proteins such as 
porins that allow the diffusion of essential molecules across this otherwise relatively impermeable 
barrier. The OM can also contain efflux pumps which are associated with readily removing antibiotics 
from the bacterial cell (16). The OM is attached to a layer of peptidoglycan by lipoproteins (17). 
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Gram-positive and –negative bacteria both harbour a peptidoglycan layer although the thickness varies. 
Peptidoglycan confers rigidity to the bacteria and is composed of repeating and cross linked units of N-
acetylglucosamine and N-acetylmuramic acid. The peptidoglycan layer is outermost in Gram-positive 
bacteria and contains several layers that range from 30-100 nm thick whereas Gram-negative only have 
a few layers approximately 1-7 nm thick (18). Gram-negative bacteria contain several structures in the 
peptidoglycan layer including wall-associated proteins, teichoic acid and lipoteichoic acid which 
imbeds into the IM. 
 
The IM, similar to eukaryotic cells, is a phospholipid bilayer. Gram-negative bacteria have an 
additional compartment situated between the IM and peptidoglycan layer known as the periplasm. The 
IM has several integral spanning membrane proteins and surrounds the cytoplasm. Unlike eukaryotic 
cells, the cytoplasm does not consist of organelles to facilitate certain cellular activities. The cytoplasm 
harbours a large circular DNA genome, ribosomes and in some circumstances, smaller circular 
genomes known as plasmids (14). 
 
Bacteria have the capability to alter particular components in the cell in the event of environmental 
cues such as hostile conditions and in response to antibiotic targeting. The additional complexity of the 
Gram-negative bacteria cell wall hinders the infiltration of various antibiotics. Furthermore, Gram-
negative bacteria have been identified to harbour a high abundance of efflux pumps which further 
impedes the capacity for antibiotics to kill these cells (16). 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Composition of the Gram-positive and Gram-negative cell wall. (a) Gram-positive cell 
walls consist of a thick peptidoglycan layer with teichoic acid (TA), lipoteichoic acid (LTA) and wall-
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associated proteins (WAPs). (b) Gram-negative cell walls contain an outer membrane (OM) with outer 
membrane proteins (OMPs) and lipopolysaccharide (LPS). LPS comprises of lipid A (LA), keto-
deoxyoctulosonate (KDO), core polysaccharide (CP) and O-specific polysaccharide (OP). The OM is 
attached to a thin peptidoglycan layer via lipoproteins (LPs) and the region between the outer and inner 
membrane is known as the periplasm. Both cell walls contain an inner membrane (IM) with integrated 
membrane proteins (IMPs). Figure adapted from (14). 
 
1.3. Treatment regimes for multidrug-resistant Gram-negative infections 
 
Several antibiotic classes are commonly used to treat multidrug-resistant (MDR) infections. These 
include carbapenems, fosfomycin, tigecycline and polymyxins (2). However, resistance is emerging 
which is facilitated via mutations in the genome (carbapenems (19), fosfomycin (20), tigecycline (21), 
polymyxins (22)) or by plasmid encoded resistance (carbapenems (23), fosfomycin (24), polymyxins 
(22)). To overcome resistance, these classes can be administered in combination with other antibiotics, 
however, difficulties with dosage and adverse effects arise (2). This literature review will primarily 
focus on one of these classes, the polymyxins. 
 
1.4. The Polymyxins 
 
1.4.1. Discovery and usage 
 
Clinically used polymyxins include polymyxin B (PMB) and polymyxin E, also known as colistin 
(CST), which is generally administered as its inactive prodrug, colistin methanesulfonate (CMS) (25). 
These antibiotics were initially isolated from a soil bacterium, Paenibacillus polymyxa, in 1949 and 
were identified to be secondary metabolite nonribosomal peptides (26). Upon realising their potent 
activity against Gram-negative bacteria, particularly Pseudomonas aeruginosa, CMS was implemented 
in the clinic in 1959. However, reports arose of potential neuro- and nephro-toxicity, thus, these 
antibiotics were largely replaced by aminoglycosides in the 1970s (27). Due to this early introduction 
into the clinic, CMS never underwent proper drug development and dosing optimisation procedures to 
try to reduce toxicity. The late 1980s and early 1990s witnessed the resurgence of polymyxins in the 
clinic which has led to more in depth pharmacodynamic analysis and the development of improved 
dosing regimens (28). 
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This reintroduction was primarily due to the lack of effective antibiotics to treat severe MDR Gram-
negative infections, which still retained sensitivity to the polymyxins. This need was in particular 
fuelled by the reduction in bacteria responding to treatment by carbapenems, a prior last-line antibiotic. 
Carbapenems belong to the β-lactam class of antibiotics that inhibit peptidoglycan synthesis through 
binding to penicillin-binding proteins (PBPs), leading to autolysis (29). The carbapenem structure was 
also found to overcome the majority of β-lactamases, enzymes produced by bacteria that hydrolyse the 
majority of other β-lactam antibiotics such as penicillin (30). Mechanisms of resistance to carbapenems 
includes differing classes of β-lactamases, efflux pumps and mutations changing the expression and/ or 
function of porins and PBPs (31). β-Lactamases with the capacity to target carbapenems are known as 
carbapenemases and have been reported in a vast array of bacteria (32-34). Some carbapenemases 
produced by Enterobacteriaceae are K. pneumoniae carbapenemase (KPC), Verona Integron-Mediated 
Metallo-β-lactamase (VIM), the widely publicised New Delhi Metallo-β-lactamase (NDM) and 
oxacillinase (OXA). Notably, carbapenemases are not only integrated in the genome but also located 
on plasmids (35). The rapid transfer of plasmids harbouring these genes has influenced the polymyxin 
resurgence in the clinic. 
 
 1.4.2. Structure and mode of action 
 
The polymyxin structure comprises of three main components including the heptapeptide ring, a linear 
tripeptide segment, and an N-terminal fatty acid tail (Figure 1.3.). CST and PMB harbour high 
similarity with only one amino acid variation at position 6 in the heptapeptide ring. PMB contains a D-
phenylalanine and CST harbours a D-leucine. The fatty acid component has a number of variations, 
with clinically used PMB and CST consisting predominantly of 6-methyloctanoate and 6-
methylhepanoate. 
 
Polymyxins initially interact with the basal component of LPS, lipid A (36). Lipid A assists with the 
tight packing of fatty acyl chains for OM stability (37). An electrostatic interaction occurs between the 
positively charged L-α-γ-diaminobutyric acid (Dab) residues located in the heptapeptide ring and the 
negatively charged phosphate groups in lipid A. Lipid A normally attracts calcium (Ca2+) and 
magnesium (Mg2+) ions to achieve OM stabilisation, but the polymyxin Dab residues harbour a higher 
affinity for lipid A (36). This binding displaces Ca2+ and Mg2+ from the bacterial OM thereby allowing 
the accumulation of polymyxin destabilising the OM, followed by cytoplasmic leakage and subsequent 
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cell death (38, 39). The exact mechanism of uptake remains elusive. Domingues et al. revealed that this 
permeabilisation of the outer membrane was concentration dependent (40). Furthermore, studies have 
indicated a potential secondary mode of action. Deris et al. indicated this could potentially be 
facilitated by inhibiting NAPH-quinone oxidoreductase activity, critical enzymes in the bacteria IM 
(41). Furthermore, McCoy et al. have revealed that polymyxins have the capacity to bind to ribosomal 
RNA and perturb translation (42). Polymyxins have the capacity to permeabilise the IM and several 
hypotheses have been suggested. These include permeating the phospholipid bilayer/ pore formation 
and the potential for phospholipid exchange resulting in osmotic imbalance and bacteriolysis (42). 
 
Derivatization of the polymyxin structure has been undertaken to further understand how this antibiotic 
interacts with lipid A. Furthermore, this allows for information regarding how regions of the structure 
contribute to antimicrobial activity and toxicity. It has been found that the fatty acid tail plays a key 
role in its bactericidal effect. Derivative NAB741 lacks this component and although it does not have 
the capacity to kill bacteria, is able to synergise with other antibiotics (43). Another derivative, PMB 
nonapeptide (PMBN) lacks the terminal Dab acid residue along with the fatty acid region which results 
in reduced and even negated antibacterial activity (36). Similar to NAB741, PMBN was able to bind to 
the OM and synergise with other antibiotics. The fatty acid has been proposed to insert into the OM 
and mediate infiltration of these antibiotics. Further common modifications include altering the size of 
the cyclic ring (44, 45) or negating or reducing the amount of positively charged Dab groups (46). Both 
of these forms of modification severely impair antimicrobial activity. 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Structural comparison of colistin, polymyxin B and octapeptin C4. Colistin (a) and 
polymyxin B (b) differ by one amino acid (polymyxin B: phenylalanine and colistin: leucine). The 
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main difference between polymyxins and octapeptins is that the latter consist of 8 amino acids rather 
than the 10 found in polymyxins. In addition, a leucine residue replaces threonine at the C-terminal 
ring cyclisation position, and the exocyclic diaminobutyric acid (Dab) (labelled) residue is the D-
enantiomer. 
 
1.4.3. Mechanisms of resistance 
 
Resistance to polymyxins was first reported in P. aeruginosa in 2000, not long after its reintroduction 
into the clinic (47). Certain species of bacteria harbour intrinsic resistant to polymyxins including 
Proteus spp., Serratia spp. and Burkholderia spp. (48). There have been increasing reports of 
polymyxin resistance in the clinic particularly for K. pneumoniae, P. aeruginosa, A. baumannii and E. 
coli (49). Resistance is achieved in these species via chromosomal variants and/ or plasmid encoded 
resistance (22). Various phenotypic changes are attributed to resistance including lipid A 
modifications, capsule production and efflux pumps (Figure 1.4.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Mechanisms utilised by Gram-negative bacteria to facilitate polymyxin resistance. (1) In 
susceptible bacteria, the positively diaminobutyric acid (Dab) residues (depicted as ● in the polymyxin 
structure) interact with the negatively charged phosphate groups on lipid A (the basal component of 
Chapter 1   
8 
 
lipopolysaccharide). This enables polymxyins to traverse across the outer membrane, cause 
cytoplasmic leakage and subsequent cell death. (2) Polymyxin-resistant isolates modify the phosphate 
groups of lipid A via 4-amino-4-deoxy-arabinose (Ara4N), phosphoethanolamine (pEtN) and/ or 
galactosamine (GalN). These modifications can arise via chromosomal mutations or plasmid encoded 
resistance. This negates the interaction between polymyxins and lipid A. (3) The capsule, which is an 
additional polysaccharide layer surrounding several bacterial species, has been speculated to contribute 
to resistance. The negative charge of the polysaccharides is anticipated to act as a decoy, in which 
polymyxins will bind. (4) Efflux pumps allow for the removal of polymyxins once traversing the outer 
membrane. This reduces the abundance of polymyxin in the cell to enable resistance. 
 
  1.4.3.1. Lipid A modifications 
 
The most prevalent mechanism of resistance are modifications to the basal component of LPS, lipid A. 
Lipid A is composed of a two phosphate groups, two glucosamines and acyl chains (commonly 4 to 7, 
length between 12 and 16 carbons) (Figure 1.5.) (50). Resistance occurs via the addition of 4-amino-4-
deoxy-arabinose (Ara4N), phosphoethanolamine (pEtN) and/ or galactosamine to lipid A phosphate 
group/ s (22, 48-51). These modifications to phosphate group/ s confer resistance by reducing the 
negative charge of the bacterial surface thereby minimising the electrostatic interaction of polymyxins. 
The addition of Ara4N is the most frequent LPS modification (37). Ara4N changes the negative 
phosphate groups on lipid A to 0 whilst pEtN alters the net charge from -1.5 to -1, meaning that the 
Ara4N addition is the most effective modification (37). The Ara4N motif is added to lipid A in Proteus 
spp., Serratia spp. and Burkholderia spp., causing their resistance (48, 52-55). Interestingly, these 
modifications to lipid A not only assist with polymyxin resistance, but play a role in immune evasion in 
vivo. Modified lipid A enables bacteria to overcome cationic antimicrobial peptides secreted by host 
immune cells and immune recognition by Toll-like Receptor 4 (50, 56). 
 
The Ara4N and pEtN modifications are achieved through the PhoPQ and PmrAB two-component 
regulatory system (TCS) (57-59). This is widespread in bacteria with only some interspecies regulation 
changes such as PhoPQ and PmrAB signalling dependent or independent from one another (60, 61). 
This system is activated by environmental stimuli whereby PhoQ and PmrB are sensor kinases located 
in the IM that become autophosphorylated. Environmental cues involve high concentrations of Fe3+ or 
low pH for PmrB (62), while PhoQ is sensitive to low concentrations of Mg2+ or Ca2+ (59, 63). This 
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stimuli allows the transfer of a phosphate group from PhoQ to PhoP or PmrB to PmrA which enables 
PhoP and PmrA to become transcription factors. This transcription facilitates the addition of Ara4N 
and/ or pEtN to lipid A. Notably, a fitness cost can arise in various species due to these modifications, 
thus, in the absence of polymyxins, bacteria will readily lose resistance (48).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Generic structure for the basal component of lipopolysaccharide, lipid A and common 
modifications involved in polymyxin resistance. Common features include 2 glucosamines, 2 
phosphate groups and acyl chains varying in number (between 4 and 7) and length (12 to 16 carbons). 
In the occurrence of polymyxin resistance, 4-amino-4-deoxy-arabinose (Ara4N), phosphoethanolamine 
(pEtN) and/ or galactosamine are added to lipid A phosphate group/ s. 
 
Several other modifications have been identified to contribute to resistance including the extent of lipid 
A acylation. Velkov et al. identified that, in K. pneumoniae, hexa-acylated lipid A increased resistance 
compared to the penta-acylated species (64). However, Clements et al. identified an increased 
susceptibility for hexa-acylated lipid A in K. pneumoniae (65). In E. coli and S. typhimurium, the 
addition of a 14 carbon acyl chain or myristate caused polymyxin resistance (66). Interestingly, a recent 
report by Han et al. revealed that, in P. aeruginosa, penta-acylated lipid A reduced PMB penetration 
compared to the hexa-acylated species (67). Overall, elevated polymyxin resistance is influenced by the 
number of acyl chains which alters the hydrophobicity and fluidity of the OM. Complete loss of LPS 
can also arise, however, this incurs a fitness cost (68, 69).  
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  1.4.3.2. Capsule production 
 
Capsules are predominantly composed of polysaccharides and encase bacteria. The constitution of 
capsule production and its effects on polymyxin resistance still remains debatable. Llobet et al. 
reported that K. pneumoniae were able to disperse capsule polysaccharides (CPs) from the surface to 
allow polymyxin binding to these rather than the bacteria membrane (70). These CPs are anionic and 
act as decoys. Campos et al. also highlighted that K. pneumoniae mutants with the capacity to over 
express CPs were able to resist PMB in a dose dependent manner (71). However, several other studies 
disagree with the capsule contributing to resistance (65, 72, 73). 
 
  1.4.3.3. Efflux pumps 
 
Efflux pumps are integrated proteins in the outer and/ or inner membrane that facilitate the removal of 
particular compounds from the cell. Impairment of an efflux pump, AcrAB, due to a mutation in acrB 
was previously associated with susceptibility to polymyxins (74). Another efflux pump, KpnEF, was 
also shown to facilitate polymyxin resistance (75). Srinivasan and Rajamohan identified susceptibility 
towards colistin once this gene was removed (ΔkpnEF mutant) and upon complementation, resistance 
was restored.  
 
  1.4.3.4. Genomic basis for polymyxin resistance 
 
Genomic modifications to orchestrate polymyxin resistance have been commonly associated with 
alterations in TCS. As mentioned in section 1.4.3.1., the TCSs comprise of two proteins, a sensor 
histidine kinase imbedded in the IM and a response regulator in the cytoplasm. Upon environmental 
stimuli, the histidine kinase will phosphorylate the response regulator and allow this protein to bind to 
certain target promoters in the genome and result in expression of a subset of genes (58). Mutations 
contributing to polymyxin resistance have been shown to occur across multiple regions in these TCS 
genes and are more frequently reported in the histidine kinase (48). Although mutations have been 
reported in these genes, multiple studies lack characterisation such as complementation assays. These 
experiments involve cloning the mutant gene and introducing this vector into a susceptible isolate 
which would discern whether this mutation contributes to resistance. Hence, the role of these mutations 
remain under-characterised. Studies which have verified resistance conferring mutations have shown 
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an unregulated phosphorylation of the response regulator via the histidine kinase and heightened 
expression of target genes (48). These genes commonly impact LPS synthesis including the Ara4N and 
pEtN modifications to lipid A. 
 
Disruptions in pmrAB and/ or phoPQ have been identified in A. baumannii, E. aerogenes, E. coli, K. 
pneumoniae, P. aeruginosa and S. enterica. This can occur via missense mutation, nonsense mutations, 
partial or complete deletion of genes or insertion sequence (IS) elements (48). In P. aeruginosa, three 
other TCS exist which contribute to polymyxin resistance which includes ParRS, ColRS and CprRS 
(76, 77). Similarly, K. pneumoniae also harbours an additional TCS involved in polymyxin resistance, 
CrrAB (78, 79). Furthermore, K. pneumoniae has a negative regulator of PhoPQ, mgrB, which is the 
most prevalent gene impacted in clinical isolates (80, 81). Once this negative regulator is disrupted, 
over-expression of the pmrCAB and pmrHFIJKLM operon arises (78). This enables the fortification of 
pEtN and/ or Ara4N to lipid A.  
 
Other pathways associated with LPS synthesis have also shown an involvement in polymyxin 
resistance. Notably, an IS element disruption in A. baumannii genes lpxA, lpxC and lpxD facilitated the 
complete loss of LPS (68). Furthermore, alterations in ramA which influences the expression of various 
genes, including lpxC, lpxL and lpxO, has been shown to cause decreased susceptibility to polymyxin 
(82).  
 
Plasmid encoded polymyxin resistance has been a recent phenomenon and first reported in early 2016 
(83). The gene mcr-1 was identified to be facilitating resistance which encodes a pEtN transferase 
enzyme and the subsequent pEtN addition to lipid A (83, 84). Currently, 12 variants of mcr-1 have 
been detected and differing mcr genes have been found (mcr-2, -3, -4, -5) (85). The acquisition of this 
gene has commonly been found in E. coli (85). Interestingly, this species specificity may be due to this 
gene incurring a fitness cost in certain species. Tietgen et al. identified a fitness cost in K. pneumoniae, 
however, this was not apparent in E. coli (86). Although several pathways have been associated with 
resistance, there are various isolates in which the molecular mechanisms for polymyxin resistance 
remains unknown (22). 
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1.4.4. Detection methods for resistance 
 
Conventional methods to detect polymyxin resistance are broth microdilution (BMD), VITEK 
(bioMérieux), disk diffusion and Etest (87, 88). However, these methods require at least 24 hours 
following an overnight inoculation (16-20 hours) and in the instance of agar based methods (disk 
diffusion, Etest), poor diffusion of polymyxin has been identified and resulted in false negative 
(indicating susceptibility rather than resistance) results (87, 88). Overall, VITEK has been deemed 
unreliable for detecting polymyxin resistance and BMD is the recommended method (87, 88, also refer 
to EUCAST guidelines v8.1 (http://www.eucast.org)). An alternative method for detecting resistance is 
the Nordmann/Poirel test (89). Briefly, this method inoculates bacteria with polymyxin, a pH indicator 
(phenol red) and glucose. If bacteria are resistant, this will enable growth, metabolism of glucose which 
alters the solution pH and results in a colour change. Another promising method utilises mass 
spectrometry to detect lipid A, and potentially revealing modifications conferring polymyxin 
resistance, in the absence of time consuming extraction methods (90). However, the major challenge 
for all methods is detecting heteroresistance. Heteroresistance is defined as a subpopulation of bacteria 
present in a phenotypically susceptible isolate and is associated with polymyxin resistance (91, 92).  
 
Sequencing also has the potential to detect antibiotic resistance although in the instance of polymyxin 
resistance, chromosomal mutations or plasmid encoded resistance need to be confirmed via further 
functional experiments which include complementation assays (22, 48). Prior studies have commonly 
investigated TCS genes associated with polymyxin resistance and identified mutations via Sanger 
sequencing (48). However, this negates the involvement of other mutations and pathways potentially 
contributing to resistance. Hence, whole genome sequencing, predominantly via Illumina short read 
sequencing, has been employed. This has enabled the detection of other pathways contributing to 
resistance such as CrrAB in K. pneumoniae (78). Illumina sequencing platforms have the capacity to 
detect mutations, owing to their high sequencing accuracy, and can even potentially identify 
heteroresistance (resistance conferring mutation present only in a subpopulation of a phenotypically 
susceptible bacterial isolate), provided there is sufficient coverage of the genome (92). One limitation 
of short read sequencing (150 to 300 nucleotide reads) is the inability to resolve the genome, in 
particular, long repetitive regions. Therefore, short-read platforms cannot determine whether resistance 
genes are located on the chromosome or plasmid/s. Furthermore, with traditional sequencing 
methodologies, data can only be analysed upon the completion of the sequencing run. A promising new 
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sequencing technology that can be applied to evaluate antibiotic resistance is MinION sequencing 
(Oxford Nanopore Technologies) (93, 94). This long read sequencing technology has the ability to span 
long repeats and resolve these regions in the genome, therefore distinguishing plasmid from 
chromosomal locations. This technology also has the ability to analyse data as soon as it is generated 
by applying ‘real-time’ sequencing algorithms (94). However, poor accuracy is currently limiting its 
capacity to detect mutations. 
 
1.4.5. Complications of colistin therapy 
 
Several adverse effects have been reported for polymyxins including nephrotoxicity and neurotoxicity. 
Due to the poor characterisation of polymyxins in earlier studies, the incidence of these events was 
potentially exacerbated due to inaccurate administration of the antibiotic, and/ or impure composition 
of the antibiotic. There is still some dispute about the exact incidence of these events, however, it is 
clear that neurotoxicity is rarely reported (95). Nephrotoxicity is the major complication associated 
with these antibiotics. The rate of incidence varies amongst studies dependent on the criteria used to 
determine acute kidney injury. The RIFLE or risk, injury, failure, loss and end-stage renal disease 
criterion encompasses monitoring creatinine levels and the glomular filtration rate. This assessment 
allows for more accurate monitoring of nephrotoxicity with biomarkers for this condition. When the 
RIFLE criterion was implemented, incidence was calculated to be between 18-53.5% (95-97). Notably, 
higher doses correlated with increased incidence of toxicity. It was found that administration of 3-4.9 
mg/kg/day would result in >30% of patients harbouring renal toxicity whilst ≥5 mg/kg/day, the upper 
limit of dosage, would elevate damage to 69% (97). This is a major dose limitation for polymyxins and 
has been shown that the current regimes are only suboptimal in regards to preventing resistance (98). 
 
Studies involving human, rat, pig or mouse kidney samples have identified mass accumulation of 
polymyxin in a specific renal cell type, proximal tubular epithelial cells (99-102). These cells are 
responsible for glomeruli reabsorption of essential molecules which would otherwise be lost in the 
urine. Recent findings have identified that this accumulation leads to apoptosis in these cells and cell 
cycle arrest (103-105).  
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1.5. Octapeptins, the next last-line antibiotic? 
 
1.5.1. Discovery and usage 
 
Octapeptins, otherwise formally known as the EM49 series, were initially discovered in 1973 (106). 
There have been 18 differing naturally occurring octapeptins identified which were isolated from 
Bacillus circulans (106, 107) and Paenibacillus tianmuensis (108). These antibiotics were not 
advanced into the clinic due to inadequate potency, however there is renewed interest in purified 
compounds due to their activity against polymyxin-resistant strains. 
 
1.5.2. Structure and mode of action 
 
The vast majority of investigations into octapeptin classification were in the 1970-80’s. These naturally 
occurring octapeptins are classed into 4 subclasses: A, B, C and D. The subclasses are dependent on 
amino acid changes in the cyclic ring at positions 4, 5 and 8 (108-113). The major differences in 
octapeptin and polymyxin structure are position 7 in the cyclic ring, where octapeptin contains an L-
leucine and polymyxins an L-threonine (Figure 1.3.), and in the tail, where octapeptins contain only 
one amino acid in the linear chain whereas polymyxins have three; octapeptins also contain β-hydroxy 
fatty acids instead of purely alkyl fatty acids. 
 
Earlier studies on octapeptin activity were commonly conducted using mixtures of the classes. A 
mixture of class A and B (EM49) revealed broad-spectrum antimicrobial activity against Gram-positive 
and –negative bacteria along with fungi and protozoa (110, 114-116). However, when purified, there is 
high selectivity towards Gram-negative bacteria and, of particular interest, a capacity to target MDR, 
XDR and polymyxin-resistant bacteria (117, 118). Few publications exist which characterise purified 
octapeptins (octapeptin A3, C4, B5), however, this is increasing over the past few years with their first 
chemical syntheses (108, 119-122). 
 
The exact mode of action for octapeptins remains elusive. Initial studies on EM49 revealed its capacity 
to release phospholipids, LPS and membrane fragments from the E. coli OM (123). Qian et al. 
highlighted that octapeptin B5 or battacin was able to disrupt the P. aeruginosa OM similar to PMB, 
however it permeabilises the IM to a lesser degree to PMB (108). A linear analog of battacin was found 
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to be potent against P. aeruginosa and S. aureus. This analog was shown to damage the OM and IM in 
a concentration-dependent manner which was validated via the N-phenylnaphthylamine dye assay, 
propidium iodide fluorescent assay and scanning electron microscopy (124). Octapeptin C4 was 
identified to require a higher concentration, compared to PMB and CST, to facilitate OM and IM 
permeabilisation in E. coli (122). Asymmetric OM models have been constructed using polymyxin-
resistant P. aeruginosa and the interaction with octapeptin A3 interrogated (120). Neutron 
reflectometry studies identified that octapeptin A3 was able to bind to Ara4N-modified lipid A and 
penetrate the OM. PMB was shown to bind to Ara4N-modified lipid A but was unable to imbed in the 
membrane. Furthermore, octapeptin A3 was found to bind independently to phospholipids. Although 
LPS-independent binding was shown, isothermal titration calorimetry studies identified that octapeptin 
A3 exhibited a higher binding affinity to LPS compared to CST (120). This was additionally observed 
with octapeptin C4 using surface plasmon resonance experiments. Artificial membranes have been 
created using differing ratios of 2-oleoyl-1-palmitoyl-sn-glycero-3-phosphocholine and 2-oleoyl-1-
palmitoyl-sn-glycero-3-glycerol. Once supplemented with E. coli lipid A, octapeptin C4 showed 
stronger binding compared to PMB and CST (122). Furthermore, NMR studies revealed octapeptin C4 
Dab residues interact with the lipid A Kdo2 sugars which may identify why octapeptins can overcome 
Ara4N-modified lipid A (122). 
 
1.5.3. Resistance mechanisms 
 
Resistance mechanisms remain uncharacterised, however, earlier studies have revealed resistance did 
not occur when P. aeruginosa, E. coli, S. aureus and Candida albicans were subcultured ten times in 
the presence of EM49 (114). A recent study investigated a single overnight treatment of differing 
concentrations of octapeptin C4 (2 or 32 mg/L) in P. aeruginosa. Characterising lipid A identified 
increases in the addition of an acyl chain (palmitoylate) when exposed to 32 mg/L (122). Several 
species, such as Proteus spp. and S. marcescens (118), have been shown to harbour intrinsic resistance 
to octapeptins. Several species have been shown to harbour intrinsic resistance to octapeptins which 
include Proteus spp. and S. marcescens (118). Interestingly, these species fortify lipid A with Ara4N, 
however, their differing acylation may be contributing to resistance and warrants further investigation 
(52, 54). 
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1.5.4. Associated complications 
 
Octapeptins are reported to be less toxic than polymyxins. Qian et al. showed low haemolytic activity 
and no cytotoxicity against HEK293 with a concentration 32-64 times the minimum inhibitory 
concentration (108). In vitro studies using human proximal kidney tubule cells identified reduced 
toxicity for octapeptin C4 compared to PMB and CST (122). Similarly, in vivo studies have shown that 
the lethal dose of octapeptin B5 is only 2.3-fold higher than PMB (108). Studies in mice using 
octapeptin C4 showed no acute effects at 40 mg/kg compared to PMB which caused death (122) 
Furthermore, dosing at 72 mg/kg in 24 hours revealed no kidney damage in octapeptin C4-treated mice 
compared to mice treated with polymyxins, which had noticeable damage (122). The reduction in 
toxicity for octapeptin reveals that this antibiotic class is desirable for treating severe MDR Gram-
negative infections and can potentially negate the dose limiting factor associated with polymxyins. 
 
1.6. Conclusions 
 
Overall, the development of new antibiotics to overcome resistant Gram-negative infections is crucial. 
Polymyxins remain one class commonly used as a ‘last resort’, however, these are quickly becoming 
obsolete. Due to nephrotoxicity, suboptimal dosing is administered which can select for resistant 
populations. Detection methods for resistance are not sufficient and currently lack sensitivity to 
identify heteroresistance. This can occur via chromosomal mutations and plasmid encoded resistance. 
Furthermore, resistance facilitated via mutations require rigorous functional assays to discern whether 
these changes are conferring resistance. This has led to various isolates identified as polymyxin-
resistant in the clinic but do not undergo further characterisation to determine the molecular 
mechanisms underpinning resistance. 
 
The structurally similar class of antibiotics, the octapeptins, have the capacity to target not only MDR 
infections but also isolates which are polymyxin-resistant. The mode of action remains elusive and 
desperately requires further characterisation. Studies have shown the capacity for octapeptins to 
interact with Ara4N-modified lipid A and phospholipids. Early literature identified no resistance in 
several species upon repeated exposure. Furthermore, in vivo studies show reduced nephrotoxicity 
compared to polymyxins. Due to these desirable aspects, the octapeptin class warrants further 
investigation. 
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1.7. Thesis aims 
 
This thesis will focus on polymyxin resistance in K. pneumoniae. K. pneumoniae belongs to the 
Enterobacteriaceae family and is considered a commensal bacteria and opportunistic pathogen. Strains 
which facilitate disease are community and hospital-acquired and frequently harbour high levels of 
resistance (125). Colonisation by this bacterium can lead to pneumonia, urinary tract infections, 
meningitis, septicaemia and soft tissue infections (125). The advent of carbapenem resistance, the prior 
last-line antibiotic for resistant K. pneumoniae, was defined as a critical threat by both the WHO and 
CDC (9, 11). K. pneumoniae harbouring this resistance causes high morbidity and an overall mortality 
of 48% (126). 
 
The work in this thesis characterises various K. pneumoniae clinical strains exhibiting a polymyxin-
resistant extensively drug-resistant (XDR) phenotype which is verging on pandrug resistance. This 
thesis aimed to identify the genetic basis underpinning polymyxin resistance in clinical isolates and 
validate the role of mutations via functional assays. Additionally, this thesis endeavoured to resolve the 
assembly of these highly resistant strains to discern whether various resistance is residing on the 
chromosome or plasmids. Furthermore, this work aimed to uncover the level of transcription for 
multiple resistance genes and identify transcriptional markers for polymyxin resistance. Finally, this 
thesis anticipated to characterise the acquisition of resistance in XDR K. pneumoniae genotypically and 
phenotypically when exposed to polymyxins and octapeptin C4. 
 
1.8. Thesis outline 
 
This thesis encompasses three research chapters. Chapter 2 interrogates the genomes of 24 XDR K. 
pneumoniae clinical isolates. These were collected from Greece and Brazil between 2012 and 2014. 
Illumina MiSeq sequencing was performed to identify the genetic basis for polymyxin resistance and 
complementation assays were implemented to discern the role of these mutations. Five of these isolates 
were polymyxin-susceptible to serve as a reference. The predominant gene impacted was mgrB (90% 
of isolates) and was altered via missense mutation, nonsense mutation, partial deletion or IS elements 
within or upstream of the gene. Interestingly, several mutations were segregating with these mgrB 
disruptions and were identified to potentially be partial suppressor mutations. Heterogeneity of 
mutations and heteroresistance was also identified. Furthermore, genes not influencing resistance were 
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apparent via complementation assays. These studies highlight the complexity of polymyxin resistance 
in K. pneumoniae and the difficulties detecting resistance solely via sequencing. 
 
Chapter 3 selects four isolates from Chapter 2 exhibiting high levels of resistance (including one 
polymyxin-susceptible isolate), belonging to differing lineages and possessing differing plasmids. This 
chapter utilised a long read sequencing technology, Oxford Nanopore Technologies (ONT) MinION 
sequencing. This enabled the chromosome and plasmids in these isolates to be resolved and on average, 
these were identified to have ≥75% of resistance genes residing on up to 5 plasmids. ONT MinION 
sequencing can also analyse sequencing data in real-time. Utilising a real-time emulation, ≥70% of 
resistance genes were detected within 2 hours via DNA sequencing. Direct RNA sequencing was also 
implemented and resistance towards various antibiotic classes was detected, however, the amount 
detected was dependent on the level of transcription. High levels of expression were detected for pmrH 
and pmrK in the polymyxin-resistant isolates indicating transcription could also be used to detect 
resistance. 
 
Chapter 4 involves an induction of resistance against polymyxins and octapeptin C4 over a 20 day 
time course. This evoked a 1000-fold MIC increase for polymyxins and only a 4-fold rise for 
octapeptin C4. Subsequent isolates underwent whole genome sequencing (Illumina), complementation 
assays, antimicrobial susceptibility testing and lipid A analysis. These studies identified several novel 
genomic changes for polymyxin-resistant isolates. A differing pathway was associated with octapeptin 
C4 which was reflected in the lipid A analysis and lack of cross-reactivity. The slow progression of 
resistance and novel pathway impacted for octapeptin C4 are desirable traits for a future antibiotic. 
 
Chapter 1   
19 
 
1.9. References 
 
1. Bhatt P, Tandel K, Shete V, Rathi KR. Burden of extensively drug-resistant and pandrug-
resistant Gram-negative bacteria at a tertiary-care centre. New Microbes and New Infections 
2015;8:166-170. 
2. Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-
negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 
2014;15:1351-1370. 
3. Gould IM. Antibiotic resistance: the perfect storm. Int J Antimicrob Agents 2009;34 Suppl 
3:S2-5. 
4. Sommer MOA, Munck C, Toft-Kehler RV, Andersson DI. Prediction of antibiotic 
resistance: time for a new preclinical paradigm? Nat Rev Microbiol 2017;15:689-696. 
5. Butler MS, Blaskovich MA, Cooper MA. Antibiotics in the clinical pipeline at the end of 
2015. J Antibiot (Tokyo) 2017;70:3-24. 
6. Cooper MA, Shlaes D. Fix the antibiotics pipeline. Nature 2011;472:32. 
7. Falagas ME, Bliziotis IA. Pandrug-resistant Gram-negative bacteria: the dawn of the post-
antibiotic era? Int J Antimicrob Agents 2007;29:630-636. 
8. O’Neill J. Tackling Drug-Resistant Infection Globally: An Overview of Our Work. The Review 
on Antimicrobial Resisance 2016. https://amr-review.org/. 
9. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United 
States, 2013. 2013. https://www.cdc.gov/drugresistance/threat-report-2013/index.html. 
10. Graves N, Halton K, Patterson D, Whitby M. The economic rationale for infection control in 
Australian hospitals Healthcare Infection. 2009;14:81-88. 
11. World Health Organisation. Antimicrobial resistance: a global report on surveillance 2014. 
2014. http://www.who.int/drugresistance/documents/surveillancereport/en/. 
12. Silver LL. Challenges of antibacterial discovery. Clin Microbiol Rev 2011;24:71-109. 
13. Clatworthy AE, Pierson E, Hung DT. Targeting virulence: a new paradigm for antimicrobial 
therapy. Nat Chem Biol 2007;3:541-548. 
14. Silhavy TJ, Kahne D, Walker S. The bacterial cell envelope. Cold Spring Harb Perspect Biol 
2010;2:a000414. 
15. Osborn MJ, Rosen SM, Rothfield L, Zeleznick LD, Horecker BL. Lipopolysaccharide of 
the gram-negative cell wall. Science 1964;145:783-789. 
Chapter 1   
20 
 
16. Ahmad I, Nawaz N, Dermani FK, Kohlan AK, Saidijam M, Patching SG. Bacterial 
Multidrug Efflux Proteins: A Major Mechanism of Antimicrobial Resistance. Curr Drug 
Targets 2018. doi: 10.2174/1389450119666180426103300. 
17. Cowan SW, Schirmer T, Rummel G, Steiert M, Ghosh R et al. Crystal structures explain 
functional properties of two E. coli porins. Nature 1992;358:727-733. 
18. Vollmer W. Structural variation in the glycan strands of bacterial peptidoglycan. FEMS 
Microbiol Rev 2008;32:287-306. 
19. Wozniak A, Villagra NA, Undabarrena A, Gallardo N, Keller N et al. Porin alterations 
present in non-carbapenemase-producing Enterobacteriaceae with high and intermediate levels 
of carbapenem resistance in Chile. J Med Microbiol 2012;61:1270-1279. 
20. Tsuruoka T, Miyata A, Yamada Y. Two kinds of mutants defective in multiple carbohydrate 
utilization isolated from in vitro fosfomycin-resistant strains of Escherichia coli K-12. J 
Antibiot (Tokyo) 1978;31:192-201. 
21. Sun Y, Cai Y, Liu X, Bai N, Liang B, Wang R. The emergence of clinical resistance to 
tigecycline. Int J Antimicrob Agents 2013;41:110-116. 
22. Baron S, Hadjadj L, Rolain JM, Olaitan AO. Molecular mechanisms of polymyxin 
resistance: knowns and unknowns. Int J Antimicrob Agents 2016;48:583-591. 
23. Schultsz C, Geerlings S. Plasmid-mediated resistance in Enterobacteriaceae: changing 
landscape and implications for therapy. Drugs 2012;72:1-16. 
24. Arca P, Reguera G, Hardisson C. Plasmid-encoded fosfomycin resistance in bacteria isolated 
from the urinary tract in a multicentre survey. J Antimicrob Chemother 1997;40:393-399. 
25. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of 
colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50:1953-1958. 
26. Stansly PG, Shepherd RG, White HJ. Polymyxin: a new chemotherapeutic agent. Bull Johns 
Hopkins Hosp 1947;81:43-54. 
27. Tallgren LG, Liewendahl K, Kuhlbaeck B. The therapeutic success and nephrotoxicity of 
colistin in acute and chronic nephropathies with impaired renal function. Acta Med Scand 
1965;177:717-728. 
28. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K et al. Colistin: the re-emerging 
antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 
2006;6:589-601. 
Chapter 1   
21 
 
29. Hashizume T, Ishino F, Nakagawa J, Tamaki S, Matsuhashi M. Studies on the mechanism 
of action of imipenem (N-formimidoylthienamycin) in vitro: binding to the penicillin-binding 
proteins (PBPs) in Escherichia coli  and Pseudomonas aeruginosa, and inhibition of enzyme 
activities due to the PBPs in E. coli. J Antibiot (Tokyo) 1984;37:394-400. 
30. Moellering RC, Jr., Eliopoulos GM, Sentochnik DE. The carbapenems: new broad spectrum 
beta-lactam antibiotics. J Antimicrob Chemother 1989;24 Suppl A:1-7. 
31. Codjoe FS, Donkor ES. Carbapenem Resistance: A Review. Med Sci (Basel) 2017;6. doi: 
10.3390/medsci6010001. 
32. Jeong HW, Cheong HJ, Kim WJ, Kim MJ, Song KJ et al. Loss of the 29-kilodalton outer 
membrane protein in the presence of OXA-51-like enzymes in Acinetobacter baumannii is 
associated with decreased imipenem susceptibility. Microb Drug Resist 2009;15:151-158. 
33. Mena A, Plasencia V, Garcia L, Hidalgo O, Ayestaran JI et al. Characterization of a large 
outbreak by CTX-M-1-producing Klebsiella pneumoniae and mechanisms leading to in vivo 
carbapenem resistance development. J Clin Microbiol 2006;44:2831-2837. 
34. Rodriguez-Martinez JM, Poirel L, Nordmann P. Molecular epidemiology and mechanisms 
of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 
2009;53:4783-4788. 
35. Canton R, Akova M, Carmeli Y, Giske CG, Glupczynski Y et al. Rapid evolution and 
spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 
2012;18:413-431. 
36. Clausell A, Garcia-Subirats M, Pujol M, Busquets MA, Rabanal F, Cajal Y. Gram-
negative outer and inner membrane models: insertion of cyclic cationic lipopeptides. J Phys 
Chem B 2007;111:551-563. 
37. Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol 
Biol Rev 2003;67:593-656. 
38. Hancock RE. Antibacterial peptides and the outer membranes of gram-negative bacilli. J Med 
Microbiol 1997;46:1-3. 
39. Koike M, Iida K, Matsuo T. Electron microscopic studies on mode of action of polymyxin. J 
Bacteriol 1969;97:448-452. 
40. Domingues MM, Inacio RG, Raimundo JM, Martins M, Castanho MA, Santos NC. 
Biophysical characterization of polymyxin B interaction with LPS aggregates and membrane 
model systems. Biopolymers 2012;98:338-344. 
Chapter 1   
22 
 
41. Deris ZZ, Akter J, Sivanesan S, Roberts KD, Thompson PE et al. A secondary mode of 
action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone 
oxidoreductase activity. J Antibiot (Tokyo) 2014;67:147-151. 
42. McCoy LS, Roberts KD, Nation RL, Thompson PE, Velkov T et al. Polymyxins and 
analogues bind to ribosomal RNA and interfere with eukaryotic translation in vitro. 
Chembiochem 2013;14:2083-2086. 
43. Vaara M, Siikanen O, Apajalahti J, Fox J, Frimodt-Moller N et al. A novel polymyxin 
derivative that lacks the fatty acid tail and carries only three positive charges has strong 
synergism with agents excluded by the intact outer membrane. Antimicrob Agents Chemother 
2010;54:3341-3346. 
44. Vogler K, Studer RO, Lanz P, Lergier W, Bohni E. Total synthesis of two cyclodecapeptides 
exerting polymyxin-like activity. Experientia 1961;17:223-224. 
45. Tsubery H, Ofek I, Cohen S, Fridkin M. Structure-function studies of polymyxin B 
nonapeptide: implications to sensitization of gram-negative bacteria. J Med Chem 
2000;43:3085-3092. 
46. Beveridge EG, Martin AJ. Sodium sulphomethyl derivatives of polymyxins. Br J Pharmacol 
Chemother 1967;29:125-135. 
47. Moskowitz S, Burns J, Miller S, Ernst R, Hoiby N, Nguyen C. Polymyxin resistance and 
lipid A structure of Pseudomonas aeruginosa isolated from colistin-treated and colistin-naïve 
cystic fibrosis patients. Pediatr pulm 2000;30:272. 
48. Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin resistance: acquired and 
intrinsic resistance in bacteria. Front Microbiol 2014;5:643. 
49. Falagas ME, Rafailidis PI, Matthaiou DK. Resistance to polymyxins: Mechanisms, 
frequency and treatment options. Drug Resist Updat 2010;13:132-138. 
50. Steimle A, Autenrieth IB, Frick JS. Structure and function: Lipid A modifications in 
commensals and pathogens. Int J Med Microbiol 2016;306:290-301. 
51. Poirel L, Jayol A, Nordmann P. Polymyxins: Antibacterial Activity, Susceptibility Testing, 
and Resistance Mechanisms Encoded by Plasmids or Chromosomes. Clin Microbiol Rev 
2017;30:557-596. 
52. Sidorczyk Z, Zahringer U, Rietschel ET. Chemical structure of the lipid A component of the 
lipopolysaccharide from a Proteus mirabilis Re-mutant. Eur J Biochem 1983;137:15-22. 
Chapter 1   
23 
 
53. Makimura Y, Asai Y, Sugiyama A, Ogawa T. Chemical structure and immunobiological 
activity of lipid A from Serratia marcescens LPS. J Med Microbiol 2007;56:1440-1446. 
54. Vinogradov E, Lindner B, Seltmann G, Radziejewska-Lebrecht J, Holst O. 
Lipopolysaccharides from Serratia marcescens possess one or two 4-amino-4-deoxy-L-
arabinopyranose 1-phosphate residues in the lipid A and D-glycero-D-talo-oct-2-ulopyranosonic 
acid in the inner core region. Chemistry 2006;12:6692-6700. 
55. Silipo A, Molinaro A, Cescutti P, Bedini E, Rizzo R et al. Complete structural 
characterization of the lipid A fraction of a clinical strain of B. cepacia genomovar I 
lipopolysaccharide. Glycobiology. 2005;15:561-570. 
56. Needham BD, Trent MS. Fortifying the barrier: the impact of lipid A remodelling on bacterial 
pathogenesis. Nat Rev Microbiol 2013;11:467-481. 
57. Gunn JS, Lim KB, Krueger J, Kim K, Guo L et al. PmrA-PmrB-regulated genes necessary 
for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol Microbiol 
1998;27:1171-1182. 
58. Cheng HY, Chen YF, Peng HL. Molecular characterization of the PhoPQ-PmrD-PmrAB 
mediated pathway regulating polymyxin B resistance in Klebsiella pneumoniae CG43. J 
Biomed Sci 2010;17:60. 
59. Moskowitz SM, Ernst RK, Miller SI. PmrAB, a two-component regulatory system of 
Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and 
addition of aminoarabinose to lipid A. J Bacteriol 2004;186:575-579. 
60. Winfield MD, Groisman EA. Phenotypic differences between Salmonella and Escherichia 
coli resulting from the disparate regulation of homologous genes. Proc Natl Acad Sci U S A 
2004;101:17162-17167. 
61. Winfield MD, Latifi T, Groisman EA. Transcriptional regulation of the 4-amino-4-deoxy-L-
arabinose biosynthetic genes in Yersinia pestis. J Biol Chem 2005;280:14765-14772. 
62. McPhee JB, Lewenza S, Hancock RE. Cationic antimicrobial peptides activate a two-
component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and 
cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol Microbiol 2003;50:205-217. 
63. Gunn JS, Miller SI. PhoP-PhoQ activates transcription of pmrAB, encoding a two-component 
regulatory system involved in Salmonella typhimurium antimicrobial peptide resistance. J 
Bacteriol 1996;178:6857-6864. 
Chapter 1   
24 
 
64. Velkov T, Soon RL, Chong PL, Huang JX, Cooper MA et al. Molecular basis for the 
increased polymyxin susceptibility of Klebsiella pneumoniae strains with under-acylated lipid 
A. Innate Immun 2013;19:265-277. 
65. Clements A, Tull D, Jenney AW, Farn JL, Kim SH et al. Secondary acylation of Klebsiella 
pneumoniae lipopolysaccharide contributes to sensitivity to antibacterial peptides. J Biol Chem 
2007;282:15569-15577. 
66. Tran AX, Lester ME, Stead CM, Raetz CR, Maskell DJ et al. Resistance to the 
antimicrobial peptide polymyxin requires myristoylation of Escherichia coli  and Salmonella 
typhimurium lipid A. J Biol Chem 2005;280:28186-28194. 
67. Han ML, Velkov T, Zhu Y, Roberts KD, Le Brun AP et al. Polymyxin-Induced Lipid A 
Deacylation in Pseudomonas aeruginosa Perturbs Polymyxin Penetration and Confers High-
Level Resistance. ACS Chem Biol 2018;13:121-130. 
68. Moffatt JH, Harper M, Adler B, Nation RL, Li J, Boyce JD. Insertion sequence ISAba11 is 
involved in colistin resistance and loss of lipopolysaccharide in Acinetobacter baumannii. 
Antimicrob Agents Chemother 2011;55:3022-3024. 
69. Beceiro A, Moreno A, Fernandez N, Vallejo JA, Aranda J et al. Biological cost of different 
mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii. 
Antimicrob Agents Chemother 2014;58:518-526. 
70. Llobet E, Tomas JM, Bengoechea JA. Capsule polysaccharide is a bacterial decoy for 
antimicrobial peptides. Microbiology 2008;154:3877-3886. 
71. Campos MA, Vargas MA, Regueiro V, Llompart CM, Alberti S, Bengoechea JA. Capsule 
polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect Immun 
2004;72:7107-7114. 
72. Weiss J, Victor M, Cross AS, Elsbach P. Sensitivity of K1-encapsulated Escherichia coli  to 
killing by the bactericidal/permeability-increasing protein of rabbit and human neutrophils. 
Infect Immun 1982;38:1149-1153. 
73. Mularski A, Wilksch J, Hanssen E, Li J, Tomita T et al. A nanomechanical study of the 
effects of colistin on the Klebsiella pneumoniae AJ218 capsule. Eur Biophys J 2017;46:351-
361. 
74. Padilla E, Llobet E, Domenech-Sanchez A, Martinez-Martinez L, Bengoechea JA, Alberti 
S. Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and 
virulence. Antimicrob Agents Chemother 2010;54:177-183. 
Chapter 1   
25 
 
75. Srinivasan VB, Rajamohan G. KpnEF, a new member of the Klebsiella pneumoniae cell 
envelope stress response regulon, is an SMR-type efflux pump involved in broad-spectrum 
antimicrobial resistance. Antimicrob Agents Chemother 2013;57:4449-4462. 
76. Fernandez L, Jenssen H, Bains M, Wiegand I, Gooderham WJ, Hancock RE. The two-
component system CprRS senses cationic peptides and triggers adaptive resistance in 
Pseudomonas aeruginosa independently of ParRS. Antimicrob Agents Chemother 
2012;56:6212-6222. 
77. Gutu AD, Sgambati N, Strasbourger P, Brannon MK, Jacobs MA et al. Polymyxin 
resistance of Pseudomonas aeruginosa phoQ mutants is dependent on additional two-
component regulatory systems. Antimicrob Agents Chemother 2013;57:2204-2215. 
78. Wright MS, Suzuki Y, Jones MB, Marshall SH, Rudin SD et al. Genomic and 
transcriptomic analyses of colistin-resistant clinical isolates of Klebsiella pneumoniae reveal 
multiple pathways of resistance. Antimicrob Agents Chemother 2015;59:536-543. 
79. Cheng YH, Lin TL, Lin YT, Wang JT. Amino acid substitutions of CrrB responsible for 
resistance to colistin through CrrC in Klebsiella pneumoniae. Antimicrob Agents Chemother 
2016;60:3709-3716. 
80. Cannatelli A, Giani T, D'Andrea MM, Di Pilato V, Arena F et al. MgrB inactivation is a 
common mechanism of colistin resistance in KPC-producing Klebsiella pneumoniae of clinical 
origin. Antimicrob Agents Chemother 2014;58:5696-5703. 
81. Poirel L, Jayol A, Bontron S, Villegas MV, Ozdamar M et al. The mgrB gene as a key target 
for acquired resistance to colistin in Klebsiella pneumoniae. J Antimicrob Chemother 
2015;70:75-80. 
82. De Majumdar S, Yu J, Fookes M, McAteer SP, Llobet E et al. Elucidation of the RamA 
regulon in Klebsiella pneumoniae reveals a role in LPS regulation. PLoS Pathog 
2015;11:e1004627. 
83. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R et al. Emergence of plasmid-mediated colistin 
resistance mechanism MCR-1 in animals and human beings in China: a microbiological and 
molecular biological study. Lancet Infect Dis 2016;16:161-168. 
84. Stoesser N, Mathers AJ, Moore CE, Day NP, Crook DW. Colistin resistance gene mcr-1 and 
pHNSHP45 plasmid in human isolates of Escherichia coli  and Klebsiella pneumoniae. Lancet 
Infect Dis 2016;16:285-286. 
Chapter 1   
26 
 
85. Sun J, Zhang H, Liu YH, Feng Y. Towards Understanding MCR-like Colistin Resistance. 
Trends Microbiol 2018;pii: S0966-842X(18)30042-8. 
86. Tietgen M, Semmler T, Riedel-Christ S, Kempf VAJ, Molinaro A et al. Impact of the 
colistin resistance gene mcr-1 on bacterial fitness. Int J Antimicrob Agents 2018;51:554-561. 
87. Hindler JA, Humphries RM. Colistin MIC variability by method for contemporary clinical 
isolates of multidrug-resistant Gram-negative bacilli. J Clin Microbiol 2013;51:1678-1684. 
88. Tan TY, Ng SY. Comparison of Etest, Vitek and agar dilution for susceptibility testing of 
colistin. Clin Microbiol Infect 2007;13:541-544. 
89. Nordmann P, Jayol A, Poirel L. Rapid Detection of Polymyxin Resistance in 
Enterobacteriaceae. Emerg Infect Dis 2016;22:1038-1043. 
90. Larrouy-Maumus G, Clements A, Filloux A, McCarthy RR, Mostowy S. Direct detection 
of lipid A on intact Gram-negative bacteria by MALDI-TOF mass spectrometry. J Microbiol 
Methods 2016;120:68-71. 
91. Srinivas P, Hunt LN, Pouch SM, Thomas K, Goff DA et al. Detection of colistin 
heteroresistance in Acinetobacter baumannii from blood and respiratory isolates. Diagn 
Microbiol Infect Dis 2018;91:194-198. 
92. Halaby T, Kucukkose E, Janssen AB, Rogers MR, Doorduijn DJ et al. Genomic 
characterization of colistin heteroresistance in Klebsiella pneumoniae during a nosocomial 
outbreak. Antimicrob Agents Chemother 2016. 
93. Gardy JL, Loman NJ. Towards a genomics-informed, real-time, global pathogen surveillance 
system. Nat Rev Genet 2018;19:9-20. 
94. Cao MD, Ganesamoorthy D, Elliott AG, Zhang H, Cooper MA et al. Streaming algorithms 
for identification of pathogens and antibiotic resistance potential from real-time MinIONTM 
sequencing. Gigascience 2016;5:32. 
95. Spapen H, Jacobs R, Van Gorp V, Troubleyn J, Honore PM. Renal and neurological side 
effects of colistin in critically ill patients. Ann Intensive Care 2011;1:14. 
96. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, 
outcome measures, animal models, fluid therapy and information technology needs: the Second 
International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. 
Crit Care 2004;8:R204-212. 
Chapter 1   
27 
 
97. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ et al. Incidence of and risk factors for 
colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 
2011;53:879-884. 
98. Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML et al. High-dose, extended-interval 
colistin administration in critically ill patients: is this the right dosing strategy? A preliminary 
study. Clin Infect Dis 2012;54:1720-1726. 
99. Abdelraouf K, Chang KT, Yin T, Hu M, Tam VH. Uptake of polymyxin B into renal cells. 
Antimicrob Agents Chemother 2014;58:4200-4202. 
100. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Use of high-
performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats 
following intravenous administration. Antimicrob Agents Chemother 2003;47:1766-1770. 
101. Abdelraouf K, He J, Ledesma KR, Hu M, Tam VH. Pharmacokinetics and renal disposition 
of polymyxin B in an animal model. Antimicrob Agents Chemother 2012;56:5724-5727. 
102. Zavascki AP, Goldani LZ, Cao G, Superti SV, Lutz L et al. Pharmacokinetics of intravenous 
polymyxin B in critically ill patients. Clin Infect Dis 2008;47:1298-1304. 
103. Dai C, Li J, Tang S, Li J, Xiao X. Colistin-induced nephrotoxicity in mice involves the 
mitochondrial, death receptor, and endoplasmic reticulum pathways. Antimicrob Agents 
Chemother 2014;58:4075-4085. 
104. Azad MA, Finnin BA, Poudyal A, Davis K, Li J et al. Polymyxin B induces apoptosis in 
kidney proximal tubular cells. Antimicrob Agents Chemother 2013;57:4329-4335. 
105. Eadon MT, Hack BK, Alexander JJ, Xu C, Dolan ME, Cunningham PN. Cell cycle arrest 
in a model of colistin nephrotoxicity. Physiol Genomics 2013;45:877-888. 
106. Meyers E, Parker WL, Brown WE, Linnett P, Strominger JL. EM49: a new polypeptide 
antibiotic active against cell membranes. Ann N Y Acad Sci 1974;235:493-501. 
107. Parker WL, Rathnum ML. EM49, a new peptide antibiotic. II. Chemical characterization. J 
Antibiot (Tokyo) 1973;26:449-456. 
108. Qian CD, Wu XC, Teng Y, Zhao WP, Li O et al. Battacin (Octapeptin B5), a new cyclic 
lipopeptide antibiotic from Paenibacillus tianmuensis active against multidrug-resistant Gram-
negative bacteria. Antimicrob Agents Chemother 2012;56:1458-1465. 
109. Meyers E, Brown WE, Principe PA, Rathnum ML, Parker WL. EM49, a new peptide 
antibiotic. I. Fermentation, isolation, and preliminary characterization. J Antibiot (Tokyo) 
1973;26:444-448. 
Chapter 1   
28 
 
110. Shoji J, Hinoo H, Wakisaka Y, Koizumi K, Mayama M. Isolation of a new antibiotic 333-
25, related to antibiotic EM 49. (Studies on antibiotics from the genus Bacillus. XI). J Antibiot 
(Tokyo) 1976;29:516-520. 
111. Shoji J, Sakazaki R, Wakisaka Y, Koizumi K, Matsuura S et al. Isolation of octapeptin D 
(studies on antibiotics from the genus Bacillus. XXVII). J Antibiot (Tokyo) 1980;33:182-185. 
112. Sugawara K, Yonemoto T, Konishi M, Matsumoto K, Miyaki T, Kawaguchi H. Bu-2470, a 
new peptide antibiotic complex. II. Structure determination of Bu-2470 A, B1, B2a and B2b. J 
Antibiot (Tokyo) 1983;36:634-638. 
113. Meyers E, Parker WL, Brown WE. A nomenclature proposal for the octapeptin antibiotics. J 
Antibiot (Tokyo) 1976;29:1241-1242. 
114. Meyers E, Pansy FE, Basch HI, McRipley RJ, Slusarchyk DS et al. EM49, a new peptide 
antibiotic. III. biological characterization in vitro and in vivo. J Antibiot (Tokyo) 1973;26:457-
462. 
115. Kato T, Shoji J. The amino acid sequence of octapeptin C1 (333-25) studies on antibiotics 
from the genus Bacillus. XIX. J Antibiot (Tokyo) 1976;29:1339-1340. 
116. Cochrane SA, Vederas JC. Lipopeptides from Bacillus and Paenibacillus spp.: A Gold Mine 
of Antibiotic Candidates. Med Res Rev 2016;36:4-31. 
117. Konishi M, Sugawara K, Tomita K, Matsumoto K, Miyaki T et al. Bu-2470, a new peptide 
antibiotic complex. I. Production, isolation and properties of Bu-2470 A, B1 and B2. J Antibiot 
(Tokyo) 1983;36:625-633. 
118. Velkov T, Roberts KD, Li J. Rediscovering the octapeptins. Nat Prod Rep 2017;34:295-309. 
119. Becker B, Butler MS, Hansford KA, Gallardo-Godoy A, Elliott AG et al. Synthesis of 
octapeptin C4 and biological profiling against NDM-1 and polymyxin-resistant bacteria. Bioorg 
Med Chem Lett 2017;27:2407-2409. 
120. Han ML, Shen HH, Hansford KA, Schneider EK, Sivanesan S et al. Investigating the 
interaction of Octapeptin A3 with model bacterial membranes. ACS Infect Dis. 2017;3:606-619. 
121. Chitty JL, Butler MS, Suboh A, Edwards DJ, Cooper MA et al. Antimicrobial Octapeptin 
C4 Analogues Active against Cryptococcus Species. Antimicrob Agents Chemother 2018;62. 
122. Velkov T, Gallardo-Godoy A, Swarbrick JD, Blaskovich MAT, Elliott AG et al. Structure, 
Function, and Biosynthetic Origin of Octapeptin Antibiotics Active against Extensively Drug-
Resistant Gram-Negative Bacteria. Cell Chem Biol 2018;25:380-391.e385. 
Chapter 1   
29 
 
123. Rosenthal KS, Swanson PE, Storm DR. Disruption of Escherichia coli  outer membranes by 
EM 49. A new membrane active peptide. Biochemistry 1976;15:5783-5792. 
124. De Zoysa GH, Cameron AJ, Hegde VV, Raghothama S, Sarojini V. Antimicrobial peptides 
with potential for biofilm eradication: synthesis and structure activity relationship studies of 
battacin peptides. J Med Chem 2015;58:625-639. 
125. Martin RM, Bachman MA. Colonization, Infection, and the Accessory Genome of Klebsiella 
pneumoniae. Front Cell Infect Microbiol 2018;8:4. 
126. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant 
Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. 
Infect Control Hosp Epidemiol 2008;29:1099-1106. 
Chapter 2 
30 
 
Chapter 2 
Evaluating genomic variations contributing to polymyxin resistance in clinical isolates 
 
2.1. Chapter introduction 
 
This chapter investigates the genetic basis for polymyxin resistance in 24 clinical K. pneumoniae 
strains isolated from Greece and Brazil during 2012 to 2014. Antimicrobial susceptibility testing 
was conducted at the Institute for Molecular Bioscience (IMB) to confirm the original reported 
clinical profiles. All isolates were validated to be extensively drug-resistant (XDR). To determine 
genomic variants contributing to polymyxin resistance, whole genome sequencing (Illumina) was 
performed on 24 isolates. Five of these isolates were polymyxin-susceptible, selected to discern 
lineage specific mutations not contributing to resistance. Complementation assays were conducted 
to determine the contributions of identified genomic changes towards resistance. Mutations unique 
to resistant isolates were cloned and introduced into a susceptible isolate and vice versa. 
Supplementary information for this chapter is located in Appendix I, pages 109-116. 
 
2.2. Publication 
These research findings have been published: Pitt ME, Elliott AG, Cao MD, Ganesamoorthy D, 
Karaiskos I, Giamarellou H, Abboud CS, Blaskovich MAT, Cooper MA, Coin LJM. 
Multifactorial chromosomal variants regulate polymyxin resistance in extensively drug-resistant 
Klebsiella pneumoniae. Microb Genom 2018;doi: 10.1099/mgen.0.000158. This publication can be 
obtained, including supplementary information, via the following link: 
http://mgen.microbiologyresearch.org/content/journal/mgen/10.1099/mgen.0.000158.  
This manuscript has been reproduced on pages 31-54 of Chapter 2. Minor changes have been 
implemented to retain formatting consistency throughout this thesis including the removal of the 
impact statement, keywords and acknowledgements (refer to page X for financial support of this 
manuscript) and the modification of figure names and nomenclature. As the first author, I am the 
primary contributor to the study design, data acquisition, data analysis and writing of the 
manuscript. I have predominantly designed this study, in particular, the experimental approaches. I 
have performed experiments including the majority of the antimicrobial susceptibility assays, 
complementation assays and genomic analysis. I have contributed to the interpretation of all 
experiments or data and have generated all the tables and figures in this manuscript and 
supplementary material. I drafted this manuscript and collated all comments from other authors to 
generate this published work. 
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2.3. Abstract 
 
Extensively drug-resistant (XDR) Klebsiella pneumoniae infections cause high mortality and are 
disseminating globally. Identifying the genetic basis underpinning resistance allows for rapid 
diagnosis and treatment. XDR isolates sourced from Greece and Brazil, including nineteen 
polymyxin-resistant and five polymyxin-susceptible strains, underwent whole genome sequencing. 
Seventeen of the nineteen polymyxin-resistant isolates harboured variations upstream or within 
mgrB. The most common mutation identified was an insertion at nucleotide position 75 in mgrB via 
an ISKpn26-like element in the ST258 lineage and ISKpn13 in one ST11 isolate. Three strains 
acquired an IS1 element upstream of mgrB and another strain had an ISKpn25 insertion at 133 bp. 
Other isolates had truncations (C28STOP, Q30STOP) or a missense mutation (D29E) affecting 
mgrB. Complementation assays revealed all mgrB perturbations contributed to resistance. Missense 
mutations in phoQ (T281M, G385C) were also found to facilitate resistance. Several variants in 
phoPQ co-segregating with the ISKpn26-like insertion were identified as potential partial 
suppressor mutations. Three ST258 samples were found to contain subpopulations with different 
resistance conferring mutations, including the ISKpn26-like insertion colonising with a novel 
mutation in pmrB (P158R), both confirmed via complementation assays. These findings highlight 
the broad spectrum of chromosomal modifications which can facilitate and regulate resistance 
against polymyxins in K. pneumoniae. 
 
2.4. Introduction 
 
Klebsiella pneumoniae strains classified as extensively drug-resistant (XDR) are rapidly emerging 
due to the dissemination of plasmid-encoded resistance towards aminoglycosides, β-lactams, 
fluoroquinolones and carbapenems (1). Notably, carbapenem-resistant K. pneumoniae have been 
linked to high morbidity and an overall mortality of 48% in infected patients (2). Polymyxin B and 
colistin (polymyxin E) are now one of the last viable therapeutic options (3). Unfortunately, 
resistance to this last-line antibiotic class is an increasing global burden, with countries particularly 
impacted including Asia (South Korea (4, 5), India (6, 7)), Europe (Greece (8-10)), Italy (10, 11)) 
and Latin America (Brazil (12, 13)). Mortality is influenced by polymyxin resistance typically 
occurring on a multidrug-resistant (MDR) or XDR background; nephrotoxicity leading to 
suboptimal dosing as well as inadequacies in detection of heteroresistance (10, 14). As a result, 
there is considerable uncertainty regarding the mortality associated with polymyxin-resistant 
infections. Combining several clinical cohorts has provided overall mortality estimates ranging 
from 20% to 100% (10). 
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Polymyxins infiltrate Gram-negative bacteria via initial binding to the basal component of 
lipopolysaccharide, lipid A. This causes the displacement of Mg2+ and Ca2+, disrupting the  outer 
and inner membrane integrity, resulting in leakage of cytoplasmic contents  and subsequent cell 
death, however, the exact mechanism remains elusive (15, 16). Inhibition of an intracellular target, 
the type II NADH-quinolone oxidoreductases, imbedded in the inner membrane has also been 
identified (17). An exposure in K. pneumoniae leads to the emergence of polymyxin resistance by 
triggering the activation of the two-component regulatory systems, PmrAB and PhoPQ (18-20). 
These systems regulate a pathway that modulates pmrC and the pmrHFIJKLM operon facilitating 
the addition of phosphoethanolamine (pEtN) and/ or 4-amino-4-deoxy-L-arabinose to lipid A 
phosphate groups, resulting in impaired polymyxin binding interactions (21-23). Disruption of 
mgrB, the negative regulator of PhoPQ, has been commonly observed in isolates of clinical origin 
(8, 24). The constitutive up-regulation of pmrC and the pmrHFIJKLM operon incurs a minimal 
fitness cost and appears to be stable, with minimal reports of reversions (25, 26). Heteroresistant 
populations, where only a subset of bacteria are resistant in a phenotypically susceptible sample, 
have been reported in K. pneumoniae which complicates diagnosis (27). The emergence of 
pandrug-resistant K. pneumoniae is of grave concern (28) and this acquisition of resistance is 
further exacerbated by the recently reported plasmid-encoded colistin resistance gene mcr-1, which 
encodes a pEtN transferase enzyme (29, 30). The presence of mcr genes in K. pneumoniae is 
currently a rarity with only a few reports of mcr-1, -1.2 and -3 (31-33). Göttig et al has recently 
established a fitness cost associated with K. pneumoniae harbouring mcr-1, dissimilar Escherichia 
coli, which may explain the lack of isolates acquiring this gene (34). 
This study aimed to investigate XDR K. pneumoniae clinical isolates arising in Greece and Brazil 
during 2012 to 2014 to identify and validate genetic variants contributing to resistance. These 
variants were compared to prior clinical isolates to ascertain if these mutations have been previously 
detected globally. 
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2.5. Materials and Methods 
 
2.5.1. Bacterial isolates 
 
Polymyxin-resistant XDR K. pneumoniae clinical isolates were acquired from the Hygeia General 
Hospital, Athens, Greece and Instituto Dante Pazzanese de Cardiologia, Brazil from patients in 
2012 to 2014. These isolates were sampled at random (non-sequential). We also obtained five 
polymyxin-susceptible strains which were utilised as a genomic background reference and a 
negative control for complementation assays. Cultures were supplied as stabs/slants or on agar, and 
were subsequently cultured in Nutrient Broth. Cultures were made to 20% (v/v) glycerol and stored 
at -80 °C. When required for assay or extraction, glycerol stocks were struck out to obtain single 
colonies on either Nutrient Agar or Tryptic Soy Agar with 5% defibrinated sheep blood. Reference 
strains included Escherichia coli (ATCC 25922) and Klebsiella spp. (ATCC 13883, ATCC 700603, 
ATCC BAA-2146), which were obtained from the American Type Culture Collection (ATCC; 
Manassas, VA, USA). 
 
2.5.2. Antimicrobial susceptibility assays 
 
Species identification and susceptibility profiles of clinical isolates from Greece and Brazil were 
evaluated in the clinic using VITEK®2 (bioMérieux). Strains were further validated at the Institute 
for Molecular Bioscience (IMB) (The University of Queensland, Australia) using the standard 
Clinical & Laboratory Standards Institute (CLSI) approved broth microdilution (BMD) methods 
with cation-adjusted Mueller-Hinton Broth (caMHB). Resistance was determined as per CLSI 
guidelines (35) except for tigecycline and fosfomycin where The European Committee on 
Antimicrobial Susceptibility Testing (EUCAST) (Version 7.1, 2017) (see http://www.eucast.org) 
guidelines were implemented. Classification of isolates as MDR and XDR  was determined through 
guidelines previously outlined (36).  
 
2.5.3. DNA extraction 
 
Isolates selected for sequencing exhibited a polymyxin-resistant XDR profile with five polymyxin-
susceptible strains included to discern the mutations in mgrB, pmrAB and phoPQ segregating with 
susceptible isolates. DNA was extracted from overnight cultures using the DNeasy Blood and 
Tissue Kit (Qiagen) with the additional enzymatic lysis buffer pre-treatment as per manufacturer’s 
instructions. DNA was quantified with Qubit®3.0 (ThermoFisher Scientific).  
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2.5.4. DNA library preparation and sequencing 
 
Library preparation was performed using the Nextera XT kit (Illumina) with 1 ng input of DNA as 
per manufacturer’s instructions. Quality of libraries were checked using a 2100 Bioanalyzer 
(Agilent Technologies). Libraries were prepared using the 2 x 300 v3 MiSeq kit and sequenced on 
an Illumina MiSeq with 300 bp paired-end sequencing reads and >100X coverage per sample. 
 
2.5.5. Sequencing analysis 
 
Paired-end reads were trimmed with Trimmomatic (37) and assembled using SPAdes (38). The 
Rapid Annotation using Subsystem Technology (RAST) was utilized to annotate assembled 
genomes (39). Assemblies were also uploaded to the Centre for Genomic Epidemiology (CGE) to 
identify sequence types (STs) (MultiLocus Sequence Typing Server 1.8 (40)) and acquired 
antibiotic resistance genes (ResFinder 3.0 (41)). A neighbor-joining tree was constructed using the 
2358 Klebsiella pneumoniae/quasipneumoniae/variicola genes known to form the core genome 
MLST (cgMLST) using Ridom SeqSphere+ v4.0.1 software (42). Complete assemblies of 
publically available reference genomes were obtained from 
www.ncbi.nlm.nih.gov/genome/?term=klebsiella. Sequence type references included HS11286 
(ST11), MS6671 (ST147) and NJST258_1 and NJST258_2 (ST258). Species references were K. 
quasipneumoniae (ATCC 700603, HKUOPA4) and K. variicola (At-22, GJ1). 
 
2.5.6. Variant detection 
 
Variants both in and flanking the genes pmrAB, phoPQ and mgrB were examined and sequence 
reads of all strains were aligned to the assembly of 20_GR_12, a polymyxin-susceptible ST258 
strain with the least number of contigs, using BWA-MEM (43). The alignment was analyzed 
through FreeBayes (44) to identify single nucleotide and small indel variation, using a diploid 
analysis. The diploid analysis displays reads mapping to the predominant variant in the isolate and 
if a variant in lower abundance (≥20% of reads) was identified, this was classified as heterogeneity. 
The effects of variations were determined by snpEff (45). The impact on protein sequence was 
further confirmed by the Protein Variation Effect Analyzer (PROVEAN) (46). For the analysis of 
large chromosome changes, the gene sequences including 300 bp flanking were extracted from the 
assemblies. A multiple alignment of each gene was constructed from the pair-wise alignment to the 
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longest gene sequence. Furthermore, assemblies of the five genes were aligned to the reference 
polymyxin-susceptible isolate ATCC 700603 to discern lineage and species specific variation. 
 
2.5.7. Insertion sequence element validation 
 
ISFinder (47) was used for the identification of insertion sequence (IS) elements. To confirm 
disruptive IS elements, mgrB was amplified with primers displayed in Table S2.1. via 2X Phusion 
HF master mix (Invitrogen) under the following cycling conditions: 98 °C 10 seconds, 50 °C 30 
seconds and 72 °C 60 seconds (35X). Amplicon identity was validated via Sanger sequencing.  
 
2.5.8. Complementation assays 
 
The contribution of variants to resistance was validated through complementation assays as 
previously described (48). Briefly, genes (Table S2.1.) were amplified from a polymyxin-
susceptible isolate, 20_GR_12, and cloned into the pCR-Blunt II-TOPO vector via the Zero Blunt 
TOPO PCR cloning kit (Invitrogen). Chemically competent E. coli TOP10 cells were transformed 
and selected by the addition of 50 mg/L kanamycin in MHA. Isolation of plasmids were via the 
PureLink™ Quick Plasmid Miniprep Kit (Invitrogen). The methodology for preparing 
electrocompetent cells and complementation assays was kindly provided by Dr Aurélie Jayol and 
Professor Patrice Nordmann. Briefly, overnight cultures were subcultured into 200 ml lysogeny 
broth (1: 100 dilution) and grown to an OD600 of 0.6±0.05. Cells were chilled on ice before 
centrifugation (10 000 rpm, 10 minutes, 4°C), washed 2 times with ice cold 10% glycerol and 
concentrated to 500 µl. K. pneumoniae isolates were transformed via electroporation (25 µF, 200 Ω, 
1.25 kV/cm) with a Gene Pulser (Bio-Rad Laboratories). Selection was accomplished through 
supplementation of ≥500 mg/L zeocin in MHA plates. Transformed colonies (n= ≥2) were acquired 
and placed in MHB containing 1500 mg/L zeocin and 1 mM isopropyl β-D-1-thiogalactopyranoside 
(Sigma Aldrich). If polymyxin susceptibility was not restored upon complementation, genes 
harboring mutations were further amplified and introduced into 20_GR_12. To discern the impact 
of additional mutations in phoPQ and pmrB segregating with disrupted mgrB, mutant genes were 
introduced into a polymyxin-resistant isolate only harboring an IS element mgrB disruption, 
7_GR_13. Controls included transformation of WT genes into 20_GR_12, sequencing of amplicon 
prior to introduction in vector and K. pneumoniae transformed strains undergoing a plasmid 
extraction and further PCR of the multiple cloning site. Antimicrobial testing against colistin and 
polymyxin B were conducted as described above. 
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2.5.9. Data summary 
 
Whole genome sequencing of the 24 clinical isolates has been deposited under BioProject 
PRJNA307517 (www.ncbi.nlm.nih.gov/bioproject/PRJNA307517). 
 
2.6. Results 
 
2.6.1. Characterisation of clinical isolates 
 
K. pneumoniae isolates were all characterized in the hospital microbiology facility using VITEK®2. 
Several discrepancies were detected between VITEK®2 and broth microdilution (BMD) results 
(Table 2.1., Table S2.2.), predominantly the level of resistance towards aminoglycosides, 
tetracyclines, fosfomycin and tigecycline. A major dissimilarity was polymyxin susceptibility in 
6_GR_12 (sensitive in BMD, resistant in VITEK®2) and resistant in 23_GR_13 (resistant in BMD, 
sensitive in VITEK®2). Polymyxin resistance was identified in 19 of the isolates and MICs ranged 
from 8 to >64 mg/L. An abundance of acquired resistance genes (Table 2.2.) were detected and this 
presence corresponded to the antimicrobial testing phenotype. This analysis did not identify mcr 
genes (-1, -2, -3, -4, -5) in these strains. Only 18_GR_14 and 19_GR_14 were not identified as 
extended-spectrum beta-lactamase producers amongst the polymyxin-resistant strains. 
Consequently, all polymyxin-resistant strains that harbored non-susceptibility to at least one 
antibiotic in 15 or more of the 17 antimicrobial categories hence were defined as XDR. 
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Table 2.1. Broth microdilution and VITEK®2 antimicrobial testing for the 24 clinical isolates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strain
*
 Source
†
 
Resistance Profile
‡
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
A
M
K
 
G
E
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O
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C
P
T
 
T
Z
P
 
IP
M
 
M
E
M
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E
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T
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T
 
T
G
C
 
A
T
M
 
A
M
P
 
S
A
M
 
C
H
L
 
F
O
F
 
C
S
T
 
M
IN
 
T
E
T
 
1_GR_13 St R R R RN R R R RN R R R R R R R R R R R R R R R 
2_GR_12 U R R R RN R R R RN R R R R R R IR R R R R RS R R R 
3_GR_13 S R R R RN R R R RN RI R R R R R I R R R R R RI IR R 
4_GR_12 B R R R RN R R R RN R R R R R R IR R R R R R R IR R 
5_GR_13 St S S I RN R R R RN R R R R R R IR R R R R R R R R 
6_GR_12 St S S IR RN R R R RN R R R R R R R R R R R R SR IR R 
7_GR_13 St R S R RN R R R RN R R R R R R R R R R R R R SR SI 
8_GR_13 St R R R RN R R R RN R R R R R R R R R R R R R R R 
9_GR_12 Br IR S R RN R R R RN R R R R R R IR R R R R R R IR SI 
10_GR_13 B SR S R RN R R R RN R R R R R R I R R R R R R SR SI 
11_BR_13 U S S RN RN R R R RN R R R R R RN I R R R SN RN R SN SN 
12_BR_13 Br S RS IN RN R R R RN RI R R R R RN IR R R R RN RN R IN SN 
13_GR_14 Br IR S R RN R R R RN R RN R R R R SR R R R R R R SI SI 
14_GR_14 U IR SR R RN R R R RN R RN R R R R SR R R R R R R SR SR 
15_GR_13 St IR S R RN R R R RN RI RN R R R R IR R R R R R R SI S 
16_GR_13 St R R R RN R R R RN R RN R R R R RI R R R R R R IR R 
17_GR_14 St R R R RN R R R RN R RN R R R R I R R R R R R SR R 
18_GR_14 St IR S R RN R R R RN R R R R R R I R R R R R R SI S 
19_GR_14 St IR S R RN R R R RN R R R R R R R R R R R R R IR IR 
20_GR_12 St R S R RN R R R RN RI R R R R R R R R R R R S R R 
21_GR_13 U S SR I RN R R IR RN RI R R R S R S S R R S S S S S 
22_GR_12 S IR S R RN R R R RN RI R R R R R I R R R R RS S SI S 
23_GR_12 St R R R RN R R R RN R R R R R R R R R R R RS RS R R 
24_GR_13 St IR S R RN R R R RN RI R R R R R IR R R R R R S IR S 
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*Strain identification, numerical order catalogued at IMB_Country (GR:Greece, BR:Brazil)_last 
two digits of isolation year.  
†Source represented as B, Blood; Br; Bronchial secretion; U, Urine; S, Sputum; St, Stool. 
‡Antibiotic resistance as determined by broth microdilution according to CLSI guidelines 
(EUCAST for fosfomycin (disk diffusion) and tigecycline) and in superscript, any discrepancies 
identified in VITEK®2 results. Antibiotic classes tested include 1, Aminoglycosides (Amikacin, 
AMK; Gentamicin, GEN; Tobramycin, TOB); 2, Anti-MRSA cephalosporins (Ceftaroline, CPT); 3, 
Antipseudomonal penicillins + β-lactamase inhibitors (Piperacillin-tazobactam, TZP); 4, 
Carbapenems (Imipenem, IPM; Meropenem, MEM); 5, Non-extended spectrum cephalosporins (1st 
and 2nd generation) (Cefazolin, CFZ); 6, Extended-spectrum cephalosporins (3rd and 4th generation) 
(Cefepime, FEP; Cefotaxime, CTX, Ceftazidime, CAZ); 7, Cephamycins (Cefoxitin, FOX); 8, 
Fluoroquinolones (Ciprofloxacin, CIP); 9, Folate pathway inhibitors (Trimethoprim-
sulfamethoxazole, SXT); 10, Glycylcyclines (Tigecycline, TGC); 11, Monobactams (Aztreonam, 
ATM); 12, Penicillins (Ampicillin, AMP); 13, Penicillins + β-lactamase inhibitors (Amipicillin-
sulbactam, SAM); 14, Phenicols (Chloramphenicol, CHL); 15, Phosphonic acids (Fosfomycin, 
FOF); 16, Polymyxins (Colistin, CST); 17, Tetracyclines (Minocycline, MIN; Tetracycline, TET). 
Shading indicates R, Resistant; I, Intermediate; S, Susceptible; N, Not tested 
 
2.6.2. Sequence type determination 
 
Sixteen of the twenty-two Greece clinical strains were found to belong to ST258 and the remaining 
were ST11, ST147 or ST383 (Table 2.1.). While 5_GR_13 and 6_GR_12 were both ST383, only 
5_GR_13 was resistant to polymyxin. Among the two strains from Brazil, 11_BR_13 was ST437 
and 12_BR_13 was ST11. 21_GR_13 had a profile previously undefined and has been newly 
designated ST2401. Further cgMLST studies were conducted on the isolates using complete 
assemblies of reference genomes for ST11 (HS11286), ST147 (MS6671) ST258 (NJST258_1, 
NJST258_2), K. quasipneumoniae (K. quasipneumoniae) (ATCC 700603, HKUOPA4) and K. 
variicola (K. variicola) (At-22, GJ1) (Figure 2.1.). For the ST258 isolates, these were more similar 
to NJST258_2 rather than NJST258_1. Within this cluster, 7_GR_13, 9_GR_12 and 24_GR_13 
were closely related (≤15 allelic changes). Similarly, grouped together were 2_GR_12 and 
23_GR_12; 3_GR_13 and 22_GR_12; 13_GR_14 and 14_GR_14; and 18_GR_14 and 19_GR_14. 
In ST11, 16_GR_13 and 17_GR_14 harboured only 3 allele differences and the Brazilian isolate, 
12_BR_13, had 206 variants apparent. ST383 isolates 5_GR_13 and 6_GR_12 only exhibited 1 
allele change. ST147 1_GR_13 was not clonal to the previous pandrug resistant K. pneumoniae, 
MS6671. Clustering analysis revealed 21_GR_13 as K. quasipneumoniae rather than K. variicola. 
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Figure 2.1. Neighbor-joining tree of core genome MLST of 24 Klebsiella clinical isolates. 
Clustering of sequence type (ST) indicated at base of diverging branch. ST# indicates an 
uncharacterized MLST according to MLST server 1.8. cgMLST compared to completed assemblies 
including HS11286 (ST11), MS6671 (ST147) and NJST258_1 and NJST258_2 (ST258). 
Assemblies were also compared against K. quasipneumoniae (ATCC 700603, HKUOPA4) and K. 
variicola (At-22, GJ1) genomes. 
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2.6.3. MgrB disruption 
 
Seventeen of the nineteen polymyxin-resistant strains exhibited either missense mutations, nonsense 
mutations or IS elements in mgrB (Table 2.2.). Both 5_GR_13 and 19_GR_14 harbored a 
truncation while an amino acid change, D29E, was apparent in 3_GR_13. IS element disruptions in 
mgrB were present in fourteen strains and in nine isolates, an IS5-like element was integrated at 
nucleotide position 75 (Figure S2.1.). Sanger sequencing revealed this element was closely related 
to ISKpn26, herein known as ISKpn26-like, except for 12_BR_13 which matched ISKpn13. IS1R 
was detected upstream of mgrB in 11_BR_13 and an IS1R-like (A>C, 393 bp; C>T, 396 bp) 
element in 16_GR_13 and 17_GR_14. Strain 15_GR_13 had a deletion of the mgrB locus from 
nucleotide position 133 onwards. The 127 bp flanking region mapped to ISKpn25 with the 
transposase in the same orientation as mgrB. All 3 of IS1 element insertions, but only one of the 8 
ISKpn26-like element insertions had the transposase in the same orientation as mgrB. 
 
2.6.4. Single, multiple and heterogeneous mutations 
 
Mutations in genes commonly identified to confer polymyxin resistance in K. pneumoniae include 
mgrB, phoPQ and pmrAB (Table 2.2.). Several non-synonymous mutations were identified across 
the isolates (Table S2.3.). These mutations were analysed through the prediction tool, PROVEAN, 
and not all were identified to be deleterious, however, this does not negate a functional purpose for 
these variants. ST383 contained several mutations in pmrAB although only Q30STOP in 
polymyxin-resistant 5_GR_13 was predicted to have an impact. Similarly, neutral changes in all 
four of these genes were detected in polymyxin-susceptible K. quasipneumoniae strains ATCC 
700603 and 21_GR_13. 8_GR_13 and 9_GR_12 harbored a single detrimental missense mutation 
in phoQ. Seven of the seventeen isolates containing an mgrB variant were accompanied by one or 
more missense mutations in phoPQ and/ or pmrB. Predicted deleterious variants segregating with 
disrupted mgrB included pmrB (T140P, P158R), phoP (P74L, A95S) and phoQ (N253T, V446G), 
which were commonly in the ST258 lineage. V446G (phoQ) and P158R (pmrB) were 
heterogeneous in 13_GR_14 (65% (V446G), 66% (P158R) mutation allele frequency) and 
14_GR_14 (52% (V446G) and 57% (P158R) mutation allele frequency). Assembly revealed 
23_GR_12 harbored an ISKpn26-like disrupted mgrB alongside the intact version with mutations in 
phoP and phoQ in 57% of the sample. Furthermore, assemblies for mgrB, pmrAB and phoPQ were 
aligned to ATCC 700603 (Table S2.4.). Several non-synonymous mutations were detected, 
however, the majority were not predicted to be deleterious. Various mutations were unique to K. 
pneumoniae compared to K. quasipneumoniae. ST11, 147, 258 and 437 remained conserved across 
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these genes with the exception of mutations predicted to be deleterious. ST383 harboured several 
dissimilarities including the lack of pmrA (D131N), pmrB (S105N) and gain of pmrA (G144D, 
D149E) and pmrB (A5V, M175V). Only subtle differences were observed in K. quasipneumoniae 
isolate 21_GR_ 13 which included pmrA (I220N, D221E) and pmrB (G358A).Predicted deleterious 
mutations detected both in polymyxin-susceptible and –resistant isolates included pmrA (Q140L) 
and pmrB (R256G). 
 
2.6.5. Role of mgrB disruptions and presence of heterogeneity via complementation assays 
 
Complementation of the WT gene elucidated the role of these mutations in resistance (Figure 2.2.). 
MICs were performed against polymyxin B and colistin, however, no difference was observed. 
Introduction of pTOPO-mgrB restored susceptibility in all resistant isolates with mgrB coding 
mutations or upstream disruptions, with the exception of two strains heterogeneous for the mgrB 
disruption and a pmrB coding mutation (13_GR_14 and 14_GR_14) (Figure 2.2.a). For these two 
strains, pTOPO-mgrB restored susceptibility in zero of three 13_GR_14 colonies and one of three 
14_GR_14 colonies. Transformation of 1 out of 3 colonies for both 13_GR_14 and 14_GR_14 
strains with pTOPO-pmrB restored susceptibility (Figure 2.2.d) and mgrB amplification of these 
colonies revealed an intact mgrB locus (Figure S2.2.). Colonies which were reverted on 
complementation were further passaged 3 times with no antibiotic pressure in order to remove the 
plasmid and discern if these mutations were contributing to resistance. After passaging, pTOPO-
mgrB isolates harbored an MIC of ≥64 mg/L whilst pTOPO-pmrB colonies were 16 mg/L to 
confirm two resistant populations in these samples. 23_GR_12 was also observed to have a 
heterogeneous mgrB disruption but did not carry a corresponding pmrB mutation, however, 
harbored similar mutations to 2_GR_12 in phoPQ. Amplification of mgrB identified two of three 
23_GR_12 transformed colonies contained the IS element disruption and were reverted to 
susceptible upon complementation with pTOPO-mgrB.  
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Table 2.2. Potential mutations contributing to polymyxin resistance and acquired resistance genes 
Strain MLST
*
 Predicted polymyxin resistance variants
†
 
Acquired antibiotic resistance genes
‡
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1_GR_13 147 mgrB (N25ΔISKpn26-like
F
), pmrB (T140P)                                                                                                         
2_GR_12 258 mgrB (N25ΔISKpn26-like
R
), phoP (A95S), phoQ 
(N253T) 
                                                                                                        
3_GR_13 258 mgrB (D29E)                                                                                                         
4_GR_12 258 mgrB (N25ΔISKpn26-like
R
), phoP (P74L), phoQ 
(N253T) 
                                                                                                        
5_GR_13 383 mgrB (Q30STOP)                                                                                                         
6_GR_12 383 -                                                                                                         
7_GR_13 258 mgrB (N25ΔISKpn26-like
R
)                                                                                                         
8_GR_13 258 phoQ (G385C)                                                                                                         
9_GR_12 258 phoQ (T281M)                                                                                                         
10_GR_13 258 mgrB (N25ΔISKpn26-like
R
), phoQ (N253T)                                                                                                         
11_BR_13 437 mgrB (-35ΔIS1R
F
)                                                                                                         
12_BR_13 11 mgrB (N25ΔISKpn13
R
)                
                                                                                        
13_GR_14 258 mgrB (N25ΔISKpn26-like
R
), phoQ (V446G), pmrB 
(P158R) 
                                                                                                        
14_GR_14 258 mgrB (N25ΔISKpn26-like
R
), phoQ (V446G), pmrB 
(P158R) 
                                                                                                        
15_GR_13 258 mgrB (I45ΔISKpn25
F
)                                                                                                         
16_GR_13 11 mgrB (-19ΔIS1R-like
F
)                                                                                                         
17_GR_14 11 mgrB (-19ΔIS1R-like
F
)                                                                                                         
18_GR_14 258 mgrB (N25ΔISKpn26-like
R
)                                                                                                         
19_GR_14 258 mgrB (C28STOP)                                                                                                         
20_GR_12 258 WT                                                                                                         
21_GR_13 2401 -                                                                                                         
22_GR_12 258 WT                                                                                                         
23_GR_12 258 mgrB (N25ΔISKpn26-like
R
), phoP (A95S), phoQ 
(N253T) 
                                                                                                        
24_GR_13 258 WT                                                                                                         
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*Multilocus sequence type as identified through MultiLocus Sequence Typing Server 1.8. 
†Variations detected in mgrB, phoPQ and pmrAB potentially causing polymyxin resistance. 
Significant non-synonymous changes determined by PROVEAN analysis. WT (Wild-type) alleles 
in comparison to 20_GR_12. Displayed as gene impacted, initial amino acid, position and new 
amino acid. If - shown in front of position, variant is encoded upstream and if - is only displayed, no 
significant non-synonymous changes were detected in these loci. Insertion sequences (underlined) 
classified as Δ, identity as per ISFinder and orientation in superscript. Orientation determined as 
forward, F, if transposase is in the same direction as mgrB and conversely, reverse, R, if in the 
opposite direction to mgrB.  
‡Acquired antibiotic resistance genes detected via ResFinder 2.1. Classes of antibiotics impacted 
displayed as A, Aminoglycoside; B, Beta-lactam; F; Fosfomycin; M, Macrolide; P, Phenicol; Q, 
Quinolone; R, Rifampicin; S, Sulphonamide; T, Tetracycline; Tr, Trimethoprim. Shading indicates 
detection of gene (≥90% similarity, ≥60% sequence length). 
 
2.6.6. Validation of resistance conferring mutations in phoQ 
 
Strains 8_GR_13 and 9_GR_12 harboured a single mutation in phoQ potentially conferring 
resistance (Table 2.2.). When these isolates were transformed with pTOPO-phoQ, results remained 
variable where a lack of growth was present in a susceptible range (MIC: ≤2 mg/L), however, 
several wells containing high polymyxin B concentrations exhibited growth (Figure 2.2.c). This 
result was reproducible (n= ≥4) therefore, the mutated gene was introduced into a polymyxin-
susceptible isolate, 20_GR_12 (Figure 2.2.e). This complementation resulted in consistent 
polymyxin-resistant phenotype.  
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(a) pTOPO-mgrB (b) pTOPO-phoP 
(c) pTOPO-phoQ (d) pTOPO-pmrB 
(e) 20_GR_12 (f) 7_GR_13 
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Figure 2.2. Complementation assays and influence of gene on polymyxin resistance. Polymyxin B 
minimum inhibitory concentration (MIC) measured before (○) and after (■) complementation of 
wild-type gene (a) pTOPO-mgrB, (b) pTOPO-phoP, (c) pTOPO-phoQ, or (d) pTOPO-pmrB in 
indicated resistant isolates. (e) Mutated genes complemented into 20_GR_12 (polymyxin-
susceptible isolate) to determine if variant induces polymyxin resistance. (f) Complementation of 
7_GR_13 (IS element disrupted mgrB control) to detect potential suppressor mutations. Strains 
shown on x axis for (a-d) and superscript indicates variants in genes including mgrB (a), phoP (b), 
phoQ (c) and pmrB (d) that differ from 20_GR_12. For (e, f), the x axis shows the gene 
complemented with amino acid variation in brackets. Dotted line at 2 mg/L represents the 
breakpoint for polymyxin B. Values indicate mean±standard deviation where no error bars display 
no fluctuation in MIC (n= ≥2 colonies) 
 
2.6.7. Potential suppressor mutations in phoPQ 
 
Several mutations co-segregating with the IS element disrupted mgrB were detected including phoP 
(P74L, A95S), phoQ (N253T, V446G) and pmrB (T140P). Complementation of WT genes in these 
isolates facilitated a ≥2-fold increase in MIC with the exception of 10_GR_13, which had an 
additional predicted neutral mutation in phoQ (A225T) (Table S2.3., Figure 2.2.b-d). To evaluate 
the potential influence of these mutations on polymyxin resistance, mutated genes were introduced 
into a strain only containing the mgrB IS element disruption, 7_GR_13 (Figure 2.2.f). 
Complementation of mutant pmrB (T140P) into 7_GR_13 did not lead to an observable 
corresponding reduction in MIC, however, once transformed into 20_GR_12, a 2-fold increase in 
MIC was apparent (Figure 2.2.e). Variants in phoQ (N253T and V446G) exhibited a 2-fold 
reduction in MIC (Figure 2.2.e). Initially, the phoQ (V446G) mutation was anticipated to segregate 
with the mgrB disrupted population in 13_GR_14 and 14_GR_14, however, when phoQ was 
amplified from a colony reverted to susceptible via pTOPO-mgrB complementation, the WT phoQ 
was observed (Figure S2.3.). The phoQ (V446G) mutation was successfully amplified from a 
14_GR_14 colony containing the pmrB (T158R) mutation. Although this mutation did not segregate 
with disrupted mgrB, it may act as a partial suppressor mutation when a resistance conferring 
mutation is present in pmrB. Interestingly, a ≥4-fold reduction in MIC was witnessed for phoP 
mutations P47L and A95S which is indicative of partial suppressor mutations (Figure 2.2.e). 
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2.7. Discussion 
 
Polymyxin resistance in XDR K. pneumoniae is of grave concern given that this is a last-line 
antibiotic, and is increasingly prevalent in countries such as Greece and Brazil (10, 12-14, 49). We 
evaluated the genetic basis of polymyxin resistance in a series of Greek and Brazilian clinical 
isolates from patients in 2012 to 2014 and found variants in genes mgrB, phoPQ and pmrAB. 
Causative mutations attributed to polymyxin resistance were identified in these loci, however, the 
contribution of other genes warrants further investigation. 
 
Inactivation of mgrB was highly prevalent in these strains with an ISKpn26-like element being the 
predominant cause of resistance, as confirmed by complementation restoring susceptibility in all 
isolates. Several other studies have observed an IS5-like element integration in the same position, 
including reports from Greece, Italy, France, Turkey and Colombia (8, 9, 50, 51). The ISKpn26-like 
element resembled the same sequence from Greece isolates previously described (51). We 
identified that this mutation still persisted in 2014, after being first detected in 2012 (9). Disruptions 
in mgrB including the ISKpn26-like forward insertion at nucleotide 75 in ST147, ISKpn13 
integration at nucleotide 75 in ST11 and ISKpn25 in the ST258 lineage have yet to be reported. We 
identified IS1R or IS1R-like elements positioned upstream of mgrB in 3 isolates (11_BR_13, 
16_GR_13, 17_GR_14) which were reverted upon complementation indicating an impact on the 
promoter region. 
 
Truncations identified at position 28 and 30 of mgrB have been previously detected, although these 
were identified in differing STs indicating mutations potentially have arisen independently in 
Greece (24, 52). Complementation restored susceptibility to polymyxins for these mutations and 
this study further revealed the amino acid change D29E in 3_GR_13 to be a resistance conferring 
mutation. These findings support the notion that intact MgrB is required to confer negative 
feedback on PhoPQ (8). The inactivation of mgrB is prevalent in polymyxin-resistant K. 
pneumoniae and may arise owing to its capacity to promote virulence and further attenuate the early 
host defence response, with little or no fitness cost (53). 
 
Single predicted detrimental mutations were observed in the phoQ histidine kinase region, critical 
for phosphorylation and interaction with phoP, in 8_GR_13 (G385C) and 9_GR_12 (T281M). The 
G385C mutation had previously been reported, (24), however, in a differing ST. Complementation 
revealed an inconsistent MIC for these strains, although when a polymyxin-susceptible isolate was 
transformed with the mutated gene, full resistance was restored. Dominance of mutated phoQ has 
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recently been highlighted and these results may imply the inability of pTOPO-phoQ to override the 
resistance caused by these mutations (54). Furthermore, the inconsistencies in MIC may be 
attributed to the heightened expression of WT phoQ in the pCR-Blunt II-TOPO vector and warrants 
further investigation. 
 
Several non-synonymous changes were identified to be not deleterious according to PROVEAN 
analysis. Notably, these were abundant in K. quasipneumoniae strains including 21_GR_13 and K. 
pneumoniae ST383 isolates. When these clinical isolates were aligned to ATCC 700603, multiple 
coding changes were identified with the majority detected as neural changes with the exception of 
pmrA (Q140L) and pmrB (R256G). These mutations represent lineage specific mutations, however, 
this does not negate the possibility of previously resistance conferring variants being acquired in 
these loci with subsequent reversion mutations to give rise to a susceptible phenotype. 
Heterogeneity was apparent in several isolates. In near equal ratios, 13_GR_14 and 14_GR_14 
possessed the ISKpn26-like mgrB disruption and a new mutation conferring resistance in pmrB, 
P158R as determined by complementation. 23_GR_12 consisted of approximately half the reads 
mapping to the undisrupted genes and the other to the ISKpn26-like strain with several additional 
predicted deleterious mutations. This heterogeneity may explain the initial clinical detection for this 
isolate to be polymyxin-susceptible. 
 
Several isolates harboring ISKpn26-like element disrupted mgrB were accompanied by mutations in 
phoPQ and/ or pmrB. These changes were present in ≥98% of reads to render the involvement of 
heterogeneity unlikely. Once complemented, an increase in resistance was commonly recorded. 
This potentially reflects partial suppressor mutations as strains which solely possessed this IS 
element disruption commonly exhibited a heightened MIC of ≥64 mg/L. One variant segregating 
with this disruption included pmrB T140P. This had formerly been identified in an ST258 lineage 
but even when the resistant gene was complemented, the MIC increased by 2-fold but was not 
defined as clinically resistant (24, 55).  
 
When mutated phoP or phoQ were introduced into the mgrB disrupted isolate, a reduction in MIC 
was apparent. The involvement of additional mutations in PhoPQ to cause a suppressing effect on 
the level of resistance in a background where the disrupted mgrB is lacking has yet to be reported in 
K. pneumoniae. Previous research by Miller et al (56) determined additional mutations in PhoPQ 
altered polymyxin resistance in Pseudomonas aeruginosa. This prior study describes phoP 
mutations with the capacity to partially or fully suppress resistance-causing mutations in phoQ. 
These mutations in phoP were near or within the DNA binding site which differs to our results, 
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where the mutations are impacting the response regulatory region that interacts with PhoQ. 
Conversely, all mutations partially suppressing the MIC were identified to be targeting the HAMP 
(present in Histidine kinases, Adenylate cyclases, Methyl-accepting proteins and Phosphatases) 
domain and histadine kinase component of PhoQ. These were in regions similar to revertant P. 
aeruginosa strains identified by Lee and Ko (57). We postulate these mutations are perturbing the 
critical transfer of phosphoryl groups from the histadine kinase of PhoQ to PhoP and subsequent 
pmrD expression. Whether these mutations constitute a fitness advantage due to the reduction of 
metabolism required for the production of LPS modifications is yet to be discerned. Furthermore, 
due to variability in some of the complementation data, a knockout phoPQ background and 
introduction of genes that are potential suppressor mutations is required. 
 
Rapid and accurate detection of mutations attributed to polymyxin resistance remains a 
longstanding burden. Our research has contributed to the current understanding of the dissemination 
and evolution of this resistance in K. pneumoniae. Although the sample size is limited, this study 
highlights several issues arising from solely interrogating genomes for resistance detection 
including ST specific non-synonymous changes, and heterogeneity. Our study uncovers several 
mutations causing polymyxin resistance across various STs when comparing to prior literature. 
These include the mgrB ISKpn26-like disruption (nucleotide 75), truncations in mgrB (nucleotide 
28 and 30) and a missense mutation in phoQ (G385C). The study provides the first potential report 
of suppressor mutations for polymyxin resistance. Through complementation assays, we have 
discerned the role of these modifications and have identified resistance-causing variants that can be 
monitored during future genome-based diagnostics. 
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Chapter 3 
Detection of antibiotic resistance via MinION sequencing 
 
3.1. Chapter introduction 
 
The research conducted in Chapter 2 highlights the complications associated with detecting 
polymyxin resistance via DNA sequencing. Various genomic alterations can reside in two-
component regulatory systems (phoPQ, pmrAB), however, these may be due to lineage specific 
mutations not contributing to resistance. Analysis of mutational effects is further exacerbated by 
heterogeneity of mutations and heteroresistance (a subpopulation of resistant bacteria in a 
phenotypically susceptible isolate). To validate whether these variants are contributing to resistance, 
rigorous functional experiments, including complementation assays, are required. Chapter 3 
explores an alternative approach for detecting polymyxin resistance which includes transcriptomics. 
This was performed via MinION (Oxford Nanopore Technologies) direct RNA sequencing. This 
sequencing technology enables real-time analysis of data and may allow for a rapid approach for 
detecting resistance. Three polymyxin-resistant XDR isolates were selected from Chapter 2 which 
harboured high levels of resistance (non-susceptibility to 24 antibiotic classes or combinations, ≥26 
resistance genes) and from differing lineages (ST11, ST147 and ST258). An additional polymyxin-
susceptible isolate was selected as a reference. DNA from these isolates was also sequenced using 
this technology, as nanopore technology is able to sequence much longer reads than traditional 
methods. The MinION sequencing, in combination with Illumina data from Chapter 2, immensely 
aided with the assembly of these isolate genomes. In particular, the MinION data was able to 
resolve whether antibiotic resistance genes were residing on the chromosome or plasmid/s. The time 
and sequence yield required for detection of resistance genes was evaluated for both DNA and RNA 
sequencing for these four XDR K. pneumoniae isolates. Supplementary information for this chapter 
is located in Appendix II, page 117-125. 
 
3.2. Manuscript for publication 
 
This research has been prepared for publication and shown on pages 56-78 in Chapter 3. As the 
first author, I am the primary contributor to the study design, data acquisition, data analysis and 
writing of the manuscript. I conceived the study and performed all experiments including DNA and 
RNA extractions and processing, sequencing library preparation, quality control, Nanopore 
sequencing and qRT-PCR. I performed the RNA sequencing analysis and was involved in all 
sequencing analysis and interpretation. I have generated all the tables and figures in this manuscript. 
I drafted the manuscript and revised the text in accordance to input from other authors. 
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3.3. Abstract 
 
Klebsiella pneumoniae accounts for a high abundance of hospital-acquired infections and mortality. 
This pathogen commonly harbours multidrug resistance with conventional resistance profiling 
methodologies struggling to elucidate feasible antibiotic treatments in a timely manner. 
Implementation of sequencing in clinics remains a desirable option, in particular, MinION 
sequencing (Oxford Nanopore Technologies). This study interrogated the genome and 
transcriptome of four extensively drug-resistant (XDR) K. pneumoniae clinical isolates from a 
Greek hospital. MinION DNA sequencing discerned the majority of acquired resistance (≥75%) to 
reside on up to five plasmids. In particular, the IncA/C2 megaplasmid (≥155000 bp) was found to 
encode for resistance towards at least five antibiotic classes. The transcriptome was evaluated via 
direct RNA sequencing to ascertain the detection time and differential gene expression of the 
resistome. By emulating the acquisition of sequence data on the MinION, we could determine that, 
overall, DNA sequencing identified the majority of resistance genes (≥70%) within 2 hours. Not all 
resistance genes were identified via direct RNA sequencing, however, aminoglycoside, beta-lactam, 
trimethoprim and sulphonamide resistance was found within 6 hours. In several instances, 
quinolone, rifampicin and phenicol resistance was apparent, although the level of transcription 
varied. Tetracycline and fosfomycin resistance genes were undetected in RNA sequencing data, 
however, these genes were validated to have low expression via qRT-PCR. Furthermore, pathways 
associated with polymyxin resistance were explored transcriptionally. High levels of expression 
(≥7-fold) from the pmrHFIJKLM operon was associated with polymyxin resistance. These findings 
show the capacity for MinION sequencing to rapidly detect the XDR K. pneumoniae resistome and 
the utility of direct RNA sequencing to determine differential expression of these genes.  
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3.4. Introduction 
 
Klebsiella pneumoniae is one of the leading causes of nosocomial infections, with reports of 
mortality rates as high as 50% (1-5). This pathogen frequently exhibits multidrug resistance which 
severely limits treatment options (6). High levels of resistance are commonly encoded on plasmids, 
accounting for the rapid global dissemination of resistance (1, 6). Common therapeutic options for 
multidrug resistant infections include carbapenems, fosfomycin, tigecycline and polymyxins (7). 
However, resistance is rapidly developed against these antibiotics (6). Subsequently, pandrug-
resistant (PDR) K. pneumoniae have emerged which are resistant to all commercially available 
antibiotics (8, 9).  
One of the major contributors to the advent of antibiotic resistance is the inability for current 
methodologies to readily and accurately assess resistance profiles to allow for the physician to 
determine appropriate treatment options (10). This has resulted in the unnecessary use of powerful 
antibiotics for susceptible infections, or ineffective antibiotics being administered for resistant 
infections. Sequencing has become a desirable diagnostic methodology to employ in clinics, in 
particular, Oxford Nanopore Technologies (ONT) MinION sequencing (11). This portable device 
has the capacity to sequence long fragments of DNA and the recent ability to multiplex samples has 
immensely aided with the assembly of bacterial genomes (12-14). This allows for the adequate 
determination of whether resistance is residing on the chromosome or plasmid/s. Of interest are 
high levels of resistance encoded on plasmids that can rapidly be transferred throughout the 
bacterial population via horizontal gene transfer. Unique to this technology is the capacity for data 
to be analysed in real-time which can enable rapid detection of bacterial species and resistance (15-
18).  
ONT has recently released a direct RNA sequencing capability, which directly sequences 
transcripts. Other sequencing technologies rely on fragmentation, cDNA conversion and PCR steps 
which create experimental bias and hinder the accuracy of determining gene expression (19, 20). 
The ability for MinION sequencing to read long fragments enables full length transcripts to be 
investigated. To date, only a few direct RNA sequencing publications exist, and these have been 
studies interrogating eukaryote transcriptomes, primarily yeast (19, 21). Bacterial transcription 
differs significantly from eukaryotes in that transcription and translation occur simultaneously. As a 
result, bacterial mRNA transcripts lack poly(A) tails and alternative splicing (22). The poly(A) tail 
is critical for the library preparation for MinION sequencing technology thus, we have established a 
methodology for ligating this component onto transcripts. 
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In this study, we exploited MinION sequencing to interrogate both the genome and the 
transcriptiome (via direct RNA sequencing) for XDR K. pneumoniae clinical isolates. These 
isolates have previously undergone ‘traditional’ whole genome sequencing (Illumina) and 
antimicrobial testing (23). Three strains were selected from this cohort, based on resistance to all 24 
classes or combinations of antibiotics tested, a high abundance of antibiotic resistance genes (≥26) 
and differing lineages (ST11 (16_GR_13), ST147 (1_GR_13) and ST258 (2_GR_12)). 
Additionally, these isolates harbour polymyxin resistance which is facilitated by a disruption in or 
upstream of mgrB. MgrB is the negative regulator of PhoPQ and once altered, results in the up-
regulation of the pmrCAB and pmrHFIJKLM operon (24-26). This enables the addition of 
phosphoethanolamine and/ or 4-amino-4-deoxy-L-arabinose onto the basal component of 
lipopolysaccharide, lipid A. These modifications perturb the electrostatic interaction between lipid 
A and polymyxins (27, 28). These pathways associated with polymyxin resistance were further 
explored using direct RNA sequencing. An additional polymyxin-susceptible XDR (ST258) isolate 
was selected to determine the differential expression associated with polymyxin resistance. This 
research aimed to assemble these genomes, discern the differential expression of resistance genes 
and ascertain the time required for detection. Furthermore, comparing DNA and RNA sequencing 
as modalities for rapid identification of acquired antibiotic resistance is of interest. 
 
3.5. Materials and Methods 
 
3.5.1. Bacterial strains and growth conditions 
 
Clinically acquired XDR K. pneumoniae strains were sourced through the Hygeia General Hospital, 
Athens, Greece (23). Antimicrobial susceptibility assays, sequence typing and detection of acquired 
resistance genes for 1_GR_13, 2_GR_12, 16_GR_13 and 20_GR_12 have previously been analysed 
(23). Strains were stored at -80 °C in 20% (v/v) glycerol and the same stock was used as per the 
previous study (23). When required for extractions, glycerol stocks were struck out on lysogeny 
broth (LB) agar plates and 6 morphologically similar colonies were selected for inoculation. The 
inoculum was grown in LB overnight at 37°C shaking at 220 rpm. This overnight inoculum was 
used for both DNA and RNA extractions. 
 
3.5.2. DNA extraction and high molecular weight DNA isolation 
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DNA was extracted from 10 ml of overnight culture using the DNeasy Blood and Tissue Kit 
(Qiagen) according to manufacturer’s guidelines with the addition of the enzymatic lysis buffer pre-
treatment (60 mg/ml lysozyme). High molecular weight (HMW) DNA was extracted using the 
MagAttract HMW DNA Kit (Qiagen) as per manufacturer’s instructions. Subtle changes included 
an additional proteinase K treatment on the DNA extracts at 56°C for 10 min followed by 
supplementation of RNase A (1 mg) for 15 min at room temperature. Several attempts for extracting 
directly from bacterial cells were undertaken using the MagAttract HMW DNA kit, however, were 
unsuccessful with these isolates. Due to several issues with potential carbohydrate contamination 
(260/230 ratio: ≤0.3), 2_GR_12 was further purified with the Monarch® PCR & DNA Cleanup Kit 
(New England BioLabs) using the protocol to isolate fragments >2000 bp. DNA and RNA 
contamination was quantitated using Qubit®2.0 (ThermoFisher Scientific) and purity determined 
with NanoDrop 1000. DNA fragment sizes were determined using the Genomic DNA ScreenTape 
& Reagents (Integrated Sciences) and sizes from 200 to >60000 bp were analyzed on an Agilent 
4200 TapeStation System (Figure S3.1.). 
 
3.5.3. RNA extraction, mRNA enrichment and poly(A) ligation 
 
The overnight culture was sub-cultured in 10 ml of cation-adjusted Muller Hinton Broth (caMHB) 
to reflect conditions used for minimum inhibitory concentration (MIC) assays. Cultures were grown 
to mid-log phase (OD600 = 0.5-0.6). RNA was extracted via the PureLink
TM RNA Mini Kit 
(ThermoFisher Scientific) as per manufacturer’s protocols which included using Homogenizer 
columns (ThermoFisher Scientific). To remove DNA contamination, the TURBO DNA-freeTM kit 
was implemented. A minor adjustment was an increased concentration of TURBO DNase (4 U) 
incubated at 37°C for 30 min. The RNeasy Mini Kit (Qiagen) clean up protocol was further used to 
purify and concentrate RNA samples. Ribosomal RNA was depleted via the MICROBExpressTM 
Bacterial mRNA Enrichment Kit (ThermoFisher Scientific). Minor protocol changes included 
adding ≥2 µg of DNA depleted RNA and the enriched mRNA was precipitated for 3 h at -20°C. 
Poly(A) ligation was performed using the Poly(A) Polymerase Tailing Kit (Astral Scientific) as per 
the manufacturer’s alterative protocol (4 U input of Poly(A) Polymerase). The input RNA 
concentration was ≥800 ng and RNA samples were incubated at 37°C for 1 h. Poly(A) ligated RNA 
was purified using Agencourt AmpureXP (Beckman Coulter Australia) beads (1:1 ratio). RNA and 
DNA contamination was quantitated using the Qubit®2.0 (ThermoFisher Scientific) and purity 
determined with a NanoDrop 1000 Spectrophotometer. RNA fragment size was checked using an 
Agilent RNA 6000 Pico kit and run on a 2100 Bioanalyzer (Agilent Technologies) for the initial 
RNA extract, post ribosomal RNA depletion and after poly(A) ligation (Figure S3.2.). 
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3.5.4. Oxford Nanopore Technologies library preparation and sequencing 
 
RNA libraries (≥600 ng poly(A) ligated RNA) were prepared using the Direct RNA Sequencing kit 
(SQK-RNA001). The Rapid Barcoding Sequencing kit (SQK-RBK001) was used for high 
molecular weight DNA samples (1_GR_13, 16_GR_13, 20_GR_12; 300 ng input each isolate). 
Isolate 2_GR_12 (300 ng input) was prepared separately using the Rapid Sequencing Kit (SQK-
RAD003). Libraries were sequenced with MinION R9.4 flowcells and bases were determined using 
Albacore 2.1.1 (ONT). 
 
3.5.5. Real-time resistome detection emulation 
 
The real-time emulation was performed post sequencing and the time required to detect antibiotic 
resistance was determined as previously described (17). Briefly, this pipeline aligns Albacore base 
called reads via BWA-MEM (29) to an antibiotic resistance gene database. Antibiotic resistance 
genes were obtained from the ResFinder 3.0 (30) database (downloaded December 2017). This 
dataset comprises of 2131 genes which were clustered based on 90% similarity to form 611 groups 
or gene families. The detection of false positives is reduced via a multiple sequence alignment using 
kalign2 (31) and genes reported based on a probabilistic Finite State Machine (32).  
 
3.5.6. Assembly of genomes 
 
To assemble genomes with both Illumina and ONT reads, SPAdes v3.10.1 (33) was implemented. 
Hybrid assemblers included npScarf (34) and Unicycler v0.3.1 (35). Assemblers using only ONT 
reads included Canu v1.5 (excluding reads <500bp) (36) and also a combination of Miniasm v0.2-
r168-dirty, Minimap2v2.1-r311 and Racon git commit 834442 were used (37, 38). Consensus 
sequences were determined using Mauve (snapshot_2015-02-13) to construct the final assembly 
(39). The output from each assembly software is reported in Table S3.1.. Genomes were annotated 
using Prokka v1.12 (40). The location of acquired antibiotic resistance genes were determined using 
ResFinder 3.0 (30) and identity of plasmids via PlasmidFinder 1.3 (41). The full details of plasmids 
and resistance gene positions is displayed in Table S3.2.. To discern if these sequences have 
previously been reported, contigs underwent a BLASTn analysis across the National Center for 
Biotechnology Information (NCBI) database (https://blast.ncbi.nlm.nih.gov/Blast.cgi). 
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3.5.7. RNA alignment and expression profiling 
 
Base called RNA reads were converted to DNA (uracil bases changed to thymine) and aligned 
using BWA-MEM (parameters: -k 11 -W20 -r10 -A1 -B1 -O1 -E1 -L0 –Y) to the updated genome 
assemblies. Due to the lack of introns and full length transcripts being obtained, BEDTools 
coverage (42) was used to ascertain the relative expression of resistance genes. This was normalized 
to the number of counts obtained for the housekeeping gene, rpsL (43), to compare against qRT-
PCR results. Read alignments were further visualised using Integrative genomics viewer (IGV) 
2.3.59 (44). 
 
3.5.8. Quantitative real-time reverse transcriptase PCR (qRT-PCR) 
 
First strand synthesis to generate cDNA (1 µg total DNase-depleted RNA) was performed using 
SuperScript III (ThermoFisher Scientific) which was also used for MinION direct RNA sequencing 
library preparations. Primers used are displayed in Table S3.3.. Samples were prepared in triplicate 
via the SYBR Select Master Mix (ThermoFisher Scientific) and expression detected using a ViiA 7 
Real-time PCR system (Thermo Fisher Scientific). Cycling conditions include: Hold 50°C (2 min), 
95°C (2 min) followed by 50 cycles of: 95°C (15 sec), 55°C (1 min). A melt curve was included to 
determine the specificity of the amplification and a no template control to detect contamination or 
primer dimers. Results were analysed with QuantStudioTM Real-Time PCR Software, triplicates 
were averaged, normalised to the housekeeping gene rpsL and relative expression determined via 
the 2-ΔΔCT method (45).  
 
3.5.9. Data summary 
 
Whole genome sequencing of the 4 clinical isolates, including the recent assembly, has been 
deposited under BioProject PRJNA307517 (www.ncbi.nlm.nih.gov/bioproject/PRJNA307517). 
ONT DNA sequencing data has been deposited on the Sequence Read Archive 
(www.ncbi.nlm.nih.gov/sra/) under study SRP133040. Accession numbers are as follows: 1_GR_13 
(SRR6747887), 2_GR_12 (SRR6747886), 16_GR_13 (SRR6747885) and 20_GR_12 
(SRR6747884). ONT direct RNA sequencing data has been deposited on the Sequence Read 
Archive (www.ncbi.nlm.nih.gov/sra/) under study SRP133040. Accession numbers are as follows: 
1_GR_13 (SRR6747875), 2_GR_12 (SRR6747876), 16_GR_13 (SRR6747877) and 20_GR_12 
(SRR6747878). 
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3.6. Results 
 
3.6.1. Discerning the location of acquired resistance in the genome 
 
Utilising the capacity for MinION sequencing to read long fragments of DNA, the location of 
antibiotic resistance genes was resolved (Table 3.1.). All genomes were circular with the exception 
of 2_GR_12 where 3 plasmids remained linear. This was partly due to difficulties extracting DNA 
and not retaining long fragments (Figure S3.1.). Amongst the four isolates, the chromosome size 
ranged between 5.1-5.5 Mb which encoded resistance genes blaSHV-11, fosA and oqxAB. The 
majority of resistance (≥75%) mapped to plasmids. 
At least one megaplasmid, defined as a plasmid larger than 100000 bp, was detected in all isolates 
(Table 3.1.). These commonly harboured the replicon IncA/C2 or InFIB and IncFIIK. The IncA/C2 
plasmid was present in all samples except 20_GR_12. This plasmid contained up to 16 resistance 
genes which conferred resistance towards aminoglycosides, beta-lactams, phenicols, rifampicin, 
sulphonamides, tetracyclines and trimethoprim, with the exception of 16_GR_13. Isolate 
16_GR_13, which lacked trimethoprim resistance on its IncA/C2 plasmid. The plasmids containing 
both replicons IncFIB and IncFIIK differed vastly between all four replicates. All contained 
IncFIBpKpn3 and IncFIIK, however, 1_GR_13 differed with IncFIIpKP91. Additionally, a differing 
IncFIB replicon was detected on a separate contig in 1_GR_13 (pKPHS1) and 2_GR_12 (pQil). 
The only instance where another dual replicon was identified was in 1_GR_13 which harboured 
both IncR and IncN. This plasmid contained aminoglycoside, beta-lactam, trimethoprim, macrolide 
and sulphonamide resistance. 1_GR_13 also contained a 5.5 kb circular contig which was annotated 
as a phage genome. Various regions of these megaplasmids were unique to these isolates compared 
to prior sequences deposited on NCBI (Table S3.4.). 
The ColRNAI plasmid was present in all except 1_GR_13 which encoded aminoglycoside and 
quinolone resistance (aac(6')-Ib, aac(6')-Ib-cr) (Table 3.1.). The ColRNAI plasmid in 2_GR_12 
and 20_GR_12 was 13841 bp in size and shared 75% similarity between the two isolates. This 
plasmid differed in 16_GR_13 which contained no resistance genes and 35% the size. The same 
IncX3 plasmid (43380 bp) was apparent in isolates 2_GR_12 and 20_GR_12. Unique to 16_GR_13 
was the IncL/ MpOXA-48 plasmid containing blaOXA-48 and the 50979 bp IncN plasmid in 
20_GR_12 with resistance against 5 classes (aminoglycoside (aph(3'')-Ib, aph(6)-Id), beta-lactam 
(blaTEM-1A), sulphonamide (sul2), tetracycline (tet(A)), trimethoprim (dfrA14)) of antibiotics.  
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Multiple copies of acquired resistance genes were apparent across plasmids in several isolates. For 
1_GR_13, up to three copies were present of genes aadA24, aph(3')-Ia, aph(6)-Id, dfrA1, dfrA14, 
strA and sul1. In 2_GR_12, sul1 and blaTEM-1A were duplicated and for 16_GR_13, only sul1 was 
represented twice.  
 
3.6.2. Real-time detection emulation of resistance genes via DNA 
 
The vast majority (≥70%) of resistance genes were detected via DNA sequencing within the first 2 
hours (Table 3.2.). These genes conferred resistance towards aminoglycosides, beta-lactams, 
fosfomycin, macrolides, phenicols, quinolones, rifampicin, sulphonamides, tetracyclines and 
trimethoprim. 20_GR_12 lacked acquired resistance genes for macrolides, phenicols and 
rifampicin, however, all other classes were detected within 2 hours. All isolates, except 2_GR_12, 
were sequenced for 21 hours which was sufficient to obtain the complete genome assembly. Only a 
few genes were further detected after 10 hours and for the 2_GR_12 extended run (41 hours), no 
further genes were detected after 20 hours.  
Post 2 hours, several genes not observed in the final assembly via ResFinder 3.0 were accumulated 
(Table 3.2.). These were predominantly genes attributed to aminoglycoside, beta-lactam, rifampicin 
and phenicol resistance. Furthermore, resistance genes to additional differing classes were detected 
including fusidic acid and vancomycin. This was evident in 2_GR_12 (fusB) and 16_GR_13 (fusB, 
vanR). However, these genes had less than 30 reads and a poor mapping quality (MAPQ) score of 
≤10 (mapping accuracy of 90%). Furthermore, the majority of genes not observed in the final 
assembly exhibited a MAPQ score of ≤10.  
Several genes detected in the final assembly were not detected in the real-time emulation analysis 
(Table 3.2.). This was mainly observed for aminoglycoside resistance encoding genes. For 
1_GR_13, this included aadA1, ant(2'')-Ia, aph(6)-Id and aadA24. Similarly, 2_GR_12 and 
20_GR_12 lacked aph(3'')-Ib and aph(6)-Id. 2_GR_12 additionally had the absence of ant(2'')-Ia. 
Detection of ant(2'')-Ia, aph(3'')-Ib, aph(6)-Id was not present in 16_GR_13. 16_GR_13 further 
lacked catB4 (phenicol) and tet(A) (tetracycline). Various phenicol resistance genes were reported 
in the real-time emulation and potentially were not detected accurately due to sequencing errors and 
high similarity to other genes. The tetracycline resistance gene, tet(A), was interestingly not 
reported in this emulation with 190 reads and the majority of reads exhibiting a high mapping 
quality score (MAPQ = 60 (mapping accuracy of 99.9999%)). However, this gene was only 
detected after 10 hours for 1_GR_13 and 2_GR_12 which also harbour high levels of resistance. 
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Table 3.1. Final assembly of XDR K. pneumoniae isolates and location of antibiotic resistance genes 
*Contig identity indicating chromosome (C) and plasmid (P: replicon (determined via PlasmidFinder 1.3)) sequences; †Resistance genes determined via 
ResFinder 3.0 and displayed in alphabetical order (refer to Table S3.2. for position of genes). Bold indicates a circular contig. 
Isolate ST Contig Length (bp) Contig ID* Resistance Genes† 
1_GR_13 147 
1 5181675 C blaSHV-11, fosA, oqxA, oqxB 
2 192771 P: IncA/C2 
aadA1, ant(2'')-Ia, aph(6)-Id, ARR-2, blaOXA-10, blaTEM-1B, blaVEB-1, 
cmlA1, dfrA14, dfrA23, rmtB, strA, sul1, sul2, tet(A), tet(G) 
3 168873 P: IncFIBpKpn3, IncFIIpKP91 aadA24, aph(3')-Ia, aph(6)-Id, dfrA1, dfrA14, strA 
4 108879 P: IncFIBpKPHS1 - 
5 55018 - - 
6 53495 P: IncR, IncN 
aadA24, aph(3')-Ia, aph(6)-Id, blaVIM-27, dfrA1, 
mph(A), strA, sul1 
2_GR_12 258 
1 5466424 C blaSHV-11, fosA, oqxA, oqxB 
2 197872 P: IncFIBpKpn3, IncFIIK aadA2, aph(3')-Ia, catA1, dfrA12, mph(A), sul1 
3 175636 P: IncA/C2 
aadA1, ant(2'')-Ia, aph(3'')-Ib, aph(6)-Id, ARR-2, blaOXA-10, blaTEM-1A, 
blaVEB-1, cmlA1, dfrA14, dfrA23, rmtB, sul1, sul2, tet(A), tet(G) 
4 95481 P: IncFIBpQil blaKPC-2, blaOXA-9, blaTEM-1A 
5 43380 P: IncX3 blaSHV-12 
6 13841 P: ColRNAI aac(6')-Ib, aac(6')Ib-cr 
16_GR_13 11 
1 5426917 C blaSHV-11, fosA, oqxA, oqxB 
2 187670 P: IncFIBpKpn3; IncFIIK 
aac(3)-IIa, aac(6')Ib-cr, aadA2, aph(3')-Ia, blaCTX-M-15, blaOXA-1, catB4, 
dfrA12, mph(A), sul1 
3 155161 P: IncA/ C2 
aadA1, ant(2'')-Ia, aph(3'')-Ib, aph(6)-Id, ARR-2, blaOXA-10, blaTEM-1B, 
blaVEB-1, cmlA1, rmtB, sul1, sul2, tet(A), tet(G) 
4 63589 P: IncL/ MpOXA-48 blaOXA-48 
5 5234 - - 
6 4940 P: ColRNAI - 
20_GR_12 258 
1 5395894 C blaSHV-11, fosA, oqxA, oqxB 
2 170467 P: IncFIBpKpn3; IncFIIK aph(3')-Ia, blaKPC-2, blaOXA-9, blaTEM-1A 
3 50979 P: IncN aph(3'')-Ib, aph(6)-Id, blaTEM-1A, dfrA14, sul2, tet(A) 
4 43380 P: IncX3 blaSHV-12 
5 13841 P: ColRNAI aac(6')-Ib, aac(6')Ib-cr 
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Table 3.2. Real-time emulation of time to detect resistance genes from DNA sequencing 
 
 
Isolate* Time (mins) Resistance gene/s detected† 
1_GR_13 
(1279.35) 
10 
oqxA (Q), dfrA1 (Tr), dfrA14 (Tr), dfrA23 (Tr), blaVIM-27# (B), sul1/3 
(S), strA (A), aph(3’)-Ia/c (A), strB (A), aadB (A), mph(A) (M), 
blaTEM-1B# (B), oqxB (Q), rmtB2 (A) 
30 
sul2 (S), ARR-2/3/6 (R), blaOXA-10# (B), blaVEB-1# (B), tet(G) (T), 
cmlA1 (P), floR (P), blaSHV-11# (B), fosA (F) 
60 ARR-3 (R), aac(6’)Ib# (A), ARR-7 (R), aac(2’) (A), cml (P) 
120 aac(3’)-IIIc (A) 
300 fosA (F), aac(3’)-IIIb (A), aac(6’)-Ic (A), 
600 blaPAO (B), aph(3’)-IIb (A), aph(6)-Ic (A) 
900 catpC233 (P), blaOKP (B) 
1200 tet(A) (T) 
2_GR_12 
(2468.23) 
10 
blaKPC-2# (B), blaTEM-1A#(B), aac6Ib/-cr# (A), cmlA1 (P), dfrA12 
(Tr), sul1/ 3 (S) 
30 rmtB2 (A), oqxA (Q), dfrA14 (Tr), blaPAO (B) 
60 
oqxB (Q), strA (A), strB (A), aph(3’)-1a/c (A), sul2 (S), blaSHV-11/12# 
(B), mph(A) (M), catA1 (P), tet(G) (T), blaOXA-9# (B), aadA1/2# (A), 
fusB (Fu), aac(6’)/aph(2”) (A) 
120 
blaOXA-10# (B), floR (P), ARR-2/3/6 (R), aadB (A), fosA (F), blaVEB-
1# (B), cml (P), dfrA23 (Tr) 
300 aac(3’)-IIIc (A), catpC233 (P), aac(3’)-IIIb (A), ARR-3 (R) 
600 tet(A) (T), fosA (F) 
900 aph(6)-Ic (A) 
1200 - 
16_GR_13 
(1277.47) 
10 
blaOXA-436 (B), sul1/3 (S), dfrA12 (Tr), fosA (F), aadB (A), strA (A), 
sul2 (S), strB (A), blaCTX-M-64 (B) 
30 
blaOXA-48# (B), aph(3’)-1a/c (A), mph(A) (M), rmtB2 (A), floR (P), 
blaCTX-M-15# (B), aac(6’)Ib-cr# (A), blaOXA-1# (B), oqxB (Q), oqxA 
(Q), blaTEM-1B# (B), blaVEB-1# (B), cmlA1 (P) 
60 
tet(G) (T), blaOXA-10# (B), blaSHV-11# (B), aac(3’)-IIa# (A), ARR-
2/3/6 (R) 
120 
aadA1/2# (A), fusB (Fu), ermT (M), str (A), rmtG (A), fosA (F), 
aac(6’)/aph(2”) (A) 
300 ARR-3 (R), catpC233 (P), cml (P), aph(6)-Ic (A), aac(3’)-IIIb (A) 
600 vanR (V), dfrA14 (Tr) 
900 blaPAO (B) 
1200 aph(3’)-IIb (A) 
20_GR_12 
(1277.25) 
10 
aac(6’)Ib/-cr# (A), blaTEM-1A# (B), dfrA14 (Tr), sul2 (S), strB (A), 
blaKPC-2# (B), tet(A) (T) 
30 
oqxA (Q), blaSHV-11/12# (B), aph(3’)-Ia (A), fosA (F), fosA (F), 
blaOXA-9 (B), oqxB (Q), aph(6)-Ic (A) 
60 - 
120 aac(2’) (A), catpC233 (P), aac(3’)-IIIb (A) 
300 ermT (M), blaPAO (B), aac(6’)/aph(2”) (A), catpC221 (P) 
600 rmtf (A), ermG (M) 
900 aac(3’)-IIIc (A), aac(6’)-Ic (A) 
1200 vatB (M), ARR-2/3/6 (R), aadB (A) 
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*Isolate name and in brackets, the total sequencing run time in minutes 
†Resistance genes detected as per the real-time emulation. Bold represents gene or gene family 
detected in final assembly and # displays more than three genes grouped within this family. Genes 
displayed in order of time detected. An underline identifies genes with a poor mapping quality reads 
(MAPQ: ≤10). Brackets represent class of antibiotic this gene confers resistance which includes: A, 
aminoglycoside; B, beta-lactam; F; fosfomycin; Fu; fusidic acid, M, macrolide; P, phenicol; Q, 
quinolone; R, rifampicin; S, sulphonamide; T, tetracycline; Tr, trimethoprim; V, vancomycin. 
 
 
3.6.3. Direct RNA sequencing resistance detection 
 
The time required to detect resistance was further interrogated using RNA. Rapid detection was 
apparent for several resistance genes via direct RNA sequencing (Figure 3.1.). This was evident for 
genes conferring resistance to aminoglycosides, beta-lactams, sulphonamides and trimethoprim for 
all four isolates. In some instances, quinolone, rifampicin and phenicol resistance was detected. 
Absent from this analysis were genes attributed to macrolide (mph(A)), fosfomycin (fosA) and 
tetracycline (tet(A), tet(G)) resistance. No new genes were detected after 12 hours of sequencing. 
The time required to detect a gene did not necessarily correspond to the number of reads as several 
genes were detected earlier with less reads, however, the mapping quality was high (MAPQ = 60). 
Similar to the DNA real-time detection, several genes not found in the final assembly were 
apparent. With the exception of 20_GR_12, this included aadB and strB for all isolates. Additional 
genes detected included ARR-7 in 1_GR_13, strA in 2_GR_12 and for 16_GR_13, blaCTX-M-64, 
blaOXA-436 and strA. Similar genes or gene families were identified when comparing DNA and 
direct RNA sequencing. Overall, genes were detected more readily via DNA rather than RNA 
sequencing. There were only a few instances where RNA detected resistance quicker which 
included aac(3’)-IIa in 16_GR_13 and sul2, blaSHV-11/12 and catA1 in 2_GR_12. 
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Figure 3.1. Real-time emulation for the detection of resistance gene expression via MinION direct 
RNA sequencing. Strains investigated include (a) 1_GR_13, (b) 2_GR_12, (c) 16_GR_13 and (d) 
20_GR_12. Legends identify the class of antibiotic to which the gene confers resistance, / on y-axis 
indicates reads detected to more than one resistance gene, # is a family of genes detected (>3), bold 
displays a gene identified in the final assembly. Values on bars are displayed as the number of total 
reads mapping to that gene (time to detect gene via direct RNA sequencing in minutes). The dotted 
line indicates when the run stopped (∙∙∙) or for the instance with 2_GR_12, the run stopped 
unexpectedly and required a restart (green dashed line (---)).  
 
(a) (b) 
(c) (d) 
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3.6.4. Relative expression of resistance genes 
 
RNA sequencing accumulated over approximately 40 hours yielded between 0.9 and 1.7 million 
reads for these isolates (Figure S3.3.). However, only 10 to 14% of these reads successfully passed 
base calling. The low proportion of base called reads reflects the fact that base calling algorithms 
have not yet been optimised for direct RNA sequencing, and even less so for bacterial RNA 
sequencing. When aligning these reads to the final assembly, ≥98% of reads were mappable, 
however, only 25 to 40% of these had MAPQ score ≥10.  
Amongst the four isolates, levels of expression for resistance genes on the chromosome (blaSHV-
11, fosA and oqxAB) were low with only up to 25 reads mapping to these genes (Figure 3.2.). The 
remaining resistance genes were located on plasmids. Resistance genes exhibiting high levels of 
expression (≥50 reads) were apparent in 1_GR_13 (blaTEM-1B, sul2, blaVIM-27, dfrA1, sul1, 
aph(3’)-Ia), 2_GR_12 (aac(6’)-Ib, blaTEM-1A, catA1, blaKPC-2), 16_GR_13 (aac(6’)Ib, aac(3)-
IIa, blaCTX-M-15, dfrA12, sul2, aph(3”)-Ib, blaTEM-1B, rmtB, blaOXA-48) and 20_GR_12 
(blaKPC-2, blaSHV-12, aac(6’)Ib). Counts for aac(6’)-1b and aac(6’)-1b-cr in 2_GR_12 and 
20_GR_12 were grouped. The gene aac(6’)-1b-cr is a shortened version of aac(6’)-1b hence, was 
incorrectly identified and localised to the same position (Table S3.2.). All highly expressed genes 
were detected within 6 hours as per the real-time detection emulation. As anticipated, low levels of 
expression were observed for fosfomycin (fosA), tetracycline (tet(A), tet(B)) and macrolide 
(mph(A)) resistance with, at most, 7 reads (16_GR_13, mph(A)) mapping to these genes. 
Several resistance genes which represent resistance across various classes of antibiotics were 
evaluated to validate differential gene expression in these RNA extractions via qRT-PCR. These 
included resistance towards aminoglycosides (aac(6’)Ib, strA), beta-lactams (blaKPC-2, blaOXA-
10, blaTEM-1), phenicols (cmlA1), trimethoprim (dfrA14), fosfomycin (fosA), quinolone (oqxA), 
sulphonamides (sul2) and tetracyclines (tet(A)). Due to high similarity between several genes, 
primers for aac(6’)Ib also recognise genes aac(6’)Ib-cr and aacA24. Additionally, strA detects 
expression of aph(3”)-Ib. A similar trend was observed between direct RNA sequencing and qRT-
PCR results (Figure 3.2. and Figure 3.3. respectively). Relatively high levels of expression were 
reported for aac(6’)Ib, blaKPC-2 and blaTEM-1 amongst isolates. Additionally, low levels of 
expression for fosA and tet(A) were apparent. 
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Figure 3.2. Relative expression of resistance genes normalised to housekeeping gene, rpsL, via direct RNA sequencing. Strains investigated include 
(a) 1_GR_13, (b) 2_GR_12, (c) 16_GR_13 and (d) 20_GR_12. X-axis depicts the resistance genes and are grouped based on the location in the 
genome where P indicates a plasmid followed by replicon identity. 
(a) (b) 
(c) (d) 
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3.6.5. Transcriptional biomarkers for polymyxin resistance 
 
Three of the isolates harboured resistance towards polymyxins via disruptions in mgrB which 
included 1_GR_13, 2_GR_12 and 16_GR_13. 1_GR_13 exhibited an insertion sequence (IS) 
element, ISKpn26-like, at nucleotide position 75 in the same orientation as mgrB. 2_GR_12 also 
contained an insertion at the same position, however, in the opposite orientation and additional 
mutations in phoP (A95S) and phoQ (N253T). 16_GR_13 possessed an IS element, IS1R-like, 19 
bp upstream of mgrB. Transcription associated with this pathway were explored which included 
expression of phoP, phoQ, pmrA, pmrB, pmrC, pmrD, pmrE, pmrH and pmrK (Figure 3.4.). Direct 
RNA sequencing revealed a slight increase in transcription of phoPQ (≥2-fold). A ≥14-fold increase 
in expression was observed for pmrH and ≥7-fold elevation for pmrK. Similar trends for expression 
were also reported using qRT-PCR (Figure 3.4.b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Relative expression of resistance genes as per qRT-PCR. Strains investigated included 
(a) 1_GR_13, (b) 2_GR_12, (c) 16_GR_13 and (d) 20_GR_12. Relative expression calculated via 
(a) (b) 
(c) (d) 
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the 2-ΔΔCT method and normalised to housekeeping gene rpsL. * Symbolises the absence of this 
gene in the assembly and was used as a negative control. # Primer can recognise other genes such as 
aac(6’)Ib: aac(6’)Ib-cr, aadA24, strA: aph(3'')-Ib and blaTEM-1: blaTEM-1A, blaTEM-1B. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Expression of genes associated with the polymyxin resistance pathway. Comparison 
between (a) direct RNA sequencing and (b) qRT-PCR. Isolates harbouring resistance to polymyxins 
(MIC: >2 mg/L) include 1_GR_13, 2_GR_12 and 16_GR_13. 
 
 
3.7. Discussion 
 
XDR K. pneumoniae pose as a major threat to modern medicine with rapid diagnostics critical to 
discern adequate treatment options (1, 6). The MinION sequencing employed in this study 
demonstrated the potential of the technique to detect antibiotic resistance, as shown with four XDR 
K. pneumoniae isolates. Furthermore, this sequencing was able to resolve the assembly of plasmids 
harbouring high levels of resistance and the expression from the resistome in the absence of 
antibiotic treatment. 
The ability for ONT to sequence long fragments of DNA has significantly aided the assembly of 
bacterial genomes and plasmids (12-14). In this study, multiple megaplasmids (≥100000 bp) were 
identified which were previously unresolved via Illumina sequencing (23). These harboured 
replicons IncA/C2 or a dual replicon, IncFIIK and IncFIB. The IncA/C, IncF and IncN plasmids 
have been commonly associated with multidrug resistance (46). Although several plasmids in this 
study revealed similarity to previously reported isolates via NCBI, various sequences deviated. In 
(a) (b) 
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particular, the IncA/C2 plasmid exhibited multiple regions unique to these isolates. Several IncA/C2 
megaplasmids have been previously described which harbour various resistance genes, however, the 
extent of resistance in this study has yet to be unveiled (47, 48). Prior studies have shown the 
IncFIIK and IncFIB replicons to localise on the same plasmid and also megaplasmids with 
multidrug resistance (6). The IncFIBpQil plasmid in this study contained various beta-lactam resistance 
genes (blaKPC-2, blaOXA-9, blaTEM-1A) which has been identified previously (49). Similarly, 
blaOXA-48 segregated with the IncL/M replicon (50, 51), however, deviations in this plasmid were 
identified.  
The real-time analysis capability entailed in MinION sequencing has the potential to rapidly detect 
this antibiotic resistance. Previously, this device has been utilised to rapidly assemble bacterial 
genomes, discern species and detect antibiotic resistance (15-18). This study investigated the 
potential time required to discern resistance via a real-time emulation as previously described (17). 
The majority (≥70%) of resistance genes were detected via DNA sequencing within 2 hours. 
However, several genes absent from the final assembly were apparent after 2 hours. This may be 
attributed to the high similarity (≥80%) amongst various genes, in particular, those associated with 
aminoglycoside, beta-lactam, rifampicin and phenicol resistance. Furthermore, the accumulation of 
errors associated with ONT sequencing may result in the incorrect detection of closely related 
genes. Nanopore DNA sequencing currently has an accuracy ranging from 80 to 90% which limits 
its ability to detect mutations (17). Various resistance genes only differ by a few nucleotides which 
significantly impacts the resistance phenotype and the antibiotics which can be utilised to treat these 
infections. Furthermore, direct RNA sequencing entails an average error rate of 12% (21). Hence, it 
is essential for the technology to increase its accuracy in order to correctly and rapidly diagnose 
antibiotic resistance. 
Investigating the transcriptome of these isolates elucidated the correlation between genotype and the 
subsequent resistant phenotype. Furthermore, one of the advantages of RNA sequencing is 
exploring the conditions in which a resistance gene is present but not expressed and potentially 
resulting in a susceptible phenotype. Direct RNA sequencing revealed high levels of transcription 
from genes associated with aminoglycoside, beta-lactam, sulphonamide and trimethoprim resistance 
within 6 hours. The detection of quinolone, rifampicin and phenicol resistance correlated to the 
levels of transcription within samples. All isolates exhibited low levels of expression for 
fosfomycin, macrolide and tetracycline resistance. Whether this transcription is due to prior 
exposure to these antibiotics in the clinic and the longevity of this expression post exposure 
warrants further investigation. The changes in transcription levels in response to antibiotic exposure 
also need to be assessed in future experiments. Furthermore, the time required to detect resistance 
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may be hindered by the slower translocation speed associated with direct RNA sequencing 
compared to DNA sequencing. Furthermore, insufficient base calling of data could be impacting the 
detection of this low level expression.  
Another variable to consider when evaluating differential expression is the operon or promoter 
which can further be explored via cloning. In particular, the highest levels of expression were 
observed for blaKPC-2 in 2_GR_12 and 20_GR_12. Alterations in the promoter region have 
previously been reported to influence high levels of expression (52). Furthermore, despite low 
levels of transcription for fosfomycin (fosA) and tetracycline (tet(A), tet(G)), phenotypically these 
isolates consistently retain resistance (23). FosA, an enzyme involved in the degradation of 
fosfomycin, is commonly encoded chromosomally in K. pneumoniae and a combination of 
expression and enzymatic activity contributes to resistance (53). Genes tet(A) and tet(G) encode 
efflux pumps which, in the absence of tetracycline, are lowly expressed (54). Detecting inducible 
resistance such as tetracycline resistance highlights one of the advantages of investigating the 
transcriptome. Additionally, copy number of plasmids can further alter the levels of expression 
detected for these resistance genes. 
In this study we also investigated pathways attributed to polymyxin resistance. Three of these 
strains exhibited an IS element upstream of within mgrB, the negative regulator of PhoPQ (24, 25). 
Elevated expression was apparent for phoPQ and also the pmrHFIJKLM operon. This has 
previously been witnessed for other K. pneumoniae isolates harbouring mgrB disruptions and is a 
potential transcriptional marker for polymyxin resistance (26, 43, 55, 56). However, this study is 
limited to four isolates and one mechanism associated with polymyxin resistance. Other pathways 
have previously been identified including the role of other TCSs such as CrrAB (57). The ability to 
use relative expression of key genes to detect polymyxin resistance requires further validation, 
including an increased sample size of resistant and non-resistant isolates. Furthermore, additional 
functional experiments such as complementation assays would be required in order to validate the 
contribution of a certain mutation to the transcriptome and subsequent resistance. 
This study has utilised MinION sequencing to assemble four XDR K. pneumoniae genomes and has 
revealed several unique plasmids harbouring multidrug resistance. Furthermore, the vast majority of 
this resistance was detectable within 2 hours of sequencing. Exploiting this analysis in real-time 
would allow for a rapid diagnostic. This research established a methodology and analysis for 
bacterial direct RNA sequencing. The differential expression of resistance genes were successfully 
detected via this technology and can be exploited for bacterial transcriptomics. Overall, this study 
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unravelled the association between genotype, transcription and subsequent resistant phenotype in 
these XDR K. pneumoniae clinical isolates. 
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Chapter 4 
Characteristics of induced resistance against polymyxins and octapeptin C4 
 
4.1. Chapter introduction 
 
As previously described in Chapter 2, there is an increasing occurrence of polymyxin-resistant 
isolates globally. This is coupled with a dire lack of new antibiotics, particularly classes with the 
capacity to target MDR, XDR and/ or PDR bacteria. As illustrated in Chapter 3, these isolates 
harbour high levels of resistance encoded on mobile elements or plasmids and remain 
transcriptionally active in the absence of antibiotic exposure. Hence, an antibiotic class with the 
ability to target these clinical isolates is urgently desired. A new class of lipopeptide antibiotics, the 
octapeptins, have shown promising activity against Gram-negative bacteria with an XDR 
phenotype. Chapter 4 explores prolonged exposure of one of these clinical isolates, 20_GR_12, to 
a representative of this new class, octapeptin C4. This experiment was performed over 20 days, 
followed by an additional 5 days culture in the presence of no antibiotic to discern the stability of 
any induced resistance. In parallel, this polymyxin-susceptible isolate was also exposed to 
polymyxin B or colistin (structurally similar lipopeptides) to compare the acquisition of resistance. 
MIC studies were performed to identify any cross-resistance between antibiotics, and modifications 
in lipid A structure (the primary target of the polymyxins) were explored. Additionally, whole 
genome sequencing (Illumina) was conducted on the initial isolate and day 20 isolates from each 
treatment group. Genomic variants were investigated and complementation assays performed to 
ascertain the mutations contributing to resistance. Supplementary information for this chapter is 
located in Appendix III, page 126-132. 
 
4.2. Accepted manuscript for publication 
 
These research findings have been accepted for publication (Pitt ME, Cao MD, Butler MS, Ramu 
S, Ganesamoorthy D, Blaskovich MAT, Coin LJM, Cooper MA. Octapeptin C4 and polymyxin 
resistance occur via distinct pathways in an epidemic XDR Klebsiella pneumoniae ST258 isolate. J 
Antimicrob Chemother 2018;doi: 10.1093/jac/dky458) and are shown on pages 80-105 in Chapter 
4. As the first author, I am the primary contributor to the study design, data acquisition, data 
analysis and writing of the manuscript. I conceived the study, designed and performed the 
experiments which include MICs, induction of resistance, lipid A extractions and analysis, 
sequencing and complementation assays. I performed the sequencing library preparation, analysis 
and interpretation. I have generated all the figures and tables. I drafted the manuscript and collated 
author comments to generate this accepted manuscript. 
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4.3. Abstract 
 
Polymyxin B and E (colistin) have been pivotal in the treatment of extensively drug-resistant 
(XDR) Gram-negative bacterial infections, with increasing use over the past decade. Unfortunately, 
resistance to these antibiotics is rapidly emerging. The structurally-related octapeptin C4 (OctC4) 
has shown significant potency against XDR bacteria, including against polymyxin-resistant strains, 
but its mode of action remains undefined. We sought to compare and contrast the acquisition of 
XDR Klebsiella pneumoniae (ST258) resistance in vitro with all three lipopeptides to help elucidate 
the mode of action of the drugs and potential mechanisms of resistance evolution. Strikingly, 20 
days of exposure to the polymyxins resulted in a dramatic (1000-fold) increase in the minimum 
inhibitory concentration (MIC) for the polymyxins, reflecting the evolution of resistance seen in 
clinical isolates, whereas for OctC4 only a 4-fold increase was witnessed. There was also no cross-
resistance observed between the polymyxin- and octapeptin-induced resistant strains. Sequencing 
revealed previously known gene alterations for polymyxin resistance, including mutations in crrB, 
mgrB, pmrB, phoPQ and yciM, and the novel contribution of mutations in qseC. In contrast, 
perturbations in octapeptin-resistant isolates were found in mlaDF and pqiB, which are related to 
phospholipid transport. These genetic variations were reflected in phenotypic changes to lipid A. 
polymyxin-resistant isolates increased 4-amino-4-deoxy-arabinose fortification to phosphate groups 
of lipid A, whereas OctC4 induced strains harboured a higher abundance of hydroxymyristate and 
palmitoylate. The results reveal a differing mode of action compared to polymyxins which provides 
hope for future therapeutics to combat the increasing threat of XDR bacteria. 
Chapter 4 
81 
 
4.4. Introduction 
 
Infections by extensively drug-resistant (XDR) bacteria are an increasing concern due to the lack of 
effective antibiotics, thereby resulting in high mortality (1, 2). Common therapeutic interventions 
include fosfomycin, tigecycline and polymyxins (2, 3). However, the effectiveness of these 
therapies is short lived due to plasmid-encoded resistance (fosfomycin (4), polymyxin (5)) and rapid 
acquisition of resistance through mutation (fosfomycin (6), tigecycline (7) and polymyxin (8, 9)). 
New antibiotics with the capacity to combat these XDR bacteria are urgently desired. 
Octapeptins are structurally similar to the polymyxins, with both lipopeptide classes consisting of a 
cyclic heptapeptide ring and linear tail capped with a fatty acid, containing multiple positively 
charged diaminobutyric acid (Dab) residues (10-12) (Figure 4.1.). These Dab residues are critical 
for interactions of the polymyxins with the basal component of lipopolysaccharide (LPS), lipid A. 
Their mode of action involves the initial binding to lipid A, displacement of magnesium (Mg2+) and 
calcium (Ca2+), permeabilization of the outer and inner membrane, leakage of cytoplasmic contents 
and subsequent cell death, however, the exact mechanism is yet to be discerned (13, 14). Polymyxin 
resistance leads to modifications of the phosphate groups on lipid A with 4-amino-4-deoxy-
arabinose (Ara4N) and/ or phosphoethanolamine (pEtN). This reduces polymyxin binding by 
removing the negative phosphate that attracts the cationic Dab residues, stabilising the outer 
membrane and negating the infiltration of this antibiotic class (15, 16). Constitutive up-regulation of 
this pathway is achieved through chromosomal variations in the two-component regulatory systems 
(TCS) crrAB, pmrAB, phoPQ and the negative regulator mgrB in Klebsiella pneumoniae (8, 9, 17). 
The structurally similar octapeptins retain most of the key binding motifs, and might be expected to 
employ a similar mode of action. The most significant structural difference between the polymyxins 
and octapeptins is a truncated linear exocyclic peptide (one residue instead of three) linked to a β-
hydroxy-fatty acid (instead of an alkyl fatty acid) in the octapeptins (10-12). Loss of the fatty acid 
tail component has been shown to attenuate activity in polymyxins (18). More minor variations 
include L-Dab to D-Dab and L-Thr to L-Leu substitutions. Despite their similarity, prior research has 
revealed octapeptins retain the ability to kill polymyxin-resistant bacteria, inferring an alternative 
mode of action (10). In addition, some octapeptins have broad spectrum activity with potency 
against Gram-positive bacteria, fungi and protozoa (19, 20). 
We have recently reported the first syntheses of octapeptin C4 (OctC4) (10) and octapeptin A3 (21), 
followed by detailed biological characterisation of OctC4 that demonstrates its potential as a new 
‘last resort’ antibiotic to treat serious extensively drug-resistant Gram-negative infections. (22). In 
view of the limited understanding of the mechanism by which octapeptins target bacteria, we sought 
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to investigate the differences driving development of OctC4 and polymyxin resistance at a genetic 
level. Two studies have previously investigated the acquisition of resistance towards octapeptins. 
One was performed using EM49 (a mixture of octapeptin classes A and B) which exhibited no 
increase in resistance after 10 passages for Pseudomonas aeruginosa, Escherichia coli, 
Staphylococcus aureus and Candida albicans (23). The other investigated lipid A modifications in 
P. aeruginosa isolates resistant to OctC4 obtained from a subculture surviving a single overnight 
treatment at 2 or 32 mg/L. We have now evaluated induced resistance for OctC4, colistin and 
polymyxin B in an epidemic lineage of K. pneumoniae, ST258, isolated from a Greek hospital (24).  
The ST258 lineage of K. pneumoniae is commonly involved in outbreaks, in particular, USA, 
Greece, Italy and Israel (25-27). These isolates pose as a major threat due to frequently harbouring 
carbapenem resistance, predominantly facilitated via blaKPC genes encoded on plasmids (25, 28). 
We selected the highly resistant strain 20_GR_12 (aac(6’)Ib, aac(6’)Ib-cr, aph(3’)-Ia, aph(3”)-Ib, 
aph(6)-Id, blaKPC-2, blaLEN-12, blaOXA-9, blaTEM-1B, fosA, oqxAB, sul2, tet(A), dfrA14 
positive) as representative of the type of pathogens for which a ‘last resort’ antibiotic is employed, 
and one where high levels of clinical resistance to polymyxins have already been well characterised 
at a genetic level (24). A key reason for selecting this isolate is that we have whole genome 
sequencing of both it, and closely related clinical isolates which have become resistant to 
polymyxin (24). We are therefore able to assess how closely our laboratory-induced resistance to 
polymyxin matches the clinical development, providing greater confidence that the studies with 
OctC4 could be predictive of future clinical resistance susceptibility. The resistance induction 
experiments were followed by characterisation of antibiotic susceptibility, whole genome 
sequencing, and analysis of lipid A composition. This research has uncovered significant 
differences in the development of resistance induced by the two classes of antibiotics, both in the 
level of resistance created and in the underlying genetic mutations. The results provide strong 
support for further development of the octapeptins as potential last-resort therapeutics. 
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Figure 4.1. Structural comparison between the 3 lipopeptide antibiotics used in this study. Colistin 
(A) and polymyxin B (B) differ by one amino acid (polymyxin B: phenylalanine and colistin: 
leucine (R1)). One defining feature of octapeptin C4 (C) is that it contains 8 amino acids rather than 
10 in polymyxins. In addition, a leucine residue replaces threonine within the ring (R2), the 
exocyclic diaminobutyric acid (Dab) residue is the D-enantiomer, and the fatty acid tail contains a 3-
hydroxy group (R3). 
 
 
4.5. Materials and Methods 
 
4.5.1. Bacterial strains and growth conditions 
 
Clinical polymyxin-susceptible XDR K. pneumoniae ST258 isolate, 20_GR_12, was sourced 
through Hygeia General Hospital, Athens, Greece as previously described (24). Cultures were 
grown in lysogeny broth (LB) and for single colony isolation, cultures were grown on either LB or 
Nutrient Agar (NA) plates. 
 
4.5.2. Antimicrobial susceptibility assays 
 
Minimum inhibitory concentration was determined by the broth microdilution method according to 
Clinical & Laboratory Standards Institute (CLSI) guidelines (29). Cultures were grown in cation-
adjusted MHB and to assess cross-resistance of day 20 isolates, broth was supplemented with the 
concentration of antibiotic tolerated at that time point (Table S4.1.). Clinical breakpoints were 
determined in concordance to CLSI (30) guidelines and tigecycline as per The European Committee 
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on Antimicrobial Susceptibility Testing (EUCAST) (Version 8.0, 2018) (see 
http://www.eucast.org).  
 
4.5.3. Induction of resistance 
 
A single colony of the clinical isolate was selected and grown overnight at 37°C shaking at 220 
rpm. Similar to the broth microdilution assay, this culture was grown to log phase (OD600 = 0.4-
0.6). The culture was plated out into three separate 96-well polystyrene, non-treated plates (Sigma 
Aldrich) with six replicates for each treatment group including CST, PMB and OctC4. Plates were 
incubated overnight and OD600 was read at 20 hours. The well which harboured dense growth 
(OD600 = ≥1) underwent a 1:1000 dilution, transferred to a new plate with the concentration range 
adjusted accordingly. The highest concentration used for the polymyxins was 128 mg/L and 32 
mg/L for OctC4. This process was completed for 20 days with five following days of no antibiotic 
exposure. At day 20, the culture was further diluted (1:1000) and placed in non-supplemented broth 
to be incubated overnight. Part of this culture underwent an MIC against the antibiotic it was 
exposed to in order to evaluate stability of resistance. Several time points were isolated and stored 
in 30% sterile glycerol at -80°C for future assays. Fold change significance was determined via 
GraphPad Prism 7 with a one-way ANOVA with a Tukey’s multiple comparisons test where 
significance was P<0.05. 
 
4.5.4. Lipid A modifications 
 
Lipid A was extracted using the ammonium hydroxide-isobutyric acid protocol as previously 
described (31). Day 20 cultures were grown overnight in LB supplemented with antibiotic (Table 
S4.1.). Overnight inoculums were subcultured (1:100) into 100 mL LB and grown to an OD600 = 
0.8-1. Cultures were pelleted (10000 rpm, 20 mins, 4°C), washed with 1X PBS (10000 rpm, 15 
mins, 4°C) and freeze dried. 10 mg of lyophilised cells were processed as per (25). Concisely, 
samples were suspended in isobutyric acid:ammonium hydroxide (5:3 [vol/vol]), under magnetic 
stirring at 100°C for 4 hours, supernatants isolated by centrifugation at 13000 rpm for 15 min, 
diluted with equal volume of water and freeze dried. Extracts then underwent two methanol washes 
(4000 rpm, 15 mins). The extracted lipid A was solubilised in methanol containing 5 mM 
ammonium acetate to a concentration of 1 mg/L. Samples were infused at a low rate of 5 µl/min 
into a QSTAR Elite (Applied Biosystems) hybrid quadrupole Time-of-Flight (TOF) mass 
spectrometer. To acquire adequate fragmentation for MS/MS analysis, the collision energy was 
increased from 40 to 80. Averaged spectra were accumulated over at least 1 min. Data were 
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exported from Analyst (SCIEX), normalized to the highest mass intensity and graphed in GraphPad 
Prism 7. 
 
4.5.5. DNA extractions and library preparation 
 
Glycerol stocks from day 20 isolates were grown on NA plates overnight. Single colonies were 
isolated, grown in antibiotic supplemented broth (Table S4.1.), incubated overnight and DNA 
extracted using the DNeasy Blood and Tissue Kit (Qiagen) according to manufacturer’s guidelines. 
Two colonies were selected from day 0 and 4 colonies from 4 replicates per treatment group. 
Quantification of DNA was acquired using Qubit®3.0 (ThermoFisher Scientific) and 1 ng of DNA 
underwent library preparation with the Nextera XT kit (Illumina) as per manufacturer’s instructions. 
Quality control was checked with a 2100 Bioanalyzer (Agilent Technologies) and LabChip GX 
(PerkinElmer).  
 
4.5.6. Sequencing and analysis 
 
Libraries were sequenced on an Illumina NextSeq with 150 bp paired end sequencing reads with 
≥95X coverage with the exception of CST_2 (colony 1) (48X). Trimmomatic (32) was used to trim 
paired end reads and SPAdes v3.10.1 implemented for assembly (33). Annotation of assembled 
genomes was accomplished using the Rapid Annotation using Subsystem Technology (RAST) (34). 
The Centre for Genomic Epidemiology (CGE) tools were implemented to delineate laterally 
acquired resistant genes (ResFinder 3.0) (35) and plasmids (PlasmidFinder 1.3) (36). Reads were 
aligned using BWA-MEM (37), analyzed through FreeBayes (38) and impact of change determined 
through snpEff (39). 
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4.5.7. Complementation assays 
 
Genes speculated to cause resistance underwent complementation as previously described (40). 
Briefly, genes harbouring a potential variation contributing to resistance was amplified using the 2X 
Phusion HF master mix (ThermoFisher) with primers listed in Table S4.2.. The gene was cloned 
into the pCR-BluntII-TOPO using the Zero Blunt TOPO PCR cloning kit (Invitrogen). The plasmid 
was transformed in electrocompetent EC TOP10 via electroporation, grown on MHB agar 
supplemented with kanamycin (50 mg/L) at 37°C overnight and plasmids extracted using the 
QIAprep spin miniprep column kit (Qiagen). Plasmids were transformed into the initial susceptible 
strain (20_GR_12) and incubated overnight on MHB agar containing zeocin (1500 mg/L). 
Furthermore, the wild-type gene was amplified from the initial strain and placed into the resistant 
day 20 isolates. An MIC was conducted to determine if resistance was altered as mentioned above. 
 
4.5.8. Data summary 
 
Whole genome sequencing of 50 isolates has been deposited under BioProject PRJNA415530 
(www.ncbi.nlm.nih.gov/bioproject/415530). 
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4.6. Results 
 
4.6.1. Rapid resistance acquisition for polymyxins dissimilar to OctC4 
 
Selected resistance of the XDR K. pneumoniae isolate was monitored over a 20 day time course, 
with six replicates exposed to increasing concentrations of either polymyxin B (PMB), polymyxin E 
(colistin, CST) and OctC4. Significant variability was observed between polymyxins and OctC4 
(Figure 4.2.d). Initially, an MIC of 0.125 mg/L was measured for both CST and PMB. The 
majority of replicates treated with the polymyxins had a clinical resistance phenotype of >2 mg/L 
by day 10 (Figure 4.2.a and b). At some point, every replicate had a dramatic and rapid escalation 
in MIC to >64 mg/L, generally over ≤5 days. The timing for the drastic increase varied between 
replicates, and appeared dependent on whether the replicate could tolerate 0.5 mg/L, with a steep 
escalation from the day that resistance level was exceeded. In sharp contrast, OctC4 resistance 
progressed steadily over the 20 days (Figure 4.2.c) with only a 4-fold overall increase compared to 
a ≥1000-fold increase for the polymyxins (Figure 4.2.e). The trend for a gradual increase in OctC4 
resistance was consistent amongst replicates. The induced resistance appeared to be stable after five 
additional passages without antibiotic exposure for polymyxins. The extent of growth in wells 
containing either 32 or 16 mg/L started to diminish for OctC4-induced isolates during the last 
passages. 
 
4.6.2. Lack of cross-reactivity and reduction of resistance in OctC4 induced isolates 
 
Day 20 isolate MICs were determined against a broad array of antibiotic classes to evaluate if 
acquired resistance conferred cross-resistance, or resulted in regained susceptibility (Table 4.1.). 
Remarkably, no cross-reactivity was apparent between polymyxins and OctC4. Non-susceptibility 
towards amoxicillin, aztreonam, ceftriaxone, ciprofloxacin, piperacillin and trimethoprim was 
ubiquitous amongst treatment groups. Chloramphenicol resistance was observed in the initial isolate 
but was diminished in the majority of replicates over the time course for all three antibiotics. In 
some instances, cefepime susceptibility was restored (replicates OctC4_3, OctC4_4 and OctC4_6). 
These replicates also regained susceptibility to meropenem, as did PMB_2. Replicate OctC4_2 also 
exhibited susceptibility to tetracycline and tigecycline whilst this profile for OctC4_4 varied 
extensively for these antibiotics, where resistant and susceptible MICs were recorded depending on 
the colonies selected. 
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Figure 4.2. Acquired resistance in extensively drug-resistant K. pneumoniae over time for polymyxins and octapeptin C4. (a) Colistin (b) Polymyxin B 
(c) Octapeptin C4 (d) Overall comparison of acquired resistance for 20 day antibiotic exposure and 5 days following without exposure (mean±SEM, 
n=6) (e) Fold change of colistin, polymyxin B, and octapeptin C4 in concordance to day 0 and 20 MIC (mean±SD) (****P<0.001). Line represents 
break points (2 mg/L polymyxins, 8 mg/L set for octapeptin to highlight divergence from day 0). Highest concentration used for polymyxins was 128 
mg/L and 32 mg/L for octapeptin C4. 
(a) (b) (c) 
(d) (e) 
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Table 4.1. Minimum inhibitory concentrations of day 20 replicates compared to initial isolate across several antibiotic classes 
 
 
Strain* 
Minimum inhibitory concentration (mg/L)† 
CST PMB OctC4 AMX ATM FEP CRO CHL CIP GEN MEM PIP TET TGC TMP 
Initial ≤0.25S ≤0.125S 8.00 >64.0R >64.0R ≥16.0R >64.0R ≥32.0R >64.0R ≤4.00S ≥32.0R >64.0I >64.0R ≤2.00S, I >64.0R 
CST_1 >128R >128R ≤8.00 >64.0R >64.0R ≥16.0R >64.0R ≤8.00S ≥32.0R 4.00S ≥32.0R >64.0I >64.0R ≤4.00S, R >64.0R 
CST_2 >128R >128R ≤4.00 >64.0R >64.0R >64.0R >64.0R 4.00S ≥32.0R ≤4.00S ≥32.0R >64.0I >64.0R 2.00I >64.0R 
CST_3 ≥128R ≥128R ≤4.00 >64.0R >64.0R >64.0R >64.0R 8.00S >64.0R ≤4.00S >64.0R >64.0I >64.0R ≤4.00 I, R >64.0R 
CST_4 >128R >128R ≤8.00 >64.0R >64.0R >64.0R >64.0R ≤8.00S >64.0R ≤4.00S >64.0R >64.0I >64.0R ≤4.00 I, R >64.0R 
CST_5 >128R >128R 2.00 >64.0R >64.0R >64.0R >64.0R ≤8.00S >64.0R ≤4.00S >64.0R >64.0I >64.0R ≤4.00I, R >64.0R 
CST_6 >128R >128R ≤8.00 >64.0R >64.0R >64.0R >64.0R 8.00S >64.0R ≤4.00S >64.0R >64.0I >64.0R ≥4.00R >64.0R 
PMB_1 128R 128R ≤4.00 >64.0R >64.0R >64.0R 32.0R 4.00S 32.0R ≤4.00S >64.0R >64.0I >64.0R ≤4.00I, R >64.0R 
PMB_2 >128R >128R 8.00 >64.0R >64.0R ≤8.00I >64.0R 4.00S >64.0R ≤4.00S ≤0.25S >64.0I >64.0R ≤2.00S, I >64.0R 
PMB_3 >128R >128R 4.00 >64.0R >64.0R ≥32.0R >64.0R 8.00S >64.0R 2.00S ≥32.0R >64.0I >64.0R 2.00I >64.0R 
PMB_4 >128R >128R 4.00 >64.0R >64.0R ≥8.00I,R ≥32.0R ≤2.00S 48.00R 2.00S ≥8.00R >64.0I >64.0R 2.00I >64.0R 
PMB_5 >128R >128R ≤8.00 >64.0R >64.0R ≥8.00I,R ≥32.0R ≤8.00S >64.0R ≤4.00S ≥2.00I, R >64.0I >64.0R ≤2.00S, I >64.0R 
PMB_6 >128R >128R ≤8.00 >64.0R >64.0R ≥16.0R >64.0R 8.00S >64.0R ≤4.00S ≥32.0R >64.0I >64.0R ≤4.00I, R >64.0R 
OctC4_1 0.25S ≤0.25S 32.0 >64.0R >64.0R ≥16.0R >64.0R 8.00S >64.0R ≤2.00S ≥32.0R >64.0I >64.0R ≤2.00S, I >64.0R 
OctC4_2 0.25S 0.25S 32.0 >64.0R >64.0R ≥8.00I,R >64.0R 8.00S >64.0R ≤2.00S ≥32.0R >64.0I ≤2.00S ≤1.00S ≥8.00R 
OctC4_3 ≤0.5S 0.25S 32.0 >64.0R >64.0R ≤4.00S, I 32.0R 8.00S >64.0R ≤4.00S ≤0.25S >64.0I >64.0R 2.00I >64.0R 
OctC4_4 ≤0.5S 0.25S >32.0 >64.0R >64.0R ≤4.00S, I 32.0R 8.00S >64.0R 1.00S ≤0.25S >64.0I ≥2.00S, R ≤2.00S, I ≥4.00R 
OctC4_5 0.50S 0.50S 32.0 >64.0R >64.0R >64.0R >64.0R ≤8.00S >64.0R 2.00S >64.0R >64.0I >64.0R 2.00I >64.0R 
OctC4_6 ≤0.5S ≤0.5S 32.0 >64.0R >64.0R ≤4.00S, I ≥32.0R ≤16.0S, I >64.0R 2.00S ≤0.25S >64.0I >64.0R 2.00I >64.0R 
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*Initial polymyxin-susceptible isolate is 20_GR_12 compared against 20 days of treatment against 
polymyxin B (PMB), colistin (CST) or Octapeptin C4 (OctC4). 
†Minimum Inhibitory Concentration tested for CST, Colistin; PMB, polymyxin B; OctC4, 
Octapeptin C4; AMX, Amoxicillin; ATM, Aztreonam; FEP, Cefepime; CRO, Ceftriaxone; CHL, 
Chloramphenicol; CIP, Ciprofloxacin; GEN, Gentamicin; MEM, Meropenem; PIP, Piperacillin; 
TET, Tetracycline; TGC, Tigecycline; TMP, Trimethoprim. MIC displayed as mean (n=4). 
Resistance determined as per CLSI guidelines and EUCAST for tigecycline with: S, Susceptible; I, 
Intermediate; R, Resistant. Fluctuations in MIC values are displayed by two letters defining the 
resistance level. Resistance for Octapeptin C4 defined as ≥32 mg/L. 
 
4.6.3. Octapeptin resistance induced isolates harbour an increase in hydroxymyristate and 
palmitoylate dissimilar to Ara4N lipid A modifications in polymyxin-resistant strains 
 
In the initial isolate, MS/MS analysis of extracted lipid A fractions showed that the major singly 
charged peak was m/z 1824.2, which corresponded to a hexa-acylated lipid A species comprised of 
two phosphate groups, two glucosamines and four 3-hydroxy-myristoyl groups (3-OH-C14), with 
two of these further acylated with myristate (C14) (Figure 4.3.a, Figure S4.1.). Due to the low 
intensity of this peak and the maximum detection limit of 2000 Da, in the system used, doubly 
charged masses were examined (Figure S4.1.a). This mass correlated to a doubly charged species 
of m/z 911.6 herein designated as the wild-type (WT) lipid A. Lesser quantities of various 
modifications accompanied the WT lipid A in the initial strain, including a hydroxyl modification 
of a myristate (m/z 919.6, WT+C14:OH), palmitoylation (m/z 1030.7 WT+C16) and even the addition 
of Ara4N (m/z 977.1, WT+Ara4N), a modification known to confer polymyxin resistance (Figure 
4.3.b). In sharp contrast, the predominant species found in polymyxin-resistant isolates was the near 
complete loss of WT lipid A and fortification of Ara4N on phosphate groups, mainly in 
hydroxymyristate species (m/z 985.1, WT+C14:OH+Ara4N; m/z 1042.7, WT+2(Ara4N); m/z 1050.7, 
WT+C14:OH+2(Ara4N)) (Figure 4.3.b, Figure S4.2. and S4.3.). These changes corresponded to the 
genetic changes described in the following sections. The other commonly reported lipid A 
modification for resistance, pEtN, corresponding to m/z 973.2 was never observed. The lipid A from 
the OctC4 induced isolates was substantially different from the polymyxin-resistant isolates and 
similar to the WT profile, with a major peak of the hydroxymyristate derivative and a significant 5-
fold increase in representation of palmitoylation (Figure 4.3.b, Figure S4.4.). The Ara4N 
modification was enhanced compared to WT, but not to the extent seen with polymyxin-resistant 
isolates. 
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Figure 4.3. Lipid A modifications identified after 20 days of exposure to either colistin, polymyxin B or octapeptin C4. (a) Modifications which were 
detected in wild-type (WT) hexa-acylated lipid A. This included hydroxylation of a myristate (R1), palmitoylation (R2) and the addition of 4-amino-4-
deoxy-arabinose (Ara4N) to either phosphate groups (R3, R4). (b) Doubly charged lipid A species detected for the initial isolate (n=2) and treatment 
groups (n=6). Values represent mean±SD of relative peak intensities. 
[M-2H]2- Species Initial CST PMB OctC4 
911.6 WT 100±0.0 6.2±4.6 9.6±4.8 84.2±7.6 
919.6 WT+OH 39.5±1.1 10.8±7.6 27.0±13.7 100±0.0 
977.1 WT+Ara4N 50.5±0.1 57.4±32.1 46.6±19 34.0±5.4 
985.1 WT+OH+Ara4N 22.7±0.2 78.9±38.7 88.6±18.9 45.1±3.5 
1030.7 WT+C16 21.5±3.0 4.1±3.3 16.0±14.0 41.9±6.4 
1038.7 WT+OH+C16 9.9±0.0 3.7±3.4 29.0±14.0 62.8±4.4 
1042.7 WT+2(Ara4N) 2.5±0.2 56.0±28.2 18.3±8.5 2.9±1.1 
1050.7 WT+OH+2(Ara4N) 1.2±0.1 64.6±36.4 30.7±16.3 2.3±0.3 
1096.3 WT+Ara4N+C16 9.5±0.9 33.6±20.3 48.4±32.2 8.6±1.5 
1104.3 WT+OH+Ara4N+C16 5.2±0.5 33.3±18.5 70.5±28.1 21.6±3.2 
1161.8 WT+2(Ara4N)+C16 0.4±0.0 31.2±14.2 11.7±8.5 0.5±0.1 
1169.8 WT+OH+2(Ara4N)+C16 0.3±0.0 26.3±20.4 12.0±5.7 0.5±0.1 
(b) (a) 
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I II III IV V
20_GR_12 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
CST_1 4 4 4 4 4 4 4 1 3 4 4 4 4 4 4 4 4 4 4 4 4
CST_2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
CST_3 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
CST_4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
PMB_1 4 4 4 4 4 4 4 1 3 4 4 4 4 4 4 4 4 4 4 4 4
PMB_2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
PMB_3 4 3 4 4 3 3 3 1 4 4 4 4 4 4 4 4 4 4 4 4 3
PMB_4 4 4 4 4 4 4 4 1 3 4 4 4 4 4 4 4 4 4 4 4 4
OctC4_1 4 4 4 4 1 3 4 1 4 4 4 4 4 4 4 4 4 4 4 4 4
OctC4_2 4 4 3 4 4 4 4 4 4 4 4 4 4 4
OctC4_3 4 4 2 2 4 3 4 1 2 2 4 4 4 4 2 2 2 4 4 4 2 4
OctC4_4 4 1 1 4 1 4 4 4 4 1 1 1 4 1 4
Q
Strain*
Antibiotic class impacted
†
Plasmids
‡
A B
4.6.4. Plasmid loss associated with OctC4 resistance 
 
To ascertain the genetic basis for resistance and subsequent phenotypic traits, four day 20 replicates 
were selected from each treatment group. Clonal expansion of genomic variations were monitored 
by selecting four colonies per replicate. Additionally, two colonies from the initial isolate were 
sequenced. The initial isolate harboured multiple acquired resistance genes targeting 
aminoglycosides, β-lactams, fosfomycin, quinolones, sulphonamides, tetracycline and 
trimethoprim, consistent with the parent XDR profile (Table 4.2.). Five plasmid replicons were 
identified including ColRNAI, IncFIB(K)-Kpn3, IncFII(K), IncN and IncX3. In cross-resistance 
studies, the only polymyxin-resistant replicate with an alteration in MIC profile to other antibiotics 
was PMB_2. Unique to PMB_2 was the susceptibility to meropenem and a reduction in resistance 
towards cefepime. Sequencing revealed a lack of aph(3’)-Ia, blaKPC-2, blaOXA-9 and no evidence 
of the IncX3 replicon in all four colonies. There was also a partial loss of this plasmid in PMB_3 
(Table 4.2.). High variability of acquired resistance genes and plasmids were witnessed for OctC4 
exposed replicates. Resistance genes impacted included aph(3’)-Ia, aph(3”)-Ib, aph(6)-Id, blaKPC-
2, blaOXA-9, blaTEM-1B, sul2, tet(A) and dfrA14. Furthermore, plasmid replicon loss was apparent 
in three of the four replicates including IncFIB(K)-Kpn3, IncFII(K) and IncN. Subtle discrepancies 
in β-lactamase genes were observed across the three treatment groups; however, this was attributed 
to difficulties in the assembly due to high similarity amongst these genes. 
 
Table 4.2. Detection of acquired resistance genes and plasmid replicons compared to the initial 
isolate and treatment groups 
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*Strain represents initial isolate (20_GR_12) and this strain subjected to 20 days of treatment with 
either colistin, CST; polymyxin B, PMB; Octapeptin C4 and _replicate number. 
†Acquired resistance genes as determined by ResFinder 2.1 (≥90% identity and ≥60% length) for A, 
Aminoglycoside; B, Beta-Lactam; F, Fosfomycin; Q, Quinolone; S, Sulphonamide; T, Tetracycline; 
Tr, Trimethoprim. 
‡Plasmid replicons detected by PlasmidFinder 1.3 (≥95% identity). Plasmid numbers represent I, 
ColRNAI; II, IncFIB(K)-Kpn3; III, IncFII(K); IV, IncN; V, IncX3. 
Shading represents the presence of the gene or plasmid and the number indicates the colonies 
harbouring this attribute. 
 
4.6.5. Chromosomal variations in lipopolysaccharide pathways associated with polymyxin 
resistance whilst phospholipid transport associated with OctC4 resistance 
 
Genomic alterations identified in polymyxin and OctC4 treated replicates differed significantly. In 
polymyxin-resistant replicates, genes predominantly associated with LPS processing and lipid A 
modifications were altered, including crrB, hepIII, lptC, mgrB, pmrB, phoPQ and yciM (Table 4.3.) 
An additional TCS gene, qseC, was also disrupted in PMB_3 (S8R, I283L) and PMB_4 (L40F). 
Although similar genes were impacted across replicates, the mutation positions differed. 
Additionally, an accumulation of variations in LPS pathways were apparent within a single 
replicate. All four colonies from a single replicate were commonly changed indicating clonal 
expansion of this variant. Complementation assays were further conducted to unveil the 
contributions of these genes to observed resistance (Figure 4.4.). Polymyxin susceptibility was 
restored in CST_2 (complete deletion of mgrB), CST_3 (M1I), CST_4 (N42I), PMB_2 (W47L) and 
PMB_4 (D29Y) once complemented with pTOPO-mgrB (Figure 4.4.b-d, f and h). The PmrB 
(P95L) variant in PMB_1 was validated to contribute to resistance (Figure 4.4.e). Alterations in 
CrrB (D57V), PhoP (R81C) and QseC (S8R, I283L) were confirmed to cause resistance once these 
genes were introduced into the initial strain (Figure 4.4.m). Subtle increases in polymyxin MIC 
was detected for PhoQ (P420A, G434C), PhoQ (D417N) and QseC (L40F) but did not surpass the 
breakpoint (Figure 4.4.m). This confirms the presence of multiple resistance conferring mutations 
being present in a single isolate and several contributing to the elevation of MIC. 
 
The OctC4 replicates harboured changes in mlaDF, pqiB and traH in all four colonies. Additional 
genes altered that were apparent in two colonies per replicate included azoR, hinT and rpsA. 
Strikingly, mlaF (A165P) was impacted in three different OctC4 replicates at the same position 
(Table 4.3.). Complementation assays that introduced pTOPO-mlaD, -mlaF or -pqiB into OctC4 
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induced replicates reduced the MIC by 2-fold, however, consistently only partial growth was 
observed at 8 mg/L. This finding validates the partial contribution of these genes to resistance 
(Figure 4.4.i-l). Introduction of WT genes into the initial isolate revealed that the vector and gene 
did not influence the MIC and confirmed that these alterations are responsible for the resistance 
observed (Figure 4.4.m and n). 
 
Table 4.3. Genomic alterations detected in day 20 resistance induced isolates 
*Strain represented as treatment group (Colistin, CST; Polymyxin B, PMB; Octapeptin C4, OctC4), 
_ replicate number and number of colonies impacted from the 4 selected.  
†Nucleotide variations present in ≥90% of reads and ≥50X coverage compared to initial strain, 
20_GR_12. Δ symbolises a deletion, – in front of the nucleotide position indicates an alteration 
upstream and fs represents a frameshift mutation. 
‡The introduction of a truncation in the protein downstream of the alteration is noted as tr. 
 
 
Strain* Gene Gene description Nucleotide change† 
Amino acid 
change‡ 
CST_1(4) crrB Two-component hybrid sensor and regulator  A170T D57V 
CST_2(4) hepIII Lipopolysaccharide heptosyltransferase III  A238Δfs R80Gtr 
CST_2(4) mgrB Putative inner membrane protein  1-144Δ 1-47Δ 
CST_3(4) mgrB Putative inner membrane protein  G3A M1I 
CST_3(4) phoQ Sensor protein  C1258G, G1300T 
P420A, 
G434C 
CST_4(3) epsJ Glycosyltransferase  T932G L310STOP 
CST_4(3) lptC Lipopolysaccharide export system protein  Δ498Afs N166Ktr 
CST_4(4) mgrB Putative inner membrane protein  G-41T, A125T N42I 
CST_4(4) phoQ Sensor protein  G1249A D417N 
PMB_1(4) pmrB Sensor protein  C284T P95L 
PMB_2(4) dnaJ Chaperone protein  A892C T298P 
PMB_2(4) mgrB Putative inner membrane protein  G140T W47L 
PMB_2(4) phoP Transcriptional regulatory protein  C241T R81C 
PMB_2(4) hepIII Lipopolysaccharide heptosyltransferase III  TGAAGAGACCCG153Δ Y51STOP 
PMB_3(4) qseC Sensory histidine kinase  
GCCTGAGCCTGC17Δfs, 
A847C 
S8R, I283L 
PMB_4(4) mgrB Putative inner membrane protein  G85T D29Y 
PMB_4(4) qseC Sensory histidine kinase  CTGGATAAGCTG118Δfs L40F 
PMB_4(4) yciM Lipopolysaccharide regulatory protein  T128G V43G 
OctC4_1(4) mlaD 
Uncharacterised ABC transporter, periplasmic 
component  
C403T Q135STOP 
OctC4_1(4) pqiB Paraquat-inducible protein B  C1258T Q420STOP 
OctC4_1(4) traH Conjugal transfer protein  G417T M139I 
OctC4_2(4) pqiB Paraquat-inducible protein B  A2080C T694P 
OctC4_2(2) rpsA SSU ribosomal protein S1p  T1031A L344Q 
OctC4_3(2) hinT 
YcfF/hinT protein: purine nucleoside 
phosphoramidase  
Δ240Cfs D81Rtr 
OctC4_4(2) azoR FMN-dependent NADH-azoreductase  T152A L51Q 
OctC4_2(4),3(4),
4(4) 
mlaF 
Uncharacterised ABC transporter, ATP-binding 
protein  
GCCGC493Δfs A165Ptr 
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Figure 4.4. Complementation assays to delineate contribution of variations detected in day 20 
treated strains to resistance. (a-d) Colistin treatment groups complemented with WT gene. (a) 
CST_1 with pTOPO-crrB. (b) CST_2 with pTOPO-mgrB. (c) CST_3 with pTOPO-mgrB or 
pTOPO-phoQ. (d) CST_4 with pTOPO-mgrB or pTOPO-phoQ. (e-h) Polymyxin B treatment 
groups complemented with WT gene. (e) PMB_1 with pTOPO-pmrB. (f) PMB_2 with pTOPO-
mgrB or pTOPO-phoP. (g) PMB_3 with pTOPO-qseC. (h) PMB_4 with pTOPO-mgrB or pTOPO-
qseC. (i-l) Octapeptin C4 treatment groups complemented with WT gene. (i) OctC4_1 with 
pTOPO-mlaD or pTOPO-pqiB (j) OctC4_2 with pTOPO-mlaF or pTOPO-pqiB. (k) OctC4_3 and 
with pTOPO-mlaF. (l) OctC4_4 with pTOPO-mlaF. (m) 20_GR_12, the initial strain, 
complemented with WT genes and genes harbouring mutations potentially causing polymyxin 
resistance. (n) Complementation of octapeptin C4 resistance associated WT genes in 20_GR_12. 
The (-) indicates no complementation was conducted and represents the initial MIC. The y-axis split 
signifies the breakpoint for polymyxins (2 mg/L) and initial MIC for octapeptin C4 (8 mg/L). 
Values represented as mean±SD (n=4). Values above bars (a-l) indicate amino acid change in 
induced resistant isolate. Δ represents a complete deletion of protein and * is a stop codon.
(a) (b) (c) (d) 
(e) (f) (g) (h) 
(i) (j) (k) (l) 
(m) (n) 
D57V 
Δ M1I 
P420A 
G434C 
N42I 
D417N 
P95L 
W47L 
R81C 
S8R 
I283L 
D29Y 
L40F 
Q135* Q420* A165P T694P A165P A165P 
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4.7. Discussion 
 
Polymyxins unfortunately now induce high levels of resistance during therapeutic use, which is 
further compromised by suboptimal exposure in the clinic due to the risk of nephrotoxicity (41). 
Resistance in K. pneumoniae appears to be stable and incurs a minimal fitness cost (42, 43). These 
clinical characteristics were reflected in our study whereby once the isolate could tolerate 0.5 mg/L 
of either CST or PMB, the clinical breakpoint was vastly exceeded within 48 h, well within the 
duration of clinical antibiotic therapy. This rapid induction of resistance was not observed for 
OctC4, in which only comparatively minor increases in MIC were observed. The slow progression 
in resistance profile could be an advantageous characteristic of OctC4 as a potential clinical 
intervention. 
Following 20 days of increasing sub-lethal antibiotic exposure, no cross-resistance was apparent 
between polymyxins and OctC4. CST and PMB resulted in similar resistance profiles with the only 
deviation seen in sample PMB_2 in which susceptibility to meropenem was regained. This is due to 
the absence of blaKPC-2 and blaOXA-9. Additionally, the homogenous loss of the IncX3 plasmid 
was identified. Clinically, meropenem is being used in combination with polymyxins, and these 
results suggest that, in some cases, meropenem may overcome polymyxin resistance (44, 45). 
Furthermore, previous research has identified the loss of blaKPC plasmids in polymyxin-resistant 
clinical isolates and suggests that this loss is due to a potential fitness cost (46). Our results also 
show plasmid loss in OctC4-exposed replicates, and this corresponded to a reduction in resistance 
towards cefepime, meropenem and tetracycline. Whether this resembles a fitness cost associated 
with OctC4 exposure or results from repeated passaging under no selective pressure for the genes 
harboured on these plasmids warrants further investigation. 
Interestingly, resistance towards chloramphenicol was diminished in polymyxin and OctC4 exposed 
strains. Resistance towards chloramphenicol can arise from plasmid-encoded chloramphenicol 
acetyltransferases, alterations in the target 50S ribosomal subunit, or disruptions in porins and 
efflux pumps (47). The absence of acquired resistance genes and the lack of modifications in these 
regions may imply either a down-regulation of efflux pumps or an alternative resistance 
mechanism. The synergistic mechanism of polymyxins and chloramphenicol have been extensively 
studied; however, this finding potentially indicates a novel loss of chloramphenicol resistance upon 
gaining resistance towards these lipopeptides (48, 49), and is also seen with the octapeptins. 
Analysis of genomic variations in day 20 isolates revealed major differences between isolates with 
induced resistance against polymyxins or OctC4. Polymyxins were used as a reference, with 
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resistance induction resulting in perturbations of previously known genes. The involvement of 
genes crrB, mgrB, pmrB, phoPQ and yciM have previously been described (16, 17, 50), and many 
similar genes impacted were observed in polymyxin-resistant clinical isolates related to the parent 
strain of this study (24). These mutations lead to increased levels of Ara4N–modified lipid A, as 
observed in the lipid A analysis. Interestingly, the initial polymyxin-susceptible isolate exhibited 
Ara4N lipid A modifications which reveals a heteroresistant strain where a subpopulation of 
resistant bacteria exists within a phenotypically susceptible isolate. In several instances for 
polymyxin induced isolates, mutations were present in multiple genes within a replicate. CST_3 
harboured a deleterious mutation in mgrB (M1I) and additional alterations in phoQ (P420A, 
G434C) increased tolerance to CST. This was also the circumstance for CST_4 (mgrB: N42I, phoQ: 
D417N). PMB_2 possessed a resistance conferring mutation in mgrB (W47L) and phoP (R81C). 
The notion that one alteration in TCS drives resistance, the circumstance for the majority of clinical 
isolates is well accepted (51). Our findings contradict this concept, however, this may be attributed 
to the heightened concentrations of antibiotics implemented in this in vitro experiment.  
We also identified alterations in another TCS, QseBC, which is known to facilitate cross-talk with 
PmrAB in Escherichia coli (52). In E. coli, PmrB acts as a noncognate partner to the QseBC TCS 
and has the capability to not only phosphorylate PmrA, but also QseB. The absence of QseC was 
shown to impact virulence due to the accumulation of phosphorylated QseB and in particular, 
alterations in the histidine kinase domain attenuates its ability to de-phosphorylate QseB (52, 53). 
Furthermore, the deletion of qseC and pmrA, promoting phosphorylation of QseB by PmrB, 
stimulated tolerance to PMB (54). This signalling pathway remains severely under characterised in 
K. pneumoniae. We observed partial tolerance to PMB when a frameshift mutation was apparent at 
nucleotide 118; however, full resistance in PMB_4 was promoted by alterations in mgrB (D29Y) 
and yciM (V43G), which has recently been identified to cause resistance (50). Conversely, PMB_3 
also harboured a frameshift mutation early in the coding sequence of qseC 
(GCCTGAGCCTGC17Δfs), although an additional I283L change in the histidine kinase region 
resulted in an MIC of 4 mg/L. This did not explain the full resistance profile exhibited by PMB_3 
and due to the presence of both alleles during complementation, the true extent of resistance cannot 
be deduced. Considering PMB_3 still resulted in the addition of Ara4N to lipid A, we speculate that 
due to the perturbation in the QseC kinase, this is increasing the accumulation of phosphorylated 
QseB and allows for the up-regulation of transcriptional targets. Subsequent transcription could be 
activating PmrA, similar to other TCS in K. pneumoniae, allowing for the expression of the 
pmrHFIJKLM operon (Figure 4.5.a).  
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Figure 4.5. Proposed pathway associated with K. pneumoniae polymyxin and octapeptin C4 
resistance observed in this study. (a) To facilitate resistance against polymyxins, genomic variations 
are acquired in two-component regulatory systems. These encompass CrrAB, QseBC, PmrAB and 
PhoPQ with MgrB acting as a negative repressor. Once this pathway is activated during resistance, 
sensor histidine kinases (CrrB, QseC, PmrB, PhoQ) will phosphorylate response regulators (CrrA, 
QseB, PmrA, PhoP) and allow for the expression of target genes (crrC, unknown (?), pmrD, 
pmrHFIJKLM). Disruptions in MgrB allow for the up-regulation of this pathway resulting in the 
expression of pmrHFIJKLM which allows for 4-amino-4-deoxy-arabinose to be attached to 
phosphate groups on lipid A. The phosphoethanolamine lipid A modification, facilitated via the 
pmrCAB operon, was not observed in this study (b) The major disruptions identified during 
octapeptin C4 resistance was in the Mla and Pqi pathway. OmpC removes phospholipids (PLs) 
from the outer member and transfers these to MlaA. PLs are transported across the periplasm via 
MlaC and transported to the MlaBDEF complex where the subsequent fate of PLs is unknown. An 
unknown porin complexes with PqiC to transport metabolites and potentially PLs across the 
periplasm via the PqiAB complex. Perturbations in these pathways elevated the MIC towards 
octapeptin C4 and subsequent hydroxymyristate and palmitoylation of lipid A to potentially 
stabilise the outer membrane. 
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The mutation pattern was greatly different in OctC4-exposed replicates, with all harbouring 
alterations in the Mla pathway. These genes are responsible for phospholipid (PL) importation from 
the outer membrane into the cell (55). Removal of mlaC in E. coli was previously identified to 
increase the abundance of palmitoylated lipid A to stabilise the outer membrane which correlated to 
the phenotype in our study. Similarly, prior research exposing P. aeruginosa to OctC4 (32 mg/L) 
revealed an increase in palmitoylated lipid A (22). Literature reports have demonstrated that 
octapeptins have the capacity to bind to PLs (56), and likely OctC4 utilises this pathway in order to 
traverse to the outer membrane (Figure 4.5.b). The involvement of PqiB in membrane integrity has 
only recently been characterised in EC (57). PqiB was identified to connect to PqiC and potentially 
deliver substrate/s from the outer to inner membrane. The contribution of the PqiABC appeared 
minimal compared to the Mla pathway and was proposed to either ineffectively transport PLs or 
transport different substrates with a minute impact on membrane integrity. The contribution of the 
Pqi and Mla pathway appeared to be additive when evaluating the MIC reduction in OctC4_1 and 
OctC4_2. Further genes impacted not homogeneous amongst the colonies included rpsA (40S 
ribosomal protein), azoR (quinone reductase), traH (plasmid conjugal transfer protein) and hinT 
(purine nucleoside phosphoramidase), which may indicate several intracellular targets (58-61).  
Overall, the lack of mutations associated with Ara4N-modifications to lipid A is consistent with the 
lipid A profile of the OctC4-induced isolates. This observation supports the hypothesis that the 
octapeptins work by a different mode of action compared to the polymyxins, one that does not 
require an initial binding to lipid A and explains the lack of cross-resistance between the two classes 
of lipopeptides. However, further studies are required to determine if this occurs ubiquitously for K. 
pneumoniae and if the same phenomenon is observed for other Gram-negative pathogens, in 
particular E. coli, P. aeruginosa and Acinetobacter baumannii. The development of resistance via in 
vitro experiments entails several caveats compared to the clinical in vivo condition, including a 
limited regulation of cell growth and antibiotic concentration and exposure to a concentration of 
antibiotic which may not reflect an in vivo scenario (62, 63). Hence, it would be of interest to study 
the development of octapeptin resistance in vivo. The current research has revealed various novel 
mutations and differing pathways associated with polymyxin resistance, including the QseBC TCS. 
Additionally, multiple mutations associated with polymyxin resistance were detected within several 
isolates. Whether these mutations occur in an extended sample size of clinical isolates requires 
further investigation, as does the potential fitness cost associated with OctC4 resistance. 
Nonetheless, this study has highlighted that the slow progression of resistance, potential fitness cost 
if resistance develops, and the alternative mechanism of infiltration of OctC4 demonstrate the 
potential for octapeptins as future antibiotics. 
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Chapter 5 
Conclusions and Future Directions 
 
5.1. Conclusions 
 
Antibiotic resistance is rapidly emerging in K. pneumoniae with the vast majority of isolates 
exhibiting an MDR phenotype. A high abundance of these strains remain under characterised 
genotypically and phenotypically. This lack of information hinders the identification of highly 
resistant pathogens in particular, PDR bacteria and the mechanisms entailed to facilitate this 
resistance. 
 
This thesis provides an in depth analysis of a cohort of resistant K. pneumoniae isolates from 
Greece and Brazil during 2012 to 2014. In Chapter 2, these strains underwent extensive 
antimicrobial susceptibility testing to validate an XDR phenotype. Whole genome sequencing 
revealed these isolates were predominantly from the ST258 lineage (16/ 24 isolates). Additional 
lineages included ST11, ST147 and ST383. The genetic basis for polymyxin resistance in the 19 
resistant strains was facilitated by chromosomal mutations rather than plasmid encoded resistance. 
Genes impacted included phoPQ, pmrB and in the majority of instances, mgrB (17/ 19 isolates). 
These variants were found to commonly occur homogeneously, however, heterogeneity of 
mutations were detected along with one case of a heteroresistance. Resistance attributed to mgrB 
variants were enabled via an IS element, partial deletion, missense or nonsense mutations. 
Interestingly, additional mutations were identified to segregate with the mgrB IS element disruption. 
Complementation assays uncovered the potential role of these variants as partial suppressor 
mutations which have yet to be detected in K. pneumoniae. Furthermore, complementation assays 
elucidated whether particular mutations contributed to resistance or if these were lineage specific. In 
the instance of phoQ mutations, complementation of the resistance conferring mutation into a 
susceptible isolate enabled a resistant phenotype, due to dominance of this allele, which highlights a 
limitation of this assay. Predictive analysis, PROVEAN, was unable to sufficiently predict the 
impact of mutations hence, rigorous assays are required to delineate the involvement of these 
mutations in resistance. Overall, detection via sequencing is currently limited to previously defined 
variants known to cause polymyxin resistance. 
 
Chapter 3 further interrogated four of these isolates at a genomic and transcriptomic level using the 
long read sequencing platform, ONT MinION sequencing. This sequencing resolved the location of 
various resistance genes notably, the high abundance of resistance encoded on megaplasmids 
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(≥100000 bp). Notably, IncA/C2 harboured resistance towards at least 5 classes of antibiotics (≥14 
resistance genes) across 3 isolates which highlights the success of K. pneumoniae to rapidly acquire 
an MDR phenotype. A real-time analysis emulation detected the majority of this resistance (≥70%) 
within 2 hours. Transcriptomic studies using direct RNA sequencing adequately detected highly 
expressed genes within 6 hours, however, the slower sequencing translocation speed could be 
impacting this results. Furthermore, a high percentage of failed reads were apparent indicating the 
technology requires further optimisation for bacterial transcriptomics. Despite these drawbacks, 
differential expression of resistance genes was evident and similar trends were observed via qRT-
PCR. Furthermore, heightened levels of expression from phoPQ (≥2-fold) and the pmrHFIJKLM 
operon (≥7-fold) were found in polymyxin-resistant isolates. These genes could serve as potential 
transcriptomic biomarkers for polymyxin resistance. This chapter has unravelled the correlation 
between genotype, transcription and subsequent resistant phenotype in the absence of antibiotic 
exposure in these XDR K. pneumoniae isolates. 
 
Chapter 4 revealed OctC4 induced only low levels of resistance (4-fold increase) compared to 
structurally similar polymyxins (1000-fold increase) over 20 days of exposure to these antibiotics. 
No cross-resistance was observed between these classes. Major differences were evident between 
these antibiotic classes via whole genome sequencing and lipidomic profiles. Sequencing revealed 
TCS pathways impacted during polymyxin resistance including genes crrB, mgrB, pmrB and 
phoPQ. Intriguingly, an alternative TCS gene, qseC, was shown to contribute to resistance and 
validated via complementation assays. Similar to closely related isolates in Chapter 2, multiple 
genes were found to contribute to polymyxin resistance. Octapeptin resistance differed 
significantly, involving genes associated with OM phospholipid transport and substrate transport 
instead of those associated with lipid A. These included mlaD, mlaF and pqiB and more than one of 
these genes was found to be impacted within a replicate. Alterations in this pathway was evident in 
lipidomic studies as octapeptin-exposed isolates increased the addition of palmitoylate to stabilise 
the OM. In distinct contrast, all polymyxin treated replicates increased the fortification of Ara4N on 
lipid A phosphate group/s. These findings reveal that octapeptins target bacteria via an alternative 
mechanism compared to polymyxins and in combination with a slow progression of resistance, 
highlights the potential for octapeptins to be explored as last-resort antibiotics. 
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5.2. Future Directions 
 
Although these isolates have undergone extensive characterisation, several aspects still warrant 
further investigation. In Chapter 2, strains were tested to define an XDR phenotype, however, 
several antibiotics have not been incorporated in the MIC testing to determine a PDR profile. Seven 
isolates are non-susceptible to all 24 antibiotics that were tested, and if the screening was extended 
further, PDR could be discerned. Complementation assays entail several limitations in particular, 
the presence of both WT and the mutated allele hinders resolving the true extent the mutation 
contributes to resistance. This could be overcome with a gene knockout and introducing the mutated 
allele which can be performed via allelic exchange. Once undertaken, this will unravel if additional 
variants are partial suppressor mutations and further, whether this facilitates a fitness advantage. 
Moreover, several additional isolates have been collected in 2014 and 2015 from the Hygeia 
General Hospital (Greece) and the genetic modifications involved in polymyxin resistance have yet 
to be determined. In particular, it would be of interest to determine whether mutations identified in 
this study persist in isolates from the following years and additionally, if these mutations are also 
evident in raw read data of other polymyxin-resistant K. pneumoniae genomes deposited on NCBI. 
Various components of the analysis pipeline could be additionally refined in Chapter 3. The basis 
for the high abundance of failed reads identified in ONT direct RNA sequencing requires further 
investigation and whether the addition of an artificial poly(A) tail is influencing this result. As these 
reads were not necessarily short, it would be desirable to incorporate these in the analysis. This is 
the first report of bacterial transcriptomics via direct RNA sequencing and utilising differing tools 
and parameters should be taken into consideration. Additional optimisation is required for base 
calling, read alignment and determination of relative expression. Furthermore, the comparison 
between another RNA sequencing platform such as Illumina would be of interest. 
Similar to Chapter 2, genomic variants identified in Chapter 4 require allelic exchange in order to 
confirm the extent these mutations contribute to resistance. Multiple aspects associated with 
octapeptin resistance remain undefined in particular, the involvement of the poorly characterised 
Mla and Pqi pathway in K. pneumoniae. Furthermore, it is important to determine whether an 
extended time course would enable a higher level of resistance. To date, >300 octapeptin analogues 
have been synthesised with several leads exhibiting greater potency and less toxicity than OctC4. It 
is important to assess whether these potent analogues also induce less resistance and act via the 
same pathway not only in K. pneumoniae, but an extended panel of resistant Gram-negative bacteria 
(A. baumannii, E. coli, P. aeruginosa). These findings would further discern if an octapeptin could 
be utilised as the next last-line antibiotic. 
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Table S2.1. Oligonucleotides used in this study 
Assay Gene Forward sequence (5’ to 3’) Reverse sequence (5’ to 3’) Reference 
PCR     
 mgrB ATT CTG CCG CTT TTG CTG CGT TTT GAA ACA AGT CGA TGA 1 
Complementation   
 mgrB TTA AGA AGG CCG TGC TAT CC AAG GCG TTC ATT CTA CCA CC 2 
 phoP CAC CAG GGG CCC TTT TTA T GCT AAC GCT ATA GCC CAC CA This study 
 phoQ ATA CCC ACA GGA CGT CAT CA CAG GTG TCT GAC AGG GAT TA 2 
 pmrB ACC TAC GCG AAA AGA TTG GC GAT GAG GAT AGC GCC CAT GC 2 
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Table S2.2. Broth microdilution values acquired for the 24 clinical isolates 
Strain* 
 Resistance Profile† 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
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M
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T
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T
 
ATCC 25922 ≤2 ≤0.5 
≤0.
5 
≤0.25 ≤1/4 ≤0.5 ≤0.25 ≤2 ≤0.5 ≤0.25 
≤0.
5 
≤2 ≤0.125 
≤0.5/
≤16 
≤0.25 ≤0.5 8 8/4 ≤8 ≥27 0.25 0.25 ≤0.5 ≤0.5 
ATCC 700603 ≤1 ≤8 ≤8 ≤4 
128/>
64 
≤0.5 ≤0.25 ≥64 ≤0.5 2 64 ≤16 ≤0.125 
≤2/>
128 
≥4 ≥32 >64 
>64/
≥32 
≥32 ≤12 0.5 0.5 ≥16 8 
ATCC 13883 ≤0.5 ≤0.5 
≤0.
5 
≤0.25 16/4 ≤0.5 ≤0.25 ≤2 ≤0.5 ≤0.25 
≤0.
5 
≤2 ≤0.125 
≤0.5/
≤32 
≤1 ≤0.5 >64 
>64/
≥8 
≤4 ≤18 ≤4 ≤4 ≤1 ≤0.5 
ATCC BAA-
2146 
>64 >64 >64 >32 
>128/
>64 
>32 >32 >64 >64 >32 >64 >64 >16 
>64/ 
>128 
≥4 >64 >64 
>64/
≥32 
>64 ≤20 ≤0.25 ≤0.25 ≥64 >64 
1_GR_13 >64 >64 >64 >32 
>128/ 
>64 
≥64 >32 >64 >64 >32 >64 >64 >16 
>64/ 
128 
≥2 >64 >64 
>64/ 
>64 
64 ≤19 16 ≥8 ≥16 >64 
2_GR_12 >64 >64 >64 >32 
>128/ 
>64 
≥64 >32 >64 >64 >32 >64 >64 >16 
>64/ 
128 
2 >64 >64 
>64/ 
>64 
>64 ≤20 16 8 16 >64 
3_GR_13 >64 >64 >64 >32 
>128/ 
>64 
≥16 ≥8 >64 ≥16 >32 >64 64 >16 
>64/ 
128 
2 >64 >64 
>64/ 
>64 
≥32 ≤22 16 8 ≥8 >64 
4_GR_12 >64 >64 >64 >32 
>128/ 
>64 
>64 >32 >64 >64 >32 >64 >64 >16 
>64/ 
128 
2 >64 >64 
>64/ 
>64 
>64 20 32 ≥16 ≥8 >64 
5_GR_13 ≤16 ≤4 ≥8 >32 
>128/ 
>64 
≥32 ≥4 >64 >64 >32 >64 >64 >16 
>64/ 
128 
2 >64 >64 
>64/ 
>64 
>64 ≤21 ≥16 16 16 >64 
6_GR_12 ≤8 2 8 >32 
>128/ 
>64 
32 ≥8 >64 ≥64 >32 >64 >64 >16 
>64/ 
128 
≥2 >64 >64 
>64/ 
>64 
>64 20 ≤0.5 ≤1 ≤8 >64 
7_GR_13 64 ≤2 64 >32 
>128/ 
>64 
≥64 >32 >64 >64 >32 >64 >64 >16 
>64/ 
128 
≥2 >64 >64 
>64/ 
>64 
>64 19 >64 ≥64 4 ≤4 
8_GR_13 >64 >64 >64 >32 
>128/ 
>64 
>64 >32 >64 >64 >32 >64 >64 >16 
>64/ 
128 
≥2 >64 >64 
>64/ 
>64 
>64 ≤19 64 ≥32 ≥16 >64 
9_GR_12 ≥32 ≤2 ≥32 >32 
>128/ 
>64 
16 ≥4 >64 >64 >32 >64 64 >16 
>64/ 
128 
2 >64 >64 
>64/ 
>64 
>64 ≤8 ≥16 ≥8 ≤8 ≤4 
10_GR_13 16 ≤1 ≥16 >32 
>128/ 
>64 
>64 >32 >64 >64 >32 >64 >64 >16 
>64/ 
128 
2 >64 >64 
>64/ 
>64 
>64 ≤20 64 ≥32 ≤4 ≤4 
11_BR_13 ≤16 ≤0.5 ≥16 >32 
>128/ 
>64 
>64 >32 >64 ≥64 >32 ≥64 >64 >16 
>64/ 
128 
≤2 >64 >64 
>64/ 
>64 
8 ≤15 ≥64 64 ≤4 ≤2 
12_BR_13 ≤1 >64 ≥8 >32 
>128/ 
>64 
≥64 >32 >64 >64 >32 ≥64 >64 >16 
>64/ 
128 
≤2 >64 >64 
>64/ 
>64 
>64 23 >64 >64 ≤8 ≤2 
13_GR_14 ≤32 ≤0.5 ≥16 >32 
>128/ 
>64 
>64 >32 >64 >64 >32 >64 >64 >16 
>64/ 
128 
≤1 >64 >64 
>64/ 
>64 
>64 20 16 16 ≤1 ≤0.5 
14_GR_14 ≤32 ≤0.5 ≥16 >32 
>128/ 
>64 
>64 >32 >64 >64 >32 >64 >64 >16 
>64/ 
128 
≤1 >64 >64 
>64/ 
>64 
>64 20 ≥32 ≥16 ≤2 ≤1 
15_GR_13 ≤32 ≤1 ≥16 >32 
>128/ 
>64 
32 ≥8 >64 ≥64 >32 >64 64 >16 
>64/ 
128 
2 >64 >64 
>64/ 
>64 
>64 ≤22 64 ≥32 ≤4 1 
16_GR_13 >64 >64 >64 >32 
>128/ 
>64 
≥8 ≥16 >64 >64 >32 >64 64 >16 
>64/ 
128 
≥2 >64 >64 
>64/ 
>64 
32 ≤19 64 64 ≤8 >64 
17_GR_14 >64 >64 >64 >32 
>128/ 
>64 
≥4 ≥4 >64 >64 >32 >64 32 >16 
>64/ 
128 
2 >64 >64 
>64/ 
>64 
≥16 ≤20 64 32 4 >64 
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*Strain identification, numerical order catalogued at IMB_Country (GR:Greece, BR:Brazil)_last two digits of isolation year.  
†Antibiotic resistance as determined by broth microdilution according to CLSI guidelines except fosfomycin (disk diffusion) and tigecycline which 
followed EUCAST breakpoints. Antibiotic classes tested include 1, Aminoglycosides (Amikacin, AMK; Gentamicin, GEN; Tobramycin, TOB); 2, 
Anti-MRSA cephalosporins (Ceftaroline, CPT); 3, Antipseudomonal penicillins + β-lactamase inhibitors (Piperacillin-tazobactam, TZP); 4, 
Carbapenems (Imipenem, IPM; Meropenem, MEM); 5, Non-extended spectrum cephalosporins (1st and 2nd generation) (Cefazolin, CFZ); 6, Extended-
spectrum cephalosporins (3rd and 4th generation) (Cefepime, FEP; Cefotaxime, CTX, Ceftazidime, CAZ); 7, Cephamycins (Cefoxitin, FOX); 8, 
Fluoroquinolones (Ciprofloxacin, CIP); 9, Folate pathway inhibitors (Trimethoprim-sulfamethoxazole, SXT); 10, Glycylcyclines (Tigecycline, TGC); 
11, Monobactams (Aztreonam, ATM); 12, Penicillins (Ampicillin, AMP); 13, Penicillins + β-lactamase inhibitors (Amipicillin-sulbactam, SAM); 14, 
Phenicols (Chloramphenicol, CHL); 15, Phosphonic acids (Fosfomycin, FOF); 16, Polymyxins (Colistin, CST; Polymyxin B, PMB); 17, Tetracyclines 
(Minocycline, MIN; Tetracycline, TET). The two antibiotics for TZP, SXT and SAM were assayed separately and both MICs separated with a /. 
Shading indicates R, Resistant; I, Intermediate; S, Susceptible. 
18_GR_14 ≤32 ≤0.5 ≥16 >32 
>128/ 
>64 
>64 >32 >64 >64 >32 >64 >64 >16 
>64/ 
128 
2 >64 >64 
>64/ 
>64 
≥32 ≤20 64 64 2 ≤2 
19_GR_14 ≤32 ≤0.5 ≥16 >32 
>128/ 
>64 
≥16 ≥8 >64 >64 >32 >64 >64 >16 
>64/ 
128 
≥4 >64 >64 
>64/ 
>64 
64 21 64 64 ≥8 8 
20_GR_12 64 1 64 >32 
>128/ 
>64 
≥8 ≥8 >64 ≥16 >32 >64 64 >16 
>64/ 
128 
≥2 >64 >64 
>64/ 
≥64 
≥32 ≤22 0.125 ≤0.25 16 >64 
21_GR_13 ≤4 ≤4 ≥8 >32 
>128/ 
>64 
8 ≤2 >64 ≥16 >32 >64 >64 0.25 
>64/ 
128 
1 ≤4 >64 
>64/ 
≥64 
≤4 ≥24 ≤0.25 0.125 ≤1 ≤0.5 
22_GR_12 ≤32 ≤1 ≥16 >32 
>128/ 
>64 
≥16 ≥8 >64 ≥16 >32 >64 64 >16 
>64/ 
128 
≥1 >64 >64 
>64/ 
≥64 
32 20 ≤0.25 ≤0.25 ≤4 1 
23_GR_12 >64 >64 >64 >32 
>128/ 
>64 
≥64 >32 >64 >64 >32 >64 >64 >16 
>64/ 
128 
8 >64 >64 
>64/ 
>64 
>64 ≤20 ≥8 ≥4 >64 >64 
24_GR_13 ≤32 ≤1 ≥16 >32 
>128/ 
>64 
≥8 ≥4 >64 ≥16 >32 >64 ≥32 >16 
>64/ 
128 
2 >64 >64 
>64/ 
≥64 
>64 ≤23 ≤0.25 ≤0.25 ≤8 2 
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Table S2.3. Non-synonomous changes relative to 20_GR_12 and PROVEAN prediction 
 
*Strains also harboring an IS element disruption in mgrB shown as, Δ. 
†S, Susceptible (MIC: ≤2 mg/L); R, Resistant (MIC: >2 mg/L).  
‡Variant represented as initial amino acid, position and new amino acid; () corresponds to 
percentage of reads mapping to alteration if ≤98%.  
§PROVEAN predicted deleterious score which is set to ≤-2.5; -, value not predicted deleterious. 
 
Strain* 
Polymyxin 
Profile† 
Gene Variant‡ 
PROVEAN 
score§ 
ATCC 
700603 
S 
pmrA S64A, N131D, L140Q, E199D, N219H - 
pmrB 
T8N, N105S, A228T, Q232E, I242V, N244S, G256R, 
E272Q, Q356R 
- 
phoP R34K - 
phoQ 
Q92K, A106T, E112D, I139V, L163F, V196I, T372S, 
Q424P, Q482L, Q487E 
- 
1_GR_13Δ R pmrB T140P -4.39 
2_GR_12Δ 
R 
phoP A95S -2.97 
 phoQ N253T -3.86 
3_GR_13 R mgrB D29E -3.97 
4_GR_12Δ R 
phoP P74L -9.98 
phoQ N253T -3.86 
5_GR_13 R 
mgrB Q30STOP -14.86 
pmrA N131D, G144D, D149E, N219H - 
pmrB A5V, N105S, M175V, A228T, G256R - 
6_GR_12 S 
pmrA N131D, G144D, D149E, N219H - 
pmrB A5V, N105S, M175V, A228T, G256R - 
8_GR_13 R phoQ G385C -8.06 
9_GR_12 R phoQ T281M -5.36 
10_GR_13Δ R phoQ A225T, N253T -, -3.86 
13_GR_14Δ R 
pmrB P158R (66) -8.68 
phoQ V446G (65) -5.46 
14_GR_14Δ R 
pmrB P158R (57) -8.68 
phoQ V446G (52) -5.46 
19_GR_14 R mgrB C28STOP -19.00 
21_GR_13 S 
pmrA S64A, N131D, L140Q, E199D, N219H, I220N, D221E - 
pmrB 
T8N, N105S, A228T, Q232E, I242V, N244S, G256R, 
E272Q, Q356R, G358A 
- 
phoP R34K - 
phoQ 
Q92K, A106T, E112D, I139V, L163F, V196I, T372S, 
Q424P, Q482L, Q487E 
- 
23_GR_12Δ R 
phoP A95S (57) -2.97 
phoQ N253T (57) -3.86 
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Table S2.4. Non-synonymous mutations relative to ATCC 700603 
 
MLST* 
Gene† 
mgrB phoP phoQ pmrA pmrB 
11 (3) - K34R 
K64R, K92R,T106A, 
D112E,V139E, F163L, 
I196V, S372T, P424Q, 
L482Q, E487Q 
A64S, D131N, 
Q140L, D199E, 
H219N 
N8T, S105N, T228A, 
E232Q, V242I, 
S244N,R256G, Q272E, 
R356Q, 
147 (1) - K34R 
K64R, K92R,T106A, 
D112E,V139E, F163L, 
I196V, S372T, P424Q, 
L482Q, E487Q 
A64S, D131N, 
Q140L, D199E, 
H219N 
N8T, S105N, T140P, 
T228A, E232Q, V242I, 
S244N,R256G, Q272E, 
R356Q, 
258 (16) 
C28STOP, 
D29E 
K34R, 
P74L, A95S 
K64R, K92R,T106A, 
D112E,V139E, F163L, 
I196V, A225T, N253T, 
T281M, G385C 
S372T, P424Q, V446G, 
L482Q, E487Q 
A64S, D131N, 
Q140L, D199E, 
H219N 
N8T, S105N, 
P158R,T228A, E232Q, 
V242I, S244N,R256G, 
Q272E, R356Q 
383 (2) Q30STOP K34R 
K64R, K92R,T106A, 
D112E,V139E, F163L, 
I196V, S372T, P424Q, 
L482Q, E487Q 
A64S, Q140L, 
G144D,D149E, 
D199E 
A5V, N8T,M175V, 
E232Q, V242I, S244N, 
Q272E, R356Q 
437 (1) - K34R 
K64R, K92R,T106A, 
D112E,V139E, F163L, 
I196V, S372T, P424Q, 
L482Q, E487Q 
A64S, D131N, 
Q140L, D199E, 
H219N 
N8T, S105N, T228A, 
E232Q, V242I, 
S244N,R256G, Q272E, 
R356Q 
2401 (1) - - - I220N, D221E G358A 
 
*Multi-locus sequence type and in brackets, the number of isolates in this group. 
 
†Genes mgrB, pmrAB and phoPQ were aligned to ATCC 700603 and represented as initial amino 
acid, position and new amino acid. Bold indicates a predicted deleterious variant in polymyxin-
resistant strains according to PROVEAN analysis and an underline identifies this change also being 
present in polymyxin-susceptible isolates. Strains impacted by an IS element disruption in mgrB 
only had flanking regions interrogated to detect variants. 
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Figure S2.1. Amplification of mgrB. (a) PCR products of 1, ATCC 25922 (E. coli negative control); 2, ATCC 700603; 3, ATCC 13883; 4, ATCC 
BAA-2146; 5, 1_GR_13; 6, 2_GR_12; 7, 3_GR_13; 8, 4_GR_12; 9, 5_GR_13; 10, 6_GR_12; 11, 7_GR_13; 12, 8_GR_13; 13, 9_GR_12; 14, 
10_GR_13; 15, 11_BR_13; 16, 12_BR_13; 17, 13_GR_14; 18, 14_GR_14; 19, 15_GR_13; 20, 16_GR_13; 21, 17_GR_14; 22, 18_GR_14; 23, 
19_GR_14; 24, 20_GR_12; 25, 21_GR_13; 26, 22_GR_12; 27, 23_GR_12; 28, 24_GR_13. (b) IS5-like (ISKpn26-like or ISKpn13 for 12_BR_13) 
element producing 1700 bp amplicon. (c) IS1R-like element resulting in 1268 bp amplicon in 16_GR_13 and 17_GR_14 (d) IS1R element in 
11_BR_13 resulting in 1268 bp amplicon. 
 
 1    2    3    4    5    6     7    8    9   10   11  12  13  14  15  16  17  18   19  20   21  22   23  24  25  26  27  28 
1650  
500  
(a)  
400  
 
1 144 
IS1R-like 
gacattgcgtactgatgcggGTGATGCTGC AGTCATTACCactgatgcggagagtggagt 
 
-50 -8 
 
(c)   
1 144 
IS1R 
gccgtgctatcctggcgacGGTGATGCTG 
 
AGTCATTACCcctggcgacattgcgtact 
 
-25 -50 
(d)  
 
1 75 144 
ISKpn26-like/ ISKpn13 
TCGCACCTTCcttaacgtaatgtgc 
(b)  
gactcagatgcttaaGGAAGGTGCG 
  
mgrB mgrB mgrB 
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Figure S2.2. Amplification of chromosomal mgrB for complemented 13_GR_14 (lanes 1 to 6) and 
14_GR_14 (lanes 7 to 12). Complementation via pTOPO-mgrB is shown in lanes 1 to 3 and 7 to 9 
and for pTOPO-pmrB, lanes 4 to 6 and 10 to 12. Three colonies were tested per treatment group and 
reversion to a polymyxin-susceptible phenotype is indicated by *. A 500 bp amplicon represents an 
intact mgrB whilst a 1700 bp amplicon is the result of the ISKpn26-like insertion in mgrB. 
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Figure S2.3. Sanger sequencing traces of amplified phoQ from (a) DNA extraction of 14_GR_14 
used for whole genome sequencing. (b) complementation of 14_GR_14 where susceptibility was 
recovered by pTOPO-mgrB. (c) complementation of 14_GR_14 where susceptibility was recovered 
by pTOPO-pmrB. WT sequence contains T at nucleotide position 1337 (shaded) and mutation of G 
causing V446G was isolated in condition (c). 
 
(b) 
(a) 
(c) 
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Direct RNA Sequencing 
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Figure S3.1. Tapestation traces of high molecular weight DNA samples including, (a) 1_GR_13, 
(b) 2_GR_12, (c) 16_GR_13, (d) 20_GR_12. The 100 nt marker is indicated with an M and number 
indicates the most abundant length. 
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Figure S3.2. Bioanalzyer traces comparing mRNA enrichment and subsequent poly(A) ligation for RNA samples. Sample conditions 
are as follows: (a) 1_GR_13 mRNA enrichment, (b) 1_GR_13 poly(A) ligation, (c) 2_GR_12 mRNA enrichment, (d) 2_GR_12 
poly(A) ligation, (e) 16_GR_13 mRNA enrichment, (f) 16_GR_13 poly(A) ligation, (g) 20_GR_12 mRNA enrichment, (h) 20_GR_12 
poly(A) ligation. The 25 nt marker is indicated with an M, presence of 16S rRNA (16S) and 23S rRNA (23S) are also shown.  
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Figure S3.3. Size distribution of reads for sequenced samples. Isolates sequenced by the MinION 
include (a) 1_GR_13 DNA, (b) 2_GR_12 DNA, (c) 16_GR_13 DNA, (d) 20_GR_12, (e) 1_GR_13 
RNA, (f) 2_GR_12 RNA, (g) 16_GR_13 RNA, (h) 20_GR_12 RNA. 
 
 
(a) (b) 
(c) (d) 
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(g) (h) 
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Table S3.1. Genome assembly comparison 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Output of genome assembly identifies circular sequences (bold) and in brackets, plasmid replicons present on these contigs. 
Strain 
Illumina 
coverage 
(X) 
N50 
Nanopore 
coverage 
(X) 
N50 
Assembly Method* 
SPAdes/ npScarf SPAdes/ Unicycler Canu 
Minimap2/ Miniasm/ 
Racon 
1_GR_13 63 242938 215 8712 
5289533 (IncFIB), 
193063 (IncA/C2), 
168359 (IncFIB; 
IncFII), 61039, 55020, 
53489 (IncR; IncN), 
6457 
5181675, 192771 
(IncA/C2), 159172 
(IncFIB; IncFII), 
108879 (IncFIB), 
55018, 53495 (IncR; 
IncN) 
5073727, 226704 
(IncA/C2), 184820 
(IncFIB; IncFII), 
136154 (IncFIB), 
100186, 82924 (IncR; 
IncN), 54495 
5167584, 192237 
(IncA/C2), 168292 
(IncFIB; IncFII), 
108582 (IncFIB), 
53325 (IncR; IncN) 
 
2_GR_12 158 196706 67 5251 
5485776, 457649 
(IncFIB; IncA/C2; 
IncFII), 60365 (IncFII), 
42041 (IncX3), 32458, 
21300, 13841 
(ColRNAI), 12226 
3743268, 1694231, 
175636 (IncA/C2), 
152644 (IncFIB; 
IncFII), 95481 
(IncFIB), 43380 
(IncX3), 28913, 
26127, 16781 
(IncFII), 16315, 
13841 (ColRNAI) 
5440093, 392198 
(IncFIB; IncA/C2; 
IncFII), 122463 
(IncFIB; IncFII), 57534 
(IncX3), 26891 
(ColRNAI) 
3769033, 1696038, 
204124 (IncA/C2), 
179356 (IncFIB; 
IncFII), 158561 
(IncFIB), 43085 
(IncX3), 2250, 13400 
(ColRNAI) 
 
16_GR_13 123 203529 101 5012 
5426917, 186908 
(IncFIB; IncFII), 
154971 (IncA/C2), 
63588 (IncL/M), 37608, 
35578, 5225, 4426 
(ColRNAI), 3703 
5426765, 187670 
(IncFIB; IncFII), 
155161 (IncA/C2), 
63589 (IncL/M), 
5234, 4940 
(ColRNAI), 2156 
(ColRNAI) 
5400611, 199904 
(IncFIB; IncFII), 
180542 (IncA/C2), 
83467 (IncL/M), 14853, 
11623, 9308, 9243, 
7568, 7089 
 
5410256, 186950 
(IncFIB; IncFII), 
154635 (IncA/C2), 
63299 (IncL/M), 
5100, 4900 
 
20_GR_12 262 256217 115 10151 
5391578, 163468 
(IncFIB; IncFII), 50940 
(IncN), 50856 (IncX3), 
12578 (ColRNAI) 
5395894, 170467 
(IncFIB; IncFII), 
50979 (IncN), 43380 
(IncX3), 13841 
(ColRNAI), 4645 
5342491, 192947 
(IncFIB; IncFII), 74844 
(IncX3), 72588 (IncN), 
25624 (ColRNAI) 
 
5380057, 169880 
(IncFIB; IncFII), 
50636 (IncN), 43157 
(IncX3), 13600 
(ColRNAI) 
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Table S3.2. Plasmids detected in final assembly and location of resistance genes 
Plasmid 
1_GR_13 2_GR_12 16_GR_13 20_GR_12 
Gene Position Gene Position Gene Position Gene Position 
IncA/C2 
sul2 93-908 sul2 118194-119009 sul2 118190-119005   
dfrA14 153496-153978 aph(3'')-Ib 119070-119873 aph(3'')-Ib 119066-119869   
dfrA23 156082-156642 aph(6)-Id 119873-120709 aph(6)-Id 119869-120705   
blaVEB-1 165159-166058 tet(A) 122045-123216 tet(A) 122041-123212   
ant(2'')-Ia 166203-166736 blaTEM-1A 129326-130186 blaTEM-1B 129322-130182   
ARR-2 166821-167273 rmtB 130356-131111 rmtB 130352-131107   
cmlA1 167594-168853 tet(G) 136128-137255 tet(G) 136124-137299   
blaOXA-10 169118-169918 sul1 140114-140729 sul1 140110-140725   
aadA1 169935-170726 aadA1 141147-141938 aadA1 141143-141934   
sul1 171144-171759 blaOXA-10 141955-142755 blaOXA-10 141951-142751   
tet(G) 174570-175745 cmlA1 143020-144279 cmlA1 143016-144275   
rmtB 180762-181517 ARR-2 144600-145052 ARR-2 144596-145048   
blaTEM-1B 181687-182547 ant(2'')-Ia 145137-145670 ant(2'')-Ia 145133-145666   
tet(A) 188657-189828 blaVEB-1 145815-146714 blaVEB-1 145811-146710   
aph(6)-Id 191164-192000 dfrA23 155231-155791     
strA 192000-192771 dfrA14 157895-158377     
IncFIB, 
IncFIIK 
aph(6)-Id 45220-46056 catA1 27310-27969 aac(6')Ib-cr 53245-53844 blaKPC-2 1068-1949 
strA 46056-46859 dfrA12 33980-34477 blaOXA-1 53975-54805 blaTEM-1A 11208-12068 
dfrA14 104229-104711 aadA2 34885-35676 catB4 54943-55491 blaOXA-9 12768-13607 
aph(3')-Ia 106691-107506 sul1 36094-37020 aac(3)-IIa 56248-57108 aph(3')-Ia 14667-15482 
dfrA1 110267-110740 mph(A) 42331-43236 blaCTX-M-15 62262-63137   
aadA24 110827-111539 aph(3')-Ia 44213-45028 dfrA12 68291-68788   
    aadA2 69196-69987   
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Position represents the start and end range of the resistance gene mapping to this plasmid. Shading indicates the absence of these plasmids in the 
isolate 
    sul1 70405-71331   
    mph(A) 76642-77547   
    aph(3')-Ia 78524-79339   
IncR, 
IncN 
mph(A) 15211-16116       
blaVIM-27 21747-22547       
dfrA1 23242-23715       
aadA24 23802-24515       
sul1 24935-25861       
aph(3')-Ia 27140-27955       
aph(6)-Id 41681-42517       
strA 42517-43320       
IncFIB 
  blaKPC-2 10772-11653     
  blaOXA-9 21300-22139     
  blaTEM-1A 22839-23699     
IncX   blaSHV-12 41690-42550   blaSHV-12 41690-42550 
ColRNAI 
  aac(6')Ib-cr 12868-13454   aac(6')Ib-cr 9442-10028 
  aac(6')-Ib 12868-13473   aac(6')-Ib 9442-10047 
IncL/M     blaOXA-48 42721-43518   
IncN 
      blaTEM-1A 50035-50895 
      sul2 5557-6372 
      aph(3'')-Ib 6433-6961 
      dfrA14 6972-7454 
      aph(6)-Id 7804-8640 
      tet(A) 845-2044 
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Table S3.3. Oligonucleotides used in this study for qRT-PCR 
 
 
*An (TS) indicates that primers were designed in this study. Superscript after a primer designates 
alternative coding for: 1, 1_GR_13 (ST147) and 16, 16_GR_13 (ST11). # Indicates primer recognises 
other genes, aac(6’)Ib: aac(6’)Ib-cr, aadA24, strA: aph(3'')-Ib and blaTEM-1: blaTEM-1A, 
blaTEM-1B. 
 
 
 
Assay Gene Forward sequence (5’ to 3’) Reverse sequence (5’ to 3’) Reference* 
Acquired resistance   
 aac(6’)Ib# TTG CAA TGC TGA ATG GAG AG TGG TCT ATT CCG CGT ACT CC TS 
 blaKPC-2 TGG CTA AAG GGA AAC ACG AC TAG TCA TTT GCC GTG CCA TA TS 
 blaOXA-10 GGT GGG TTG AGA AGG AGA CA ATG ATT TTG GTG GGA ATG GA TS 
 blaTEM-1# AAG CCA TAC CAA ACG ACG AG TTG CCG GGA AGC TAG AGT AA TS 
 cmlA1 AAT GGG ATG CCT GAT AGC TG ACC CAC TAG CCA CAT TGG AG TS 
 dfrA14 TTT GAA TCT ATG GGC GCA CT ATG GCC TCT TCG ATT GAC TG TS 
 fosA CGT GGC GTT TTA TCA GCA G ACA GGC ACA GCC ACA AAT C TS 
 oqxA GCG ATG ATG CTC TCC TTT CT GAT CGA CTT CAC CAG CAC CT TS 
 strA# ACT CTT CAA TGC ACG GGT CT CCA GTT CTC TTC GGC GTT AG TS 
 sul2 GAT ATT CGC GGT TTT CCA GA GTC TTG CAC CGA ATG CAT AA TS 
 tetA TTG GCA TTC TGC ATT CAC TC GAA GGC AAG CAG GAT GTA GC TS 
Polymyxin resistance   
 phoP ATT GAA GAG GTT GCC GCC CGC GCT TGA TCG GCT GGT CAT TCA CC TS 
 phoQ GCA TAT CTT CCC GCT GTC AT GCT AAC GCT ATA GCC CAC CA TS 
 pmrA GAT GAA GAC GGG CTG CAT TT ACC GCT AAT GCG ATC CTC AA 1 
 pmrB TGC CAG CTG ATA AGC GTC TT TTC TGG TTG TTG TGC CCT TC 1 
 pmrC GCG TGA TGA ATA TCC TCA CCA CAC GCC AAA GTT CCA GAT GA 1 
 pmrD GAT CGC AGA GAT TGA AGC CT GCG TTG CGA ATC TTC AAA GT 1 
   GCG TTG CGG ATC TTC AAA GT1, 16 TS 
 pmrE GGG TTG ATC TCT GTG ACA TC GCC TAC CGT AAT GCC GAC TA 1 
  GGG TTA ATC TCC GCA ACA TC16 TGC ATA TCG CAA TGC TGA CTA16 TS 
   GCA TAC CGT AAT GCC GAC TA1 TS 
 pmrH CCG CAT CCG TAG CCT GAA CGT GGG TCT GGC GAT CAT 2 
 pmrK AGT ATC GGT CAG TGG CTG TT CCG CTT ATC ACG AAA GAT CC 1 
 rpsL CCG TGG CGG TCG TGT TAA AGA GCC GTA CTT GGA GCG AGC CTG 3 
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Table S3.4. Highest similarity observed for final assembly contigs when aligned to NCBI database 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Query coverage indicates percentage (%) of sequence from NCBI database aligning to contig and identity (%) indicates sequence similarity. 
#Represents the full length of the previously reported sequence is ≥90% the length of the contig and * is a sequence longer than the contig. 
 
Isolate ST Contig Length (bp) Contig ID Accession number 
Query 
Coverage 
Identity 
1_GR_13 147 
1 5181675 C CP018719.1* 99 99 
2 192771 P: IncA/C2 CP008824.1* 76 99 
3 168873 P: IncFIBpKpn3, IncFIIpKP91 CP006657.1* 89 99 
4 108879 P: IncFIBpKPHS1 CP023929.1* 92 99 
5 55018 - CP023927.1* 100 99 
6 53495 P: IncR, IncN CP023926.1* 92 99 
2_GR_12 258 
1 5466424 C LT216436.1* 99 99 
2 197872 P: IncFIBpKpn3, IncFIIK CP021713.1* 97 99 
3 175636 P: IncA/C2 LT882698.1* 80 99 
4 95481 P: IncFIBpQil CP023928.1 100 99 
5 43380 P: IncX3 CP009776.1* 100 99 
6 13841 P: ColRNAI CP010362.1* 99 99 
16_GR_13 11 
1 5426917 C CP018438.1# 97 99 
2 187670 P: IncFIBpKpn3; IncFIIK CP018693.1# 90 100 
3 155161 P: IncA/ C2 KX029331.1# 84 99 
4 63589 P: IncL/ MpOXA-48 CP018723.1# 100 99 
5 5234 - CP025818.1* 99 99 
6 4940 P: ColRNAI CP024579.1 84 99 
20_GR_12 258 
1 5395894 C CP027160.1# 96 99 
2 170467 P: IncFIBpKpn3; IncFIIK CP022574.1# 99 99 
3 50979 P: IncN CP026053.1# 93 99 
4 43380 P: IncX3 CP009776.1* 100 99 
5 13841 P: ColRNAI CP010362.1* 100 100 
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Appendix III – Supplementary Information for Chapter 4 
 
Octapeptin C4 and polymyxin resistance occur via distinct pathways in an epidemic XDR 
Klebsiella pneumoniae ST258 isolate 
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Table S4.1. Concentration of supplemented antibiotic for cross-resistance studies and DNA 
extraction 
Strain* Antibiotic concentration (mg/L)† 
Initial 0 
CST_1 128 
CST_2 128 
CST_3 64 
CST_4 128 
CST_5 128 
CST_6 128 
PMB_1 20 
PMB_2 128 
PMB_3 128 
PMB_4 128 
PMB_5 128 
PMB_6 128 
OctC4_1 12 
OctC4_2 10 
OctC4_3 12 
OctC4_4 12 
OctC4_5 12 
OctC4_6 10 
*Strain indicated as 20_GR_12 (initial day 0 isolate) and 20 days of treatment with colistin (CST), 
polymyxin B (PMB) and octapeptin C4 (OctC4) followed by the replicate number (n=6). 
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†Highest concentration used during resistance induction was 128 mg/L for CST/ PMB and 32 mg/L 
for OctC4. Due to poor recovery of OctC4 isolates, half the MIC was supplemented in broth 
Table S4.2. Primers used for complementation assays 
Gene Forward (5’-3’) Reverse (5’-3’) Reference 
crrB CTCGGCAGTATGTGGGATCT AGCTTGAACATGCCGGATT This study 
mgrB TTAAGAAGGCCGTGCTATCC AAGGCGTTCATTCTACCACC 1 
mlaD GGTTATGACGCTATCCCCACT CCGCTTCATTCATCAGCTT This study 
mlaF AAATGCCAGCTTTCGCTAAC AACGGCGTTGAAAAGCATTA This study 
phoP CACCAGGGGCCCTTTTTAT GCTAACGCTATAGCCCACCA This study 
phoQ ATACCCACAGGACGTCATCA CAGGTGTCTGACAGGGATTA 2 
pmrB ACCTACGCGAAAAGATTGGC GATGAGGATAGCGCCCATGC 2 
pqiB CGGCGCGGTAATTTTAACT AAAAAGGGTGCGCAGTTTAG This study 
qseC AAGTTCACGTCCATCATCTGC ACGATCTTACCCCGCGAAG This study 
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Figure S4.1. Lipid A (-)-TOF mass spectrums of initial polymyxin-susceptible Klebsiella 
pneumoniae isolate, 20_GR_12. (a) Averaged (n=2) spectra evaluating doubly, indicated with a 2-, 
and singly deprotonated ions. Wording above m/z values correspond to the diversity of lipid A 
structures observed in comparison to the hexa-acylated wild-type (WT) species. Symbol + shows an 
addition or – loss of a moiety and > indicates a substitution. Structures were further elucidated via 
MS/MS analysis of (b) WT lipid A species (911.62-), (c) WT with hydroxymyristate (WT + OH) 
(919.62-), (d) WT containing a 4-amino-4-deoxy-arabinose (Ara4N) addition (977.12-), (e) WT with 
palmitoylate (C16) (1030.7
2-). Precursor ion represented as *, dashed lines on structure designate 
cleavage sites where numbers above m/z identify masses associated with assigned fragmentation. 
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Figure S4.2. Lipid A (-)-TOF mass spectrums of day 20 colistin resistance induced isolates. (a) CST_1, (b) CST_2, (c) CST_3, (d) CST_4, (e) CST_5 
and (f) CST_6. Triangles represent fold changes compared to initial susceptible isolate 20_GR_12 with a fold increase of 5 as ▲, 10 ▲▲ or 50 
▲▲▲ or a fold decrease of 5 as    , 10           or 50              . 
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Figure S4.3. Lipid A (-)-TOF mass spectrums of day 20 polymyxin B resistance induced isolates. (a) PMB_1, (b) PMB_2, (c) PMB_3, (d) PMB_4, (e) 
PMB_5 and (f) PMB_6. Triangles represent fold changes compared to initial susceptible isolate 20_GR_12 with a fold increase of 5 as ▲, 10 ▲▲ or 
50 ▲▲▲ or a fold decrease of 5 as    , 10 or           . 
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Figure S4.4. Lipid A (-)-TOF mass spectrums of day 20 octapeptin C4 resistance induced isolates. (a) OctC4_1, (b) OctC4_2, (c) OctC4_3, (d) 
OctC4_4, (e) OctC4_5 and (f) OctC4_6. Triangles represent fold changes compared to initial susceptible isolate 20_GR_12 with a fold increase of 5 as 
▲. 
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